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Abstract 
 
The experiments presented in this thesis describe the roles of the post-junctional α1, α2-
adrenoceptors (AR) and P2X purinoceptors in response to sympathetic nerve stimulation in 
mouse mesenteric and tail arteries. Such roles were determined by combining wire 
myography techniques and nerve stimulation alongside various selective antagonists. The 
influence of each receptor on the response to nerve stimulation was first defined in wild type 
(WT) mice before analysis of α1-AR knock out (KO) mice. Therefore the effect that genetic 
removal of the α1-ARs had on vascular response could be investigated. The response is the 
force generated in milligrams/tension when the nerves are stimulated and correspond to 
activation of post-junctional receptors and subsequent smooth muscle cell contraction. 
 
Systolic Blood Pressure and the α1-ARs 
The aim of the first study (Chapter Three) was to determine whether systolic blood pressure 
(BP) was different in the KO mice compared to WT controls. Tail cuff measurements of 
systolic BP were recorded in WT and AR KO mice. It was found that BP was not affected 
by loss of the α1A- and α1D-AR subtypes (ADKO) or by loss of all three α1-AR subtypes (α1-
null). Therefore, the α1-AR role in maintaining BP may not be as crucial as previously 
understood or, the remaining receptors may have compensated for the loss. 
 
Calcitonin Gene Related Peptide (CGRP) in Mouse mesenteric and tail arteries 
The second study (Chapter Four) examined whether, under the stimulation parameters used, 
the potent vasodilator CGRP masked the vasoconstrictor response to nerve stimulation in 
mouse mesenteric and tail arteries. The potent neurotoxin capsaicin depletes the sensory 
nerves of CGRP. Responses prior to capsaicin incubation were compared with those 
following capsaicin treatment in WT, ADKO and α1-null mice. In mesenteric artery from 
each mouse strain, capsaicin incubation had no significant effect on the peak response to 
nerve stimulation. Furthermore, in the tail artery, capsaicin treatment had no significant 
effects on the responses in WT and α1-null mice. However, in the ADKO mouse tail artery 
preparations, capsaicin treatment significantly increased the peak response at low frequency 
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stimulation. These findings may indicate an interaction between the α1-AR subtypes and the 
release of CGRP whereby the presence of all or none of the subtypes (WT and α1-null) has 
no effect on CGRP release but loss of the α1A- and α1D-AR subtypes alters the balance and 
reveals a CGRP induced effect.  
 
Response to perivascular nerve stimulation in Mouse mesenteric and tail 
arteries from Wild Type mice 
The aim of Chapter Five was to determine which receptors were involved in the response to 
nerve stimulation in mouse mesenteric and tail arteries. These results would then act as a 
comparison with the ADKO and α1-null responses in the later chapters. A contractile 
response to nerve stimulation was recorded in each of the studied vessels and abolished by 
combined blocked with antagonists for the α1-, α2-ARs and P2X receptors. Individual 
receptor blockade and component analysis then revealed the roles of the individual receptors. 
In the mesenteric arteries, the α1-ARs were the main contributors to the response followed 
by the P2X receptors and finally the α2-ARs which displayed both pre- and post-junctional 
effects. No interactions were discovered between the α1-ARs and the other receptors. The 
P2X receptors initiated the contraction and prolonged the response at the low frequency and 
contributed to the contractile response at the high frequency. In the tail artery, the α2-ARs 
were the dominant receptors but required the presence of the α1-ARs, and to some extent the 
P2X receptors in order to produce a full contractile response upon activation. The P2X 
receptors alone initiated the response at low frequency stimulation with both α1-ARs and 
P2X receptors involved in initiation of the contraction at the high frequency.  
 
Response to perivascular nerve stimulation in mesenteric and tail arteries 
from mice lacking α1A- and α1D-AR subtypes (ADKO) 
Chapter Six determined the role of the α1B-ARs in the response to nerve stimulation and 
therefore examined whether loss of the α1A- and α1D-AR subtypes (ADKO) affected the 
response. In the mesenteric arteries, at the low frequency, there was a potential interaction 
between the receptors. However, no single receptor was responsible for the contraction 
although there was a trend for the P2X receptors to be active at the beginning of the response 
and the α2-ARs to be active at the latter stage of the response. This was also true at the higher 
frequency. The ADKO vessels displayed no evidence of pre-junctional α2-ARs. In the 
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mesenteric arteries, there is little role for the α1B-ARs. The overall contribution in the tail 
artery was reduced in the ADKO, particularly at the higher frequency. Similar to the WT 
mice, the α2-ARs were the main contributor to the response. The P2X receptors initiated the 
contraction but required the α2-ARs to be active at the low frequency. The α1B-ARs also 
required an interaction with the other receptors at low frequency stimulation in order to 
contribute to the initiation of the response. The α1B-ARs also contributed to the initiation of 
the response at the high frequency without requiring the presence of the other receptors. 
 
Response to perivascular nerve stimulation in mesenteric and tail arteries 
from mice lacking α1A-, α1B- and α1D-AR subtypes (α1-null) 
In the final study (Chapter Seven), α1-null mice were utilised in order to determine whether 
loss of the α1-ARs had a significant effect on the response to nerve stimulation in mouse 
mesenteric and tail arteries. Furthermore, the influence of the α2-ARs and P2X receptors 
were compared with the response in the WT vessels to determine whether they compensate 
for the loss of the α1-ARs. The removal of the α1-ARs dramatically reduced the response to 
nerve stimulation in the mesenteric arteries, with no apparent compensation from the α2-ARs 
or P2X receptors. There was no evidence of pre-junctional α2-ARs. The small response 
recorded at the high frequency was initiated by the P2X receptors and maintained by the α2-
ARs and P2X receptors. The tail artery response was smaller in the α1-null mice compared 
with WT, particularly at the higher frequency. However, the response was still mediated 
largely by the α2-ARs with an interaction with the P2X receptors likely. A potential 
compensatory mechanism was recorded at the lower frequency as the response to P2X 
receptor antagonism was greater in the α1-null than in the WT mice. As was shown in the 
WT, activation of the P2X receptors initiated the contraction, particularly at the high 
frequency.  
 
Findings and Results 
Collectively, the findings of the studies presented in this thesis demonstrate that the α1-, α2-
ARs and P2X receptors are involved in the response to nerve stimulation in the mouse 
mesenteric and tail arteries. Genetic removal of the α1-ARs in the ADKO and α1-null is most 
effective in the mesenteric arteries with little evidence of any compensatory mechanisms. In 
the mouse tail artery, the α2-ARs are the main contributors to the response and so loss of the 
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α1-ARs has less of an effect. Interactions between the receptors were most clearly shown in 
the tail artery with little interaction between the α1-ARs and the other receptors demonstrated 
in the mesentery. Furthermore, it has been demonstrated here that systolic BP is unaffected 
in the KO mice and there is little input from the CGRP nerves using the parameters tested.  
From these results, the importance of α1-AR activation in nerve mediated responses was 
determined. The absence of a compensatory mechanism to match the response lost in the 
ADKO and α1-null mice, and the presentation of a normal BP alongside the survival of these 
transgenic mice challenges the importance of the α1-ARs being crucial in the maintenance 
of vascular tone. This therefore complements the knowledge that treatment of primary 
hypertension with α1-AR antagonists is largely unsuccessful. The contractile response 
mediated by α2-ARs and P2X receptors may be used as potential therapeutic targets in 
controlling hypertension.  
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1.1 Sympathetic Neurovascular Transmission 
 
The sympathetic nervous system (SNS) forms part of the autonomic nervous system (ANS). 
The SNS branch is responsible for the ‘fight or flight’ response and in maintaining 
homeostasis. In relation to the vasculature, activation of the SNS leads to release of several 
neurotransmitters that can lead to vasoconstriction and therefore directly affect blood 
pressure.  
 
1.1.1 Vascular Sympathetic Nerves and Transmitter Release 
 
The sympathetic nerves are mainly adrenergic, originating from the thoracolumbar sections 
of the spinal cord and project to many target organs including smooth muscle. The 
preganglionic neurones release acetylcholine (ACh) which binds to nicotinic receptors 
located on post-ganglionic neurones. The post-ganglionic neurones terminate at the 
adventitial-media border where activation of the nerves leads to neurotransmitter release 
from vesicles within the nerve varicosities. The neurotransmitters released include 
noradrenaline (NA) and adenosine tri-phosphate (ATP) with continued debate as to whether 
they are released in parallel or via separate mechanisms (Msghina et al., 1992; Msghina et 
al., 1999; Brock and Cunnane, 1999; Brock and Tan, 2004). The sympathetic nerves located 
close to vascular smooth muscle cells have been shown to exist alongside sensory nerves 
that are able to release vasodilators (Kawasaki et al., 1988).  
 
1.1.2 Pre- and Post-Junctional Receptors 
 
When the nerves are stimulated electrically, NA and ATP are released from the nerve 
terminals where they can then exert their effects on receptors located pre-junctionally, on 
the nerve terminal or post-junctionally, on smooth muscle cells. Post-junctional α1- and α2-
ARs can be activated by NA, and ATP can act at post-junctional P2X receptors (Brock and 
26 
 
Cunnane, 1999). Activation of these post-junctional receptors results in vessel constriction. 
The α2-ARs have also been shown to exist pre-junctionally and activation of these receptors 
inhibits further neurotransmitter release from the nerve terminals (Msghina et al., 1992; 
Starke et al., 1974; Langer, 1974). 
 
1.1.3 Post Receptor Mechanisms of Contraction 
 
The α-ARs belong to the G-protein-coupled receptor (GPCR) superfamily and are made up 
of 7 transmembrane domains which have three intracellular and three extracellular loops 
(Graham et al., 1996). The GPCRs are an extensive family of receptors which are involved 
in numerous processes within the body including regulation of the immune system and 
behavioural and mood regulation. Physiological mechanisms within the vascular system are 
regulated by noradrenaline and adrenaline (Vargas and Gorman, 1995). 
 
The α1-ARs belong to the subset of the GPCRs which also includes the α2-ARs. Located in 
the intracellular space is the C-terminus, with the N-terminus located in the extracellular 
space. The agonist binds to the ligand binding site which is formed by the collection of the 
7 α helical domains. When an agonist binds to the extracellular ligand binding site, a signal 
is passed to an intracellular receptor bound specific Gq subunit (Ruffolo et al., 1991). In the 
α1-ARs the specific G protein is either Gαq/11, Gα14 or Gα16 depending on the α1-AR subtype 
which is being activated. When noradrenaline binds to the α1-AR it activates the specific G 
protein. When the Gα sub-unit is in its inactivated state it is associated with β and γ subunits. 
These subunits dissociate when the adrenoceptors are stimulated and guanosine diphosphate 
(GDP) is converted into guanosine triphosphate (GTP). This leads to activation of 
phospholipase C (PLC). PLC cleaves phosphoinositol-4,5-bisphosphate (PIP2) into 1,2-
diaclycerol (DAG) and inositol-1,4,5-triphosphate (IP3) (Uberti et al., 2003). 
Phosphoinositide specific-phospholipase C (PI-PLC) β1 is the PLC activated by the Gαq/11, 
Gα14 or Gα16 subunits (Wu et al., 1992). IP3 interacts with the calcium channel on the 
endoplasmic reticulum which in turn leads to the release of calcium from the intracellular 
stores. This increase in [Ca2+]i leads to vasoconstriction. The release of Ca
2+ acts 
synergistically with DAG to activate protein kinase C (PKC). The activation of PKC leads 
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to phosphorylation of specific target proteins which in turn controls the cell and alters 
function (Minneman, 1988). 
 
The α2-ARs also belong to the GPCR superfamily but have a different mechanism upon 
activation. When an agonist binds to the ligand binding site, the intracellular Gα subunit 
dissociates from the β and γ subunits and GDP is converted to GTP. The GTP binding protein 
binds Gi. These proteins are known as inhibitory proteins as the Gi sub-units inhibit adenylyl 
cyclase enzymes. When the adenylyl cyclase enzyme is in its active form it is responsible 
for converting ATP into the second messenger cyclic AMP (cAMP). Formation of cAMP 
leads to activation of protein kinases which allow important cellular functions to be regulated 
(Tan et al., 2007). Therefore, the inhibition of adenylyl cyclase leads to a decrease in ion 
transport and ion channel function which increases cell excitability leading to smooth muscle 
contraction. 
 
It is not yet fully understood how activation of α2-ARs initiates depolarisation. However, 
some lab groups have investigated possible mechanisms. Tan et al. published data indicating 
that the inhibition of the ATP-sensitive K+ (KATP) channels is involved in membrane 
depolarisation in the rat tail artery. NA acting on post-junctional α2-ARs inhibits the KATP 
channels (Tan et al., 2007)    
 
1.2 α-Adrenoceptors (AR) 
 
Knowledge of the adrenoceptors (ARs) has been developing over the last 100 years; from 
the discovery of a vasoconstriction induced by adrenaline by Dale in 1906 (Dale, 1906) to 
the present recognition of three major groups of ARs and 9 AR subtypes. The effects on the 
cardiovascular system of several sympathomimetic amines were tested to advance Dale’s 
early discovery. From these results the terms α and β-adrenoceptors were suggested as the 
potency values recorded for the studied amines differed between the two proposed receptors 
(Ahlquist, 1948). The separation into α and β was confirmed in 1957 by the discovery of 
dichloroisoprenaline which was found to antagonise β- but not α-ARs (Powell and Slater, 
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1958) and further determined through concentration response curve studies in 1967 
(Furchgott, 1967). Langer and Starke et al. both discovered the division of α1- and α2-ARs 
which were then further subdivided in the 1980s (Langer, 1974; Starke et al., 1974). The AR 
subtypes are now recognised as α1A-, α1B-, α1D-, α2A-, α2B-, α2C-, β1-, β2- and β3-ARs. 
 
1.2.1 α1-Adrenoceptors 
 
Experiments carried out in the 1980s by different lab groups confirmed evidence that the α1-
ARs can be subdivided further. Coates et al., in 1982, investigated the effects of SGD 101/75 
and phenoxybenzamine on the rat anococcygeus. SGD 101/75 is a full agonist at α1-ARs in 
the rat anococcygeus. Weetman’s group concluded that there must be at least two subtypes 
present due to the results they obtained (Coates et al., 1982). The varying potencies of the 
antagonists yohimbine and prazosin on the α1-ARs of several isolated vessels was shown in 
1985 (Drew, 1985). Building on this, Flavahan and Vanhoutte divided the α1-ARs into the 
α1H- and α1L-ARs and discovered that the same antagonist could have different affinities at 
the receptors and so deduced that the adrenoceptor must have different subtypes (Flavahan 
and Vanhoutte, 1986). Muramatsu et al. (1990) also attempted to classify the α1-ARs. They 
employed five competitive α-AR antagonists and the irreversible antagonist 
chlorethylclonidine. Their results were in line with those from Flavahan and Vanhoutte. 
However, they presented a new α1-AR subtype, which they named α1N to represent the results 
that neither pointed to a high nor low affinity to the antagonists (Muramatsu et al., 1990). As 
well as the proposed nomenclature from Flavahan and Vanhoutte in 1986, Morrow and 
Creese also proposed a sub-classification of the α1-ARs. These were termed α1A- and α1B-
ARs and referred to binding sites identified through radioligand binding studies. 
Competition curves were constructed for [3H]prazosin and [3H]WB4101 which showed a 
high and low affinity component assigned α1A- and α1B-AR respectively (Morrow and 
Creese, 1986). Further radioligand binding techniques carried out in rat tissue using urapidil 
derivatives also established two distinct α1-AR binding sites. In these  results, the rat tissues 
used gave different affinity constants upon displacement of prazosin from its binding sites 
by 5-methyl-urapidil (Hanft and Gross, 1989). Molecular cloning in 1990 by Schwinn et al. 
led to the discovery of the α1C-AR subtype (Schwinn et al., 1990) and prompted lab groups 
to study the receptor pharmacology.  
29 
 
Competitive antagonists were used to compare their affinities towards the α1A- and α1C-ARs 
and it was discovered that the affinities were very similar and so the α1C-ARs are now 
accepted as the α1A-ARs (Ford et al., 1994). Lomasney et al. discovered a further subtype 
through a cDNA clone that they reported was similar to the α1a-AR subtype yet experiments 
carried out by Perez et al., discovered that this receptor subtype had a low affinity for 5-
methylurapidil and (+)-niguldipine both of which are selective α1A-AR antagonists 
(Lomasney et al., 1991; Perez et al., 1991). This novel subtype was named as the α1d-AR 
and was cloned in 1994 (Forray et al., 1994). 
 
The α1b-AR was cloned in 1988 from the cDNA of the Syrian hamster. A 515-residue 
polypeptide makes up the amino acid sequence. At the time when the affinity binding studies 
split the α1-ARs into two subtypes; α1A- and α1B-ARs, the cloned receptor was most similar 
to the α1B-ARs (Cotecchia et al., 1988). Cloning of the α1a-AR occurred two years later 
through the use of the bovine cDNA library. The amino acid sequence had a 466-residue 
polypeptide and the receptor was shown to have a 10-times greater affinity for WB4101 and 
phentolamine compared to the α1B-ARs. This cloned receptor was linked to the α1A-ARs 
(Schwinn et al., 1990). A final α1-AR subtype was cloned in 1991 and was inactivated by 
chlorethylclonidine. At the time, chlorethylclonidine was thought to act selectively at α1B-
ARs. However, the cloned receptor had a 560 amino acid protein which differed from the 
cloned α1b-AR subtype and so this novel subtype was named the α1d-AR (Perez et al., 1991).  
 
At the time of discovery of post-junctional α2-ARs, receptor reserves in the arteries were 
shown to have more α1-ARs than α2-ARs. In some cases, the difference was found to be five-
fold (Ruffolo and Yaden, 1984). This therefore means that even when the α2-ARs are being 
activated at their highest level, it still does not reach the maximum response achieved by the 
α1-ARs (Flavahan and McGrath, 1984). It is recognised and accepted that the α1A-ARs are 
involved in mediating changes in blood flow and regulating blood pressure whereas the α1D-
ARs are involved in contraction of the smooth muscle of large conduit vessels. The α1B-ARs 
are thought to play a minor role in all processes concerning the maintenance of vascular 
resistance and blood pressure (Daly et al., 2002).  
 
30 
 
The α1A-AR subtype has been shown to be involved in contraction of the mouse mesenteric 
arteries. Ibarra’s group used the α1A-AR selective agonist A61603 and found it had a 235-
fold higher potency at the ARs than phenylephrine. The α1B- and α1D-AR alkylating agent 
chlorethylclonidine only slightly altered the contraction from A61603 addition (Villalobos-
Molina et al., 2006). Further evidence of the role played by the α1A-ARs in the mouse 
mesentery was published by Methven et al. in 2009. α1BD-AR KO mice were used to isolate 
the α1A-AR subtype. Pharmacological experiments revealed that there is a greater contraction 
in the mesenteric arteries through α1A-AR activation compared with the carotid arteries 
(Methven et al., 2009a). The α1A-AR subtype selective agonist A61603 was utilised in 
studies concerning the rat tail artery. Vessel contractions in response to NA were found to 
be due to the activation of at least two α1-AR subtypes. Pharmacological studies involving 
A61603 revealed one of the subtypes to be the α1A-AR as vessel response to NA and to 
A61603 was similar suggesting that the α1A-AR subtype plays a large role in contraction of 
the rat tail artery (Lachnit et al., 1997). 
 
Cavalli et al. employed α1B-AR KO mice to study the functional role of the α1B-AR subtype 
and discovered that the mice lacking the α1B-AR had an overall decrease in α1B-AR sites in 
the liver, heart and cerebral cortex. Results from reverse transcription-PCR and ligand 
binding studies indicated that the α1B-ARs mediate the control of blood pressure in the mouse 
(Cavalli et al., 1997). However, published work by Zuscik et al. described the α1B-AR as 
being associated with metabolic and cellular responses rather than playing a central role in 
vasoconstriction. Their results were obtained from experiments carried out using transgenic 
mice overexpressing the α1B-AR subtype (Zuscik et al., 2001).  
 
The α1D-ARs have been shown to be the main α-AR subtype in the conduit arteries with 
Martinez et al. showing that even after myocardial infarction and with congestive heart 
failure, the α1D-AR population remains and continues to function in the rat (Martinez et al., 
1999). The α1D-ARs have been isolated using α1AB-AR KO mice and the carotid and 
mesenteric arteries studied. These are examples of conduit and resistance arteries 
respectively. The α1D-ARs were shown to contribute to vasoconstriction in both vessels but 
had a larger impact in the conduit artery (Methven et al., 2009b).  
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As well as adrenaline and noradrenaline being agonists at α1-ARs; there are more specific 
agonists and antagonists for the α1-ARs and the individual subtypes. Agonists selective to 
the α1-ARs relative to the α2-ARs include phenylephrine, methoxamine and cirazoline and 
the receptors are antagonised by prazosin and corynanthine. There are few selective agonists 
and antagonists for the individual receptor subtypes with the α1B-AR having no known 
selective agonists or antagonists. The α1A-ARs are activated by A61603 and antagonised by 
tamsulosin, sildosin and (+)niguldipine. The α1D-ARs have one accepted antagonist which 
is BMY7378 (Alexander et al., 2013).  
 
1.2.2 α2-Adrenoceptors 
 
Docherty and McGrath produced evidence for two types of post-junctional α-AR. They 
tested known agonists, with dose-response and frequency response curves. Results indicated 
a ‘prazosin-resistant’ post-junctional α-AR which did not fit the criteria of the α1-ARs but 
did have similarities to the pre-junctional α2-ARs (Docherty and McGrath, 1980; McGrath, 
1982). In 1985, Bylund looked at rodent and non-rodent mammalian species in order to 
determine the pharmacological properties of the α2-ARs. He proposed that the α2-AR could 
be subdivided into α2A- and α2B-AR based on their relative affinity towards prazosin. This 
assumption was based on the different affinity values for prazosin between the rodents and 
the non-rodents (Bylund, 1985). Further pharmacological studies in the rat brain by Petrash 
and Bylund confirmed the earlier finding of a α2A- and α2B-AR. [3H]yohimbine, an α2-AR 
antagonist, was used in experiments to determine how effective prazosin and 
oxymetazoloine were at inhibiting the binding of [3H]yohimbine to the α2-ARs. Different 
inhibition curves were constructed from blood vessels taken from the cerebral cortex, 
cerebellum and human caudate nucleus that confirmed the concept of more than one α2-AR 
(Petrash and Bylund, 1986). As more agonists and antagonists were discovered, more 
experiments in 1988 and 1989 were carried out to further prove the belief of multiple α2-AR 
subtypes (Bylund et al., 1988; Young et al., 1989). Bylund et al. used [3H]yohimbine and 
oxymetazoline to determine the drug affinities of many α2-AR antagonists that had been 
discovered through radio-ligand binding studies. Young et al. furthered these results in 1989 
when studying α2-ARs in rat and human tissues (Young et al., 1989) confirming, along with 
other labs at the time, that the results from Bylund’s experiments were reproducible and 
taken to be correct. Brown et al. conducted experiments in 1990 which also revealed, through 
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saturation and displacement studies, that the α2-ARs could be subdivided into α2A- and α2B-
ARs (Brown et al., 1990b; Brown et al., 1990a). Following the discovery of the α2A- and 
α2B-ARs, the possibility of further subtypes was investigated. In 1988, Murphy and Bylund 
produced evidence in support of a third receptor subtype; α2C-AR. This receptor is similar to 
the α2B-AR subtype but has a higher affinity for [3H]rauwolscine (Murphy and Bylund, 
1988).  
 
The cloning of the α2-AR subtypes occurred before the α1-ARs with the α2a-AR subtype 
being first cloned in 1987 by Kobilka et al. Xenopus laevis oocytes had the cloned receptor 
expressed and experiments revealed that the α2-AR agonists bound. The subtype was found 
to have a high affinity for yohimbine and rauwolscine and low affinity for prazosin as well 
as a similar amino acid sequence to that of the β1-ARs (Kobilka et al., 1987). The α2b-AR 
subtype was then cloned from human kidney cDNA. The subtype had a similar structure to 
the α1a-AR subtype. The subtype bound rauwolscine and had an amino acid sequence 
comparable to the α2a-AR. However, the subtype cloned had a high affinity for prazosin and 
low affinity for oxymetazoline as compared with the α2a-AR and so was named as being the 
α2B-AR (Regan et al., 1988). In 1990, the α2c-AR subtype was cloned. Different 
adrenoceptors ligands were tested which produced different binding properties. These results 
showed a unique pharmacology which could not be determined as either of the previously 
cloned α2-ARs. The subtype is made up of 250 amino acids and is located on chromosome 
2 and was designated as the α2C-AR (Lomasney et al., 1990).  
 
The development of knock-out models for each of the α2-AR subtypes has enabled the 
function of each of these subtypes to be studied. The α2A-D79N mice have point mutation at 
position 79 and were developed to gain greater understanding of the signal transduction 
mechanisms. However, further investigation into these mice revealed that as the receptors 
were unable to couple to K+ and Ca+ channels, the α2A-D79N mice could effectively act as 
α2A-AR KO mice (Lakhlani et al., 1997). The KO studies have shown the α2A-AR to be the 
main α2-AR subtype responsible for maintaining blood pressure. The α2-ARs have been 
described as mediating ‘Classical Effects’ upon activation via agonists with these effects 
including hypotension and sedation (Kable et al., 2000). In the α2A-AR KO and α2a-D79N 
mice, the agonist-induced hypotensive effect was abolished and the α2A-D79N mice did not 
responsd to the α2-AR selective agonist dexmedetomidine which reduces locomotor activity 
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in WT mice (Hunter et al., 1997). This discovery highlighted the importance of the α2A-AR 
subtype as these same experiments carried out in the α2B- and α2C-AR KO mice did not yield 
the same results (Link et al., 1996; Hunter et al., 1997). 
 
The α2B-AR subtype has been shown to contribute to the hypertensive response in mice as 
this response is abolished in the α2B-AR KO mice when they are exposed to the α2-AR 
agonist dexmedetomidine (Link et al., 1996). 
 
Scheinin’s lab has carried out experiments using the α2C-AR KO mice and mice over-
expressing (OE) the α2C-AR (α2C-OE) subtype in an attempt to define its functionality. 
Results suggest that the α2C-ARs are involved in brain regulation of dopamine and its 
metabolites as the α2C-AR KO mice have decreased levels of dopamine and the α2C-OE mice 
have raised levels of dopamine (Sallinen et al., 1997). Further studies revealed an indication 
that the α2C-ARs may be involved in stress-dependent depression as increasing levels in the 
α2C-AR KO and α2C-OE mice yielded different results (Sallinen et al., 1999). Other than 
these results, the α2C-AR subtype is believed to be a ‘silent’ receptor with no definite role in 
maintaining the homeostasis of the cardiovascular system. Some studies have implicated the 
subtype in thermoregulation as cold induces a translocation of the α2C-ARs to the cell surface 
(Bailey et al., 2004). 
 
As well as adrenaline and NA, there are other more specific agonists and antagonists for the 
α2-ARs and the individual subtypes. Relative to the α1-ARs, the agonists UK14304 and 
BHT920 are selective towards the α2-ARs. The antagonists selective for the α2-ARs relative 
to the α1-ARs are rauwolscine and yohimbine. For the α2-AR subtypes, only the agonist 
oxymetazoline has been found to be selective for the α2A-ARs with no known selective 
agonists for the other subtypes available. BRL44408 is a selective antagonist at α2A-ARs and 
imiloxan is selective for the α2B-ARs. The antagonist JP1302 is selective towards the α2C-
ARs (Alexander et al., 2013). 
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1.3 Adenosine Tri-Phosphate (ATP) in Arterial Vessels 
 
ATP, in the early 1970s, was believed to be the non-adrenergic non cholinergic (NANC) 
neurotransmitter released from the nerves that exerted their effects at the gastrointestinal 
tract (Burnstock et al., 1970). Following on from this, Burnstock et al. investigated the 
NANC response from other tissues and compared these responses to those elicited by 
exogenously added ATP. The results outlined the difference between the vessel response to 
NA and to ATP; slow and fast respectively and this fast response to ATP was mimicked by 
non-adrenergic non-cholinergic (NANC) inhibitory nerve stimulation (Burnstock et al., 
1972). As well as ATP release from NANC nerves, it was also proposed at the time that ATP 
could be co-released from vesicles containing NA (Burnstock, 1976; Kasakov and 
Burnstock, 1983).  
 
1.3.1 P2X Receptors 
 
In 1972, evidence was presented that showed that released ATP stimulated P2 receptors 
which lead to a depolarisation (Burnstock, 1972). To date, seven P2X purinoceptors have 
been identified (P2X1-7) and divided into different groups based on their efficacy towards 
various agonists. Group 1 belongs to the group of P2X receptors with a high affinity for ATP 
and rapid desensitisation. P2X1 and P2X3 are included in this group. Groups 2 and 3 
represent the receptors with low and very low receptor affinity for ATP respectively 
(Burnstock and Williams, 2000). The predominant P2X receptor subtype in smooth muscle 
cells is the P2X1 receptor which has been shown to be present in rat tail artery and mouse 
mesenteric arteries (Evans and Kennedy, 1994; Vial and Evans, 2002). In the mouse 
mesenteric arteries, the vasoconstriction due to P2X receptor activation is lost in P2X1 
deficient mice and the P2X1 receptors have been shown, using immunofluorescence and 
microscopy techniques, to be grouped together in clusters opposite from the nerve 
varicosities (Vial and Evans, 2002; Hansen et al., 1999). Patterns of stimulation of low 
frequency (< 1 Hz) stimulations favours contraction through P2X receptor activation in rat 
mesenteric arteries (Lamont and Wier, 2002).  
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The mechanism of action of the P2 receptors is via ion channels which are gated by 
extracellular ATP. A rapid response ensues upon activation which leads to depolarisation 
within milliseconds compared to depolarisation via α-ARs which take seconds to initiate. 
The ATP released from nerve terminal vesicles acts at the post-junctional P2X receptors in 
the vascular smooth muscle or pre-junctionally to modulate transmitter release. After release 
and activation of P2X receptors by ATP, ectoATPases hydrolyse the ATP to adenosine and 
the presence of adenosine has been shown to reduce transmitter output (Huidobro-Toro and 
Donoso, 2004). 
 
Kasakov and Burnstock demonstrated that the agonist α, β, methylene ATP (αβme-ATP) 
could act selectively on P2-purinoceptors. This resulted in desensitisation of the receptors 
due to the slowly degradable nature of αβme-ATP (Kasakov and Burnstock, 1983). Suramin 
has been shown to effectively antagonise P2 receptors in the mouse vas deferens; tested 
against the agonist αβme-ATP (Dunn and Blakeley, 1988). Experiments carried out in 1993 
by Bao and Stjarne revealed an increased response to NA after desensitisation of P2X 
receptors by αβme-ATP. They proposed that desensitisation of the P2X receptors removes 
an ATP inhibitory effect (Bao and Stjarne, 1993).  
 
1.4 Calcitonin Gene-Related Peptide (CGRP) 
 
The sensory nervous system is comprised of cell bodies located in spinal and cranial sensory 
ganglia with axons projecting centrally and peripherally. To maintain homeostasis, the 
sensory nerves respond to alterations in the internal and external environments. However, 
the sensory nerves can also exert effects locally, including vascular smooth muscle 
relaxation (Lee et al., 1978). 
 
The neuropeptide CGRP was discovered in 1983 by tissue-specific RNA processing 
(Rosenfeld et al., 1983) with CGRP containing nerves shown to be present throughout the 
sensory nervous system (Dhall et al., 1986; Tornebrandt et al., 1987). CGRP binding sites 
were found, by radioligand binding studies, to be numerous in the rat mesenteric arteries 
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(Wimalawansa and MacIntyre, 1988). The distribution of CGRP containing nerves 
throughout the guinea pig mesenteric arteries was shown by Uddman et al. who 
demonstrated that with raised vessel tone, addition of CGRP induced a relaxation which 
became more pronounced with increasing concentrations of CGRP (Uddman et al., 1986). 
 
Transient receptor potential vanilloid (TRPV) channels are found on sensory nerves and 
activation of TRPV1 receptors (also known as VR1) via nerve stimulation has been shown 
to cause release of CGRP (Wang et al., 2006). The VR1 receptor was cloned in 1997 and 
activation of the channel was shown to be voltage sensitive; having a high permeability to 
Ca2+. The continued excitation of this receptor, now linked to CGRP release, leads to 
desensitisation of the receptor whilst in the presence of extracellular Ca2+ (Caterina et al., 
1997). 
 
As the VR1 receptor can be desensitised, it is possible to deplete the sensory nerves of CGRP 
and thus remove the vasodilatory effect. The sensory neurotoxin capsaicin is able to do this. 
CGRP concentrations in the rat have been shown to originate mainly from capsaicin-
sensitive perivascular nerves (Zaidi et al., 1985). In perfused rat mesenteric arteries with 
raised tone, peripheral nerve stimulation elicited a relaxation that could be inhibited by 
capsaicin pre-treatment (Kawasaki et al., 1988). Fujiwara et al. have now shown this in the 
mouse mesenteric arteries and conclude that the arteries are densely innervated by CGRP 
containing nerves (Fujiwara et al., 2012). Excitatory junctional potentials (EJP) in rat 
mesenteric arteries have been potentiated when pre-incubated with capsaicin to remove 
CGRP (Dunn et al., 2003). It is therefore possible in the mouse vessels that the full 
contractile effect to nerve stimulation may be masked by CGRP release.   
 
1.5 Genetically Altered Mice 
 
In the early 1970s, lab groups began experimenting on the genetics of mice in the hope of 
developing genetically altered mice that could be used to study disease states and investigate 
which receptors may be specifically involved. This was first achieved in 1974 by Rudolph 
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Jaenisch who inserted a DNA virus into the mouse embryo. This attempt was not a success 
as the DNA virus was not present in the next generation of mice bred (Jaenisch and Mintz, 
1974). However, following two years of continuing research Jaenisch successfully 
manipulated a mouse embryo genome with Moloney murine leukaemia virus proviral DNA. 
The disease was effectively transmitted to the germ line of the resulting adults which was 
shown by the development of leukaemia in the animals (Jaenisch, 1976; Jaenisch, 1979). 
This technique has been developed and utilised by many to improve on knowledge of various 
disease states including cardiovascular disease. Uncovering the roles of the α1-AR subtypes 
using overexpression and KO techniques should contribute to this knowledge as the α1-ARs 
are believed to be crucial in the maintenance of vascular tone. Of particular interest to the 
topic of this project is the development of mice lacking the α1A- and α1D-AR subtypes 
(ADKO) and mice lacking all of the α1-AR subtypes (α1-null).  
 
1.5.1 Transgenic Mice 
 
There have been investigations into the α-ARs using mice with an overexpression of a 
particular receptor subtype. Overexpression of the α1B-AR was achieved by coupling of the 
mutant gene to a α-myosin heavy chain promoter. Results suggested that the α1B-ARs are 
involved in the development of cardiac hypertrophy (Milano et al., 1994). Furthermore, the 
α1B-ARs, through overexpression studies, have also been shown to be implicated in blood 
pressure regulation as the transgenic mice were hypotensive. However, contractile responses 
in the mesentery were not altered from WT response (Zuscik et al., 2001). Mice with an α1A-
AR overexpression have also been developed with results suggesting these receptors are 
involved in cardiac contractility (Lin et al., 2001). However, there have been no other 
overexpression studies which concentrated on vessel contractility and response.  
 
1.5.2 Knock-Out Mice 
 
The mouse is a good candidate for gene knock-out (KO) studies as it has a sequenced genome 
which is suggested to be 75 % similar to humans (Church et al., 2009) and they have a short 
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generation time, meaning many experiments can be carried out in a short space of time. The 
generation of mice lacking either one, two or three α-AR subtypes have been developed. 
 
The first knock-out mouse was developed in 1997 and was the α1B-AR KO. The hamster α1b-
AR DNA was used as a probe to screen the 129/Sv mouse genomic library. The first exon 
of the mouse α1b-AR was replaced by a 1.6 Kb cassette containing the neomycin resistance 
gene within the pBlueScript vector. The vector was then electroporated into 129 embryonic 
stem cells (ES). C57Bl/ 6J mouse blastocysts received the ES clone via microinjection before 
being transferred to pseudopregnant NMRI females. Of the seven mice that were mated, two 
contained the disrupted allele and were therefore α1B-AR KO mice (Cavalli et al., 1997). 
 
The initial experiments carried out by Cavalli et al. suggested that the α1B-ARs were 
important mediators of blood pressure and aortic contractility (Cavalli et al., 1997). 
However, further experiments have suggested more of a minor role for the α1B-ARs in the 
vasculature. The mouse aorta, carotid, mesenteric and tail arteries were employed alongside 
known antagonists. They were tested against the agonist phenylephrine and concentration 
response curves constructed. Results indicated a definite role for the α1A-and α1D-AR 
subtypes and a minor vasoconstrictor role for the α1B-ARs (Daly et al., 2002). Deighan et al. 
proposed that the α1B-ARs played a regulatory role in smooth muscle contraction of the 
mouse carotid arteries (Deighan et al., 2005). 
 
Rokosh and Simpson developed the α1A-AR KO mice utilising the same technique as Cavalli 
et al. The neomycin resistance gene was located in the vector alongside the Ecoliβ-
galactosidase gene Laz C cassette before being electroporated into RW-4 129/SVJ mouse 
ES. These cells were then transferred into C5Bl/6 blastocysts with the targeted allele 
successfully transmitted through the germ line (Rokosh and Simpson, 2002). 
 
The initial experiments by Rokosh and Simpson showed the α1A-AR KO mice to be 
hypotensive and concluded that the α1A-ARs must be important in blood pressure 
maintenance (Rokosh and Simpson, 2002).  
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The α1D-AR KO was generated in 2002 by Tanoue et al. who followed a similar protocol to 
that of Cavalli et al. The first exon of the α1D-AR gene was replaced by the neomycin 
resistance gene cassette and 129V ES. The ES were microinjected into pseudopregnant 
females. The male mice produced were mated with C57Bl/ 6J mice with litters genotyped to 
detect the α1D-AR KO strain (Tanoue et al., 2002). 
 
The initial experiments revealed the α1D-AR KO mice to have a lower systolic and mean 
arterial blood pressure. Contractile responses in the mesentery and aorta were reduced 
suggesting a definite role for α1D-ARs in the contractile response (Tanoue et al., 2002). 
Hosoda et al. also reported a lowered systolic and mean arterial blood pressure in the α1DAR 
KO mice (Hosoda et al., 2005). 
 
The α1AB-AR KO mouse was developed by crossing both the α1A- and α1B-AR KO mice. The 
male KO mice had a smaller heart size due to smaller myocytes. However, this did not impact 
on the blood pressure (O'Connell et al., 2003). Further investigations into the α1AB-AR KOs 
focussed on the adrenoceptors influence in the carotid and mesenteric arteries. Concentration 
response curves to phenylephrine were unchanged in the carotid arteries of the KO mouse 
but the pEC50 was altered in the mesenteric arteries. This supports the theory that the α1D-
ARs are the main functional subtype in the carotid arteries and the α1A-ARs drive the 
response in the mesenteric arteries (Methven et al., 2009b).  
 
The α1BD-AR KO mouse has also been generated and systolic and mean arterial BP recorded. 
The mean arterial BP was significantly reduced in α1BD-AR KO mice as was the response to 
the phenylephrine induced pressor response in the perfused mesenteric arteries (Hosoda et 
al., 2005). The development of the α1BD-AR KO allows isolation of the α1AARs which was 
then studied in the carotid and mesenteric arteries. The contractile response to phenylephrine 
was not altered in the mesenteric arteries but was greatly reduced in the carotid arteries, 
providing further evidence of the α1D-ARs role in being the main contributor in the carotid 
arteries (Methven et al., 2009a). 
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The α1AD-AR KOs have now been developed and studies are ongoing to determine the effect 
of loss of these receptor subtypes has on vascular contractility. Based on previous 
experiments, these mice would be expected to be hypotensive and display a reduced 
contractile response in the mesenteric arteries and in the aorta. 
 
The development of α1-null mice is relatively new and so there have been a limited number 
of investigations published. Some lab groups have had difficulty in breeding these mice and 
have published evidence in support of ejaculatory dysfunction in the α1-null mice. However, 
the mice that have been bred have been shown to develop normally and survive for at least 
one year. Aside from ejaculatory dysfunction, the mice also have a lower systolic blood 
pressure (Sanbe et al., 2007). This lab group have also reported an increase in sensitivity 
towards 5-hydroxytryptamine (5-HT) in the aorta of α1-null mice compared with WT 
response and suggest that the α1-ARs may play a regulatory role in connection with other 
vasoconstrictor mechanisms (Sanbe et al., 2009). 
 
1.6 Justification of Utilised Vessels 
 
The mouse and rat mesenteric arteries have been studied extensively; particularly studies 
utilising agonist and antagonist responses in isolated vessels. Previous studies show that in 
this vessel the α1-ARs predominate with some input from P2X receptors and no evidence of 
post-junctional α2-ARs (Daly et al., 2002; Martinez-Salas et al., 2007; Rummery et al., 
2007). Removal of the α1-ARs in the α1-null mice therefore simplifies post-junctional 
receptor pharmacology and allows isolation of the purinergic response and study of the pre-
junctional α2-AR population.  
 
In the rat tail artery, there are populations of α1-, α2-ARs and P2X receptors (Brock and 
Cunnane, 1999). Little is known of the response in mouse tail artery; particularly to nerve 
stimulation. It is beneficial to use the mouse tail artery due to the increase in development 
of genetically modified mice. However, before experiments can be carried out on the α1-AR 
deficient mice, WT response to nerve stimulation must be analysed to determine whether it 
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is similar to that in the rat or different. Removal of the α1-ARs in this preparation will allow 
a greater understanding of the α2-ARs and may uncover interactions between the 
adrenoceptors and the purinoceptors.  
 
In these WT and KO mouse vessels, results will further contribute to the literature using 
nerve stimulation techniques and various antagonists to determine which receptors are active 
throughout the response and in what way these receptors contribute to the response. 
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1.7 Aims and Objectives 
 
The development and advances in transgenic mouse models has enabled a more direct 
approach to studying individual receptors. The α1-ARs are considered to be the main 
mediators of constriction via vascular nerves. The genetic removal of these receptors should 
enhance understanding of α-AR function by simplifying the complex pharmacology within 
the vasculature and so reveal the other mechanisms of vascular neuroeffector control. 
Therefore, the main objectives of the research were: 
 
(i). To establish whether loss of the α1A- and α1D-ARs in the ADKO or loss of all three α1-
ARs in the α1-null has an effect on systolic blood pressure.  
 
(ii). To determine whether the vasodilatory neuropeptide CGRP affects the response to 
perivascular nerve stimulation in WT, ADKO and α1-null mouse mesenteric and tail artery 
preparations.  
 
(iii). To verify the post-junctional receptors involved in neurovascular transmission in WT 
mesenteric and tail arteries. 
 
(iv). To investigate the role of the α1B-ARs in neurovascular transmission in mouse 
mesenteric and tail arteries by utilising ADKO mice and to establish any compensatory 
mechanisms loss of the α1A- and α1D-ARs may have on the response.  
 
(v). To determine whether activation of the remaining receptors in the α1-null mice were able 
to induce a contractile response in the absence of the α1-ARs.   
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Chapter Two 
 
Materials and Methods 
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This Chapter describes the Methods and Materials used throughout the project. The 
genotyping of the mice is described in Section 2.2. The techniques used to extract the blood 
vessels and the measurement of their contractions are described in Sections 2.3 and 2.4. 
Section 2.5 provides details of the blood pressure monitoring techniques. Lastly, a 
description of the statistical techniques used for the analysis of the results obtained is given 
in Section 2.6 with a list of materials used provided in Section 2.7. 
 
2.1 Mice 
 
Mice used as controls were the C57 Black Jackson Wild Type (WT) strain. The genetically 
modified mice were originally provided as single α1-adrenoceptor (AR) subtype knockouts 
(KO). Dr Gregg Rokosh and Professor Paul C Simpson (Veterans Affairs Medical Centre, 
San Francisco, USA) provided the α1A-AR KO; Professor Susanna Cotecchia (University of 
Lausanne, Lausanne, Switzerland) provided the α1B-AR KO and Professor Gozoh Tsujimoto 
(National Children’s Medical Research Centre, Tokyo, Japan) provided the α1D-AR KO. The 
generation and background of the single knockouts have been described in detail (Rokosh 
and Simpson, 2002; Cavalli et al., 1997; Tanoue et al., 2002). 
 
Initially, double KO mice were generated by crossing the single KO mice with WT mice to 
produce F1 generation heterozygotes. These mice were then intercrossed to produce the F2 
generation which contained a mixture of all potential genotypes. WT mice produced from 
the F2 generation were bred to produce the control mice and the α1AD-AR KO (ADKO) mice 
were bred to produce more double KOs (Hosoda et al., 2005). The development of the α1D-
AR KO mice allowed the generation of triple KO (α1-null) mice in the same way as the 
double KOs. Two strains were bred specifically for the present studies.  First, the single KO 
mice were crossed to produce α1AB-AR KO (ABKO), α1BD-AR KO (BDKO) and α1AD-AR 
KO (ADKO) mice. The ABKO and BDKO mice were crossed to produce heterozygous 
α1ABD-AR mice. These mice contained the WT gene and the KO gene for each of the α1-AR 
subtypes. The heterozygous mice were crossed and the offspring genotyped to determine 
whether α1-null mice had been produced. 
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All mice used were bred at the University of Glasgow and maintained on a 12:12 hour 
light/dark schedule at 22-25°C with 45-65% humidity. They had unrestricted access to a 
standard chow diet and were provided with drinking water. All experiments utilised male 
mice aged 4-6 months weighing between 26g and 42g (WT 26g - 42g, ADKO 28g - 35g, α1-
null 26g - 35g). Mice were euthanased by the standard Schedule one carbon dioxide 
asphyxiation. The n numbers shown throughout represents the number of animals used and 
in each set of experiments only one vessel was used for each protocol. Therefore, where 
there is an n = 7, this represents seven vessels from seven animals.  
 
2.2 Genotyping 
 
2.2.1 Ear Clip collection 
 
All genetically modified mice were genotyped to ensure that the animals used were receptor 
knock-outs; either α1AD-AR KO (ADKO) or α1-null. The method employed involved 
clipping a small section from the ears of each animal. In cages containing multiple mice the 
ear clipping pattern was different for each mouse and a note kept of which pattern belonged 
to which mouse. Each ear clip was stored in a fresh sterile Eppendorf in the freezer ready for 
genotyping. 
 
2.2.2 Isolation of DNA 
 
Digestion buffer and proteinase K (10mg/1ml) were added to fresh sterile Eppendorfs. It was 
important to maintain a sterile environment to decrease any chance of contamination. The 
ear clips were then added to the solution. Proteinase K is an enzyme which breaks peptide 
bonds and thus frees the nucleic acids. The digestion buffer aids in this reaction, maintaining 
the pH and enhancing the proteinase K activity (Goldenberger et al., 1995). The Eppendorfs 
containing the ear clips were then agitated (‘Eppendorf; Thermomixer compact’) at 400 rpm 
at 55°C for approximately two hours. The samples were then vortexed and centrifuged (10 
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K for 5 minutes). This ensured that the ear clips were fully digested. A pellet containing 
those parts which did not digest was discarded following centrifugation.  
 
Fresh sterile Eppendorfs containing the precipitant isopropanol were prepared and the 
supernatant from the digest added. Since DNA is insoluble in this alcohol the isopropanol 
causes the precipitation of the nucleic acids. The solution was mixed by inversion until a 
white strand (nucleic acids) became visible. To isolate the nucleic acids, the Eppendorfs 
where centrifuged at 14 K for 10 minutes. This resulted in the formation of a pellet of nucleic 
acids. The isopropanol was replaced by 70% ethanol to aid the drying of the pellet. The 
samples were then centrifuged (10 K for 5 minutes) before the ethanol was removed. The 
pellet was then left to air dry. Finally, TE buffer was added to the pellet and it was then 
warmed to 55 °C for one hour. TE buffer contains tris(hydroxymethyl)aminomethane (Tris)  
(50 mM) which buffers the pH to 8.0 and ethylenediaminetetraacetic acid (EDTA) (100 mM) 
which chelates cations. It is a solvent for DNA and prevents its degradation (Ross et al., 
1990). The samples were then stored in the fridge.  
 
2.2.3 Polymerase Chain Reaction (PCR) 
 
The PCR technique allows the amplification of a DNA sequence to enable the detection of 
a particular gene. As each of the α1-AR KO mice strains have distinct genetic differences it 
is possible to determine, from analysing the genes of interest, which mice are ADKO and 
which are α1-nulls. 
 
The solution required for PCR must contain DNA polymerase, dNTPs 
(deoxyribonucleotides) (0.2 mM), primers (5 µM), and DNA. A PCR ‘Master Mix’ contains 
DNA polymerase which is responsible for the replication, and dNTPs which are the free base 
pairs required for building replicate strands. The primers are strands of nucleic acids that 
serve as a starting point for DNA synthesis. The primers are specific for each gene. For these 
mice, the genes for α1A-, α1B- and α1D-ARs were being targeted. Therefore, primers for each 
receptor, WT and KO, were required (Table 2-1). The primers  for detecting α1A- WT and 
α1A- KO differ enough in nucleic acid size that the reactions can be run together (within the 
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same mix). However, the others cannot and so four separate reactions are run. Once the 
reaction mixtures are prepared, they are pipetted into a PCR plate and the solution containing 
the DNA added to each well. 
 
 
Target 
Receptor 
Oligo Name Sequence (5' - 3') 
α1A-AR 
(duplex) 
a1A5'COM AGCTAACCATTTCAGCAAAGAC 
a1A3'1A CAAGATCACCCCAAGTAGAATG 
a1A3'LACZ TAACCGTGCATCTGCCAGTTTG 
α1B-AR WT 
ADRA1BCM159F CCAAAATGCTCCCAACTCTG 
ADRA1BCM2022R CCTGCAGGTATGAGGTCTGTG 
α1B-AR KO 
NEO1A1B ATTTGTCACGTCCTGCACGAC 
ADRA1BCM2022R CCTGCAGGTATGAGGTCTGTG 
α1D-AR WT 
ADRA1DCM013F GACATCCTGAGCGTCACTTTC 
ADRA1DCM293R GCTAGGAAGACACCCACTCC 
α1D-AR KO 
NeoCM2373F CTTTGTTAAGAAGGGTGAGAACAGAG 
ADRA1DCM293R GCTAGGAAGACACCCACTCC 
 
 
The PCR cycle begins by warming up the samples. This denatures the DNA, separating the 
strands. The temperature is then reduced to allow the annealing of the primers to their target 
sequences. Taq polymerase then begins to copy the template strands. This cycle is then 
repeated multiple times to amplify the quantity of DNA in the samples.  
 
2.2.4 Gel Electrophoresis 
 
Gel electrophoresis allows the nucleic acid fragments to be viewed directly therefore, 
allowing the genotypes to be identified. The gel is made up by dissolving agarose in TAE 
buffer. This buffer is made up of Tris, acetic acid and EDTA and allows the samples to move 
through the gel in response to an electrical current. The bands appear separately on the gel 
due to the nucleic acid composition in each sample. The nucleic acids migrate towards the 
positive electrode due to the number of negative charges they carry, meaning they are 
Table 2-1: Information from Sigma Aldrich showing primers used in PCR 
protocol. 
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attracted to the positive electrode when placed in an electrical field.  Larger nucleic acids 
take longer to move through the gel compared to shorter nucleic acids which are able to 
move through the pores in the gel more easily. Ethidium bromide is added to the mixture as 
this binds between the DNA bases and fluoresces orange when illuminated with ultraviolet 
(UV) light. The gel mixture is poured into a tray and plastic combs are inserted to create the 
wells for the samples.  
 
Once set, the combs are removed and the gel is submerged in TAE buffer in a gel tank. A 
field of 180V is then set up across the buffer and gel. The samples are run alongside a DNA 
ladder which acts as a standard and provides information on the size of the nucleic acids. 
After 30 - 40 minutes, the gel is viewed under UV light. A picture of the gel is taken and the 
mouse genotype is determined (Figure 2-1). 
 
 
 
 
 
 
 
 
2.3 Dissection 
 
2.3.1 Tail Artery 
 
The underside of the mouse tail was marked with a black marker pen, close to the base of 
the tail, in order to locate the tail artery. The tail was then cut near the base of the tail and 
pinned to a clean petri dish containing fresh physiological saline solution (PSS). The 
Figure 2-1: Example of gel results photograph detailing each of the PCR mixture 
outcomes.  
A duplex B WT 
B KO 
D WT 
D KO 
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composition of the PSS was as follows (in mM): 119 NaCl, 4.7 KCl, 1.2 MgSO4.H20, 1.2 
KH2PO4, 24.9 NaHCO3, 2.5 CaCl2 and 11.1 glucose.  Pins were placed at the base of the tail 
and 2 cm from the base to secure. With the aid of a Zeiss dissecting microscope and 
dissection instruments, the tail skin and membranous sheath were removed to expose the 
artery. A 4 mm section starting 2 cm from the base of the tail (“proximal segment”) was then 
removed and stored in fresh PSS. Another pin was then placed 5 cm from the base of the tail 
and the process repeated in order to remove a 4 mm section starting 5 cm from the base of 
the tail (“distal segment”). Both segments of tail artery were cleared free of fat and cut into 
two pieces ready for experimental use.  
  
2.3.2 Mesenteric Arteries 
 
A section of the mesentery containing several mesenteric arcades was removed from the 
abdominal cavity and pinned out in a clean petri dish containing fresh PSS. The superior 
mesenteric artery was located in order to determine the position of first order mesenteric 
arteries which branch off from it. Four first order mesenteric arteries were cleared free of 
fat, removed from their junction with the superior mesenteric artery, and cut into 2 mm 
pieces ready for experimental use.  
 
2.4 Myography 
 
2.4.1 Wire Myograph 
 
The ability to study mechanical responses in vessels with a small diameter (<300 µm) was 
facilitated by the introduction of the wire myograph in 1976 by Mulvany and Halpern 
(Mulvany and Halpern, 1976).  The myograph used in all myography experiments contained 
four stainless steel 8 ml baths (Multi Myograph model 610M, Danish Myotechnology, 
Aarhus, Denmark) (Figure 2-2). Each bath contained two heads; one attached to a 
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micrometer allowing length adjustments and the other attached to the force transducer which 
measures the force produced by the vessel. The term ‘the response’ is used throughout to 
describe the force produced by the vessel. Silver plates mounted within the heads functioned 
as the stimulating electrodes. Each bath contained 8 ml PSS which was continually gassed 
with 95% O2/ 5% CO2 and kept at a temperature of 37°C. A suction tube was used to remove 
PSS from the baths when fresh PSS was added. Responses were recorded from the transducer 
via an ADI Powerlab (4/20) and displayed in grams tension using Chart software (Version 
7).  The equipment was calibrated on a regular basis using a 2 g weight. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.4.2 Vessel Mounting 
 
The vessels for mounting were placed in a clean petri dish containing fresh PSS. One 40 µm 
stainless steel wire was passed through the lumen of the vessel; with the vessel then being 
positioned half-way along the wire. The vessel and wire were then transferred to a myograph 
bath containing fresh PSS and secured to the micrometer head. This was achieved by firstly 
bringing the two heads together so that the vessel was located in the gap between the two 
heads. To prevent any damage, the heads were then separated before each end of the wire 
was coiled round the screws on the myograph head and secured in place. A second wire was 
Figure 2-2: The Myograph Bath. Diagram adapted from Morton showing the 
myograph bath and stimulating electrodes (Morton, 2006). 
 stimulating 
electrodes 
8ml bath 
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then placed through the lumen of the vessel, alongside the first wire, and the heads were 
brought together in order for the second wire to be secured to the transducer head. The heads 
were then opened to the point where the two wires were just touching (Figure 2-3). 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
2.4.3 Vessel Equilibration 
 
Following the mounting of the vessels into the myograph baths, the PSS solution was 
changed and the vessels were left to equilibrate for 30 minutes. Following this equilibration 
period a resting tension of 200 mg for tail artery, and 150 mg for mesenteric arteries was 
gradually applied to the vessels. This was achieved by slowly turning the micrometer and so 
separating the wires and stretching the vessel. This tension was chosen due to previous 
1. 2. 
3. 4. 
5. 6. 
Figure 2-3: Procedure followed for mounting blood vessels: 1. Vessel positioned 
between the two heads. 2. Micrometer side moved so that both heads touching. 3. 
Ends of the wire secured to the transducer side using small screws. 4. Heads 
separated to allow second wire to pass through lumen of vessel. 5. Micrometer side 
moved so both heads touching. 6. Ends of the wire secured to micrometer side using 
small screws (Morton, 2006). 
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normalisation experiments carried out on tail artery in the lab (Daly et al., 2002). A resting 
tension of 150 mg was chosen for the mesenteric arteries as resting tension above this level 
damaged the vessel and altered the control responses. The vessels were then left to 
equilibrate for a further 45 minutes with PSS changed every 15 minutes and tension adjusted 
accordingly. 
 
2.4.4 Determination of Vessel Reactivity 
 
Noradrenaline (NA) was the initial choice of agonist used when testing vessel reactivity. In 
the WT tail vessels, addition of 1 µM NA to the bath resulted in a strong contraction with a 
defined plateau (Figure 2-4).  
 
 
 
 
 
 
 
 
 
However, the KO vessels did not respond reliably to NA addition and therefore the 
serotonergic agonist 5-hydroxytryptamine (5-HT) was used for all experiments in the tail 
artery. If the vessels were reactive, this drug was able to elicit a strong contraction and 
defined plateau regardless of strain (Figure 2-5) which disappeared when the PSS in the bath 
was changed. Following a 10 minute rest, vessels were exposed again to 5-HT, whereby a 
similar response to the first exposure was displayed (Figure 2-6). 
  
Figure 2-4: Representative trace showing WT mouse tail artery response to NA 
addition. Time scale; one box represents 10 seconds and is the same on all traces 
shown throughout. 
1 µM NA 
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1 µM 5-HT 
3 µM ACh 
Figure 2-5: Representative traces showing WT (a), ADKO (b) and α1-null (c) mouse 
tail artery response to 5-HT and ACh addition.  
1 µM 5-HT 3 µM ACh 
1 µM 5-HT 
3 µM ACh 
a 
b 
c 
54 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
At the plateau, the response to 3 µM acetylcholine (ACh) was tested. ACh acts at endothelial 
cells to initiate vessel relaxation – this response ensured that the endothelium was intact and 
the vessel could be used for experiments (Figure 2-5). 
 
The mesenteric arteries did not respond well to 5-HT incubation; they were unable to 
maintain the contraction plateau long enough for ACh addition (Figure 2-7). For these 
vessels, U46619 (U19), the thromboxane mimetic was used to contract the vessels (Figure 
2-8). Vessels were then left for 10 minutes before testing responses to perivascular nerve 
stimulation. 
1 µM 5-HT 1 µM 5-HT 
a 
1 µM 5-HT 1 µM 5-HT 
b 
1 µM 5-HT 1 µM 5-HT 
Figure 2-6: Representative traces showing WT (a), ADKO (b) and α1-null (c) mouse 
tail artery response to multiple 5-HT exposure. Bath washed between additions 
with 5 minute rest period. 
c 
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10 nM U-19 3 µM ACh 
b 
10 nM U-19 
3 µM ACh 
a 
10 nM U-19 
3 µM ACh 
c 
Figure 2-8: Representative traces showing mesenteric arteries from WT (a), ADKO 
(b) and α1-null (c) in response to U-19 and ACh exposure.  
1 µM 5-HT 
Figure 2-7: Representative traces showing mesenteric arteries from WT (a), ADKO 
(b) and α1-null (c) in response to 5-HT exposure.  
1 µM 5-HT 1 µM 5-HT 
a b 
c 
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2.4.5 Parameters of Stimulation 
 
The rat mesenteric arteries have been shown to be surrounded by a plexus of sensory nerves 
containing calcitonin gene-related peptide (CGRP) (Kawasaki et al., 1988). When activated 
they release CGRP, which is a potent vasodilator (Brain et al., 1985). Therefore, in order to 
view only the contractile response of the vessel, the CGRP component must be removed. 
Incubation with 1 µM capsaicin depletes the sensory nerves of CGRP (Fujimori et al., 1990) 
thus removing the vasodilatory effect. Capsaicin was tested in the mesenteric arteries by 
raising vessel tone and adding 1 µM capsaicin to the bath. If the nerves contain CGRP, it 
would be expected to be released and there would be a relaxation. This did occur in the 
mesenteric arteries, as shown in Figure 2-9. Consequently, 1 µM capsaicin was added prior 
to the nerve stimulation protocol in both the mesenteric and tail arteries.  
 
 
 
   
 
 
 
 
2.4.5.1 Tail Artery 
 
From the findings of Jänig and preliminary work carried out in the lab, the following 
frequencies were chosen to be tested on the vessels: 0.5 Hz, 1 Hz, 2 Hz, 4 Hz and 8 Hz 
(Janig, 2006). The pulse width was 0.3 ms so as to only excite the smooth muscle cells. 
Previous studies using pulse widths between 0.2 ms and 0.5 ms have shown that some of the 
response to 0.5 ms is due to direct stimulation of the smooth muscle as pre-treatment with 
1 µM NA 
1 µM Capsaicin 
Figure 2-9: Representative trace showing WT mesenteric arteries responding to NA 
and capsaicin exposure.  
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tetrodotoxin (TTX), which blocks nerve but not smooth muscle action potentials (Wang et 
al., 2006), did not abolish the responses to 0.5 ms pulses.  
 
The responses to 20 stimuli became larger with increasing frequency of stimulation. Only 
the lowest and highest frequencies were used in the main experimental protocols as the 
intermediate frequencies contractions showed a graded transition in shape between the lower 
and higher frequencies (Figure 2-10). Both of these frequencies are within the physiological 
range (Janig, 2006). An intermediate frequency of 2 Hz was chosen to test nerve reactivity 
before commencement of the main protocol.  
 
 
 
 
 
 
 
 
 
 
2.4.5.2 Mesenteric Arteries 
 
Responses in the mesenteric arteries were smaller than those in the tail. Therefore trains of 
50 stimuli at frequencies of 2 Hz and 8 Hz were chosen for the main experiments with 4 Hz 
delivered initially to test vessel reactivity (Figure 2-11).  
 
 
 
 
0.5 Hz 1 Hz 2 Hz 4 Hz 8 Hz 
Figure 2-10: Representative traces showing WT tail artery responding to increasing 
frequencies of nerve stimulation. The dashed vertical line represents the end of the 
stimulation period. 
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2.4.5.3 Tail and Mesenteric Arteries 
 
All vessels were stimulated with 15 V, 20 V and 30 V initially and 20 V was found to be 
supramaximal and hence used throughout the protocols. A pulse width of 0.3 ms was used 
to stimulate the nerves and release neurotransmitters. The tail arteries were stimulated with 
20 pulses in 40 seconds at 0.5 Hz and 20 pulses in 2.5 seconds at 8 Hz. The mesenteric 
arteries were stimulated with 50 pulses at 2 Hz for 25 seconds and at 8 Hz for 6.3 seconds. 
Following the return to baseline after the lower frequency stimulation, vessels were left for 
two minutes before commencement of stimulation at the next frequency.  
 
2.4.5.4 Measurement of Parameters from the Averaged Traces 
 
Responses produced at both frequencies in the tail artery contained two components: an 
initial fast component followed by a second slower component. The following points of the 
4 Hz 
Figure 2-11: Representative traces showing WT mesenteric artery responding to 
increasing frequencies in nerve stimulation – (a) response to 4 Hz; (b) response to 2 
Hz and 8 Hz. The dashed vertical bar represents the end of the stimulation period. 
a 
2 Hz 8 Hz 
b 
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responses were recorded for analysis: rate of rise, tension at the peak of both components as 
well as the tension at the end of the period of stimulation, the time taken to reach the peak 
of the second component (8 Hz) and the time taken for the peak response to reduce in 
amplitude by 50 % (decay time) (Figure 2-12). The rate of rise was calculated by measuring 
the change in tension between the beginning of the stimulation period and the peak of the 
first component and then dividing this tension by the time taken. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Various measurements from the mesenteric artery responses were also recorded. At 2 Hz 
and 8 Hz the control responses had one distinct peak. The following points of the responses 
were recorded for analysis, rate of rise, tension at the peak as well as the tension at the end 
of the pulse, the time taken to reach the peak and the time taken for the peak response to 
reduce by 50 % (decay time) (Figure 2-13).  
Figure 2-12: Representative traces showing WT tail artery responses at 0.5 Hz (a) 
and 8 Hz (b) annotated to show which parameters of the trace were measured.  
0.5 Hz 
1st peak 
Rate of rise 
Peak 
Decay time 
End of pulse 
a 
8 Hz 
Peak 
2
nd
 Peak 
End of pulse 
Rate of rise Decay time 
b 
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2.4.6 Antagonists 
 
Both prazosin (α1-AR antagonist) and rauwolscine (α2-AR antagonist) have been shown 
previously to block α1- and α2-ARs respectively at 100 nM (Shafaroudi et al., 2005; Methven 
et al., 2009a). The pA2 value is the negative logarithm of the molar concentration of an 
antagonist which reduces the effect of a dose of agonist to that of half the dose. The pA2 
value for prazosin against the α1-AR agonist phenylephrine was shown to be 9.9 in rat blood 
vessels (Hussain and Marshall, 1997) and against the α2-AR agonist UK14304 was shown 
to be 5.93 in canine saphenous vein (Guimaraes and Nunes, 1990). The pA2 value for 
rauwolscine against phenylephrine was 6.00 in the rat mesenteric arterial bed (Pipili, 1986) 
and against the α2-AR agonist clonidine was 8.10 in the rabbit vas deferens (Lattimer and 
Rhodes, 1985). For these reasons, this concentration was used throughout in both the tail 
artery and mesenteric arteries.  
2 Hz 
Peak 
Rate of rise 
End of pulse 
Decay time 
8 Hz 
Peak 
Rate of rise 
Decay time 
End of pulse 
a 
b 
Figure 2-13: Representative traces showing WT mesenteric artery responses at 2 Hz 
(a) and 8 Hz (b) annotated to show which parameters of the trace were measured.  
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The P2X receptor desensitising agent α, β, methylene ATP (αβme-ATP) has been shown 
previously to successfully block responses to exogenous ATP in various tissues (Kasakov 
and Burnstock, 1983). This was also shown to be true when used here in the WT tail artery 
preparations. The drug acts by binding to, activating and then desensitising the P2X receptors 
so that further addition of the drug does not elicit a response (Figure 2-14). 
 
 
 
 
 
 
 
 
However, in the α1-null vessels, regardless of how many times αβme-ATP was applied or 
the concentration that was used, the vessel continued to respond (Figure 2-15; n = 2). For 
this reason, the P2X receptor antagonist suramin was used in the main experiment protocols. 
A concentration of 1 mM was used to ensure all available P2X receptors were blocked (Bao 
and Stjarne, 1993).  
 
 
 
 
 
 
 
 
1 µM α,β, me-ATP 1 µM α,β, me-ATP 
Figure 2-14: Representative trace showing WT tail artery vessel response to α,β,me-
ATP.   
100 nM αβme-
ATP 
wash 
1 µM αβme-ATP 
wash 
1 µM αβme-ATP 
wash 
1 µM αβme-ATP 
wash 
1 µM αβme-ATP 
Figure 2-15: Representative trace showing α1-null tail artery vessel response to 
α,β,me-ATP.   
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2.4.7 Spontaneous Activity  
 
In some of the vessel preparations, spontaneous activity was recorded (Figure 2-16) and in 
some cases the effects can be seen in the averaged traces. The activity occurred following 
the end of the applied stimulus and did not affect the values recorded and analysed.  
 
 
 
 
 
 
 
 
2.4.8 Control Experiments 
 
During every experiment, a control vessel was set up to show that the peak responses to 
nerve stimulation did not vary with time. Therefore any change in response following drug 
incubation was due to the drug itself. Figures 2-17, 2-18 and 2-19 are averaged proximal and 
distal tail artery and mesenteric artery control traces from six wild type mice. Analysis of % 
change in each strain showed no significant differences between the strains for all vessels 
studied. Hence, only the WT traces are shown below. Tables 2-2 and 2-3 detail all of the % 
changes in each strain.  
 
 
 
 
0.5 Hz 8 Hz 
Spontaneous 
activity 
Spontaneous 
activity 
Figure 2-16: Example taken from LabChart showing α1-null tail artery spontaneous 
activity. 
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Figure 2-17: Average control traces from WT proximal mouse tail artery at 0.5 Hz 
(a) and 8 Hz (b). 1st stimulation – red; 2nd stimulation – black; 3rd stimulation – 
purple; 4th stimulation – green. The dashed line represents the end of the stimulation 
period. 
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Figure 2-18: Average control traces from WT distal mouse tail artery at 0.5 Hz (a) 
and 8 Hz (b). 1st stimulation – red; 2nd stimulation – black; 3rd stimulation – purple; 
4th stimulation – green. The dashed line represents the end of the stimulation period. 
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Strain Location 
% Change (± S.E.M) 
0.5 Hz 8 Hz 
Wild Type Proximal 15 ± 5 0.3 ± 3 
ADKO Proximal 3 ± 4 - 1 ± 2 
α1-null Proximal 5 ± 5 - 4 ± 7 
Wild Type Distal 6 ± 3 2 ± 2 
ADKO Distal 4 ± 2 3 ± 5 
α1-null Distal 5 ± 6 1 ± 5 
 
 
 
 
Table 2-2: The % change between the peak first and last control nerve stimulations 
in mouse tail artery at 0.5 Hz and 8 Hz. 
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Figure 2-19: Average control traces from WT mouse mesenteric artery at 2 Hz (a) 
and 8 Hz (b). 1st stimulation – red; 2nd stimulation – black; 3rd stimulation – purple; 
4th stimulation – green. The dashed line represents the end of the stimulation period. 
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2.5 Blood Pressure Monitoring 
 
2.5.1 Training of Mice 
 
The apparatus for measuring blood pressure was located in a different animal house to the 
one where the mice were being housed. Therefore, the mice whose blood pressures were 
going to be measured were transferred to the animal house containing the apparatus. The 
animals were left to adjust to their new surroundings for one week before commencement 
of training. Training was carried out on all mice on three separate days over a one week 
period. As well as the mice becoming accustomed to being handled they also became 
familiar with the blood pressure (BP) monitoring equipment. This involved placement of the 
tail cuff and subsequent inflation of the cuff. No measurements were recorded at this stage. 
On the same three days the following week, BP measurements were recorded.   
 
2.5.2 Tail Cuff Technique 
 
The LE 5001 Pressure Meter (Panlab Harvard Apparatus) was the tail cuff system used 
throughout. Mice were handled by the tail, placed on a clean cloth which was then wrapped 
around the mouse so that only the tail was exposed. The cuff was then slid near to the base 
Strain 
% Change (± S.E.M) 
2 Hz 8 Hz 
Wild Type - 2 ± 9 2 ± 4 
ADKO 26 ± 18 - 24 ± 11 
α1-null - 29 ± 33 - 10 ± 19 
Table 2-3: The % change between the peak first and last control nerve stimulations 
in mouse mesenteric artery at 2 Hz and 8 Hz. 
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of the tail and inflated. Measurements were recorded using the SeDaCom (Version 1.4.01) 
software. The tail cuff recorded beats per minute (BPM), systolic pressure and calculated the 
diastolic pressure from the systolic measurement. Diastolic measurement collection was not 
reliable and often did not work so only systolic measurements were analysed. The BPM 
recordings were also not reliable and so were not included in the analysis.  
 
2.5.3 Protocols 
 
On the days where BP measurements were taken, mice were removed from their cages and 
placed in a polystyrene box with a heated light bulb directed over them. As the tail artery is 
involved in temperature regulation the mice had to be warm to ensure the artery was not 
constricted. If the tail artery is constricted, a BP measurement will not be recorded by the 
cuff. A heat blanket was located under the cloth so that during BP measurements the 
temperature could be maintained. Following a 10 - 15 minute period in the polystyrene box, 
each mouse was then wrapped in the cloth and the tail placed through the cuff. Following 
six reproducible measurements the mice were then placed back in their cages. This was not 
always possible because the mice became agitated so that they were placed back in their 
cages sooner.  
 
2.6 Statistical Analysis 
 
GraphPad Prism (Version 5) was used to determine statistical significance in all tests. The 
Student’s paired t-tests were carried out when comparing a control response with an 
antagonist response and unpaired t-test used when comparing responses with different 
mouse strains. A one-way ANOVA with Bonferonni’s post-test was performed when 
analysing the time control responses and when comparing the antagonist sensitive 
components in Chapters 5-7.  
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IGOR Pro (Version 6) software produced averaged traces which are shown throughout and 
are displayed in the results sections alongside standard errors of the means (S.E.M). For each 
set of results, an average (± S.E.M) was generated from an n number of at least six mice and 
used in comparison studies.  
 
A novel way of analysing vessel response to antagonist incubation was developed whereby 
the individual ‘antagonist-sensitive’ portion of the response could be extracted from various 
incubation sequences and compared. For example, the prazosin-sensitive (PS) component 
can be obtained by subtracting the response following prazosin treatment from the control 
response. Similarly, by subtracting the response following rauwolscine plus prazosin 
treatment from the response following rauwolscine treatment, the prazosin-sensitive 
component is revealed. Prazosin, rauwolscine and suramin should be successfully blocking 
the α1-, α2-ARs and P2X receptors respectively and so the PS components represent the 
response due to activation of α1-ARs. If there are no interactions between the receptors then 
each of the revealed components would be similar. Therefore this analysis will expose 
whether the receptors interact with one another and if they are dependent on the presence of 
the other receptors in order to contribute to vessel constriction. A full worked example of 
this analysis is shown in the results section of Chapter 5 for both mesenteric and tail artery 
responses.  
 
2.7 Materials 
 
Physiological salt solution (PSS) with the following composition (in mM) was used: 119 
NaCl, 4.7 KCl, 1.2 MgSO4.H20, 1.2 KH2PO4, 24.9 NaHCO3, 2.5 CaCl2 and 11.1 glucose. 
The following stock solutions were dissolved in distilled water (dH2O) to the required 
concentrations unless otherwise stated. Materials were sourced from: Sigma Aldrich (Poole, 
UK), Tocris (Bristol, UK), Thermo Scientific (Loughborough, UK) and Invitrogen (Paisley, 
UK). To minimise any solvent effects on the responses, those drugs dissolved in solvents 
were made at higher concentrations before being diluted down using dH2O. The 
concentrations of the stock solutions are shown below in brackets. 
 
68 
 
2.7.1 Drugs used in the Nerve Stimulation Protocol 
 
Noradrenaline hydrochloride – SIGMA (10-2 M) 
5-hydroxytryptamine – SIGMA (10-2 M) 
U46619 – Available from TOCRIS – dissolved in ethanol (10-2 M) 
Acetylcholine chloride – SIGMA (10-2 M) 
Capsaicin – SIGMA – dissolved in ethanol (10-2 M) 
Prazosin hydrochloride – SIGMA – required sonication (10-3 M) 
Rauwolscine hydrochloride – SIGMA (10-3 M) 
Suramin sodium salt – SIGMA (10-2 M) 
 
 
2.7.2 Solutions used in the Genotyping Protocol 
 
Primers (Table 2-1) – THERMO SCIENTIFIC 
Readymix PCR Mastermix – THERMO SCIENTIFIC 
Digestion Buffer – Prepared in Lab 
Proteinase K – PROMEGA 
TE Buffer – INVITROGEN 
Agarose – INVITROGEN 
TAE Buffer – INVITROGEN 
Ethidium Bromide – SIGMA 
DNA Ladder - INVITROGEN 
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Chapter Three 
 
The effect of α1-adrenoceptor deletion on mouse 
blood pressure 
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3.1 Introduction 
 
3.1.1 Sympathetic control of Blood Pressure 
 
Stimulation of the neurovascular nerves results in release of noradrenaline (NA) and 
adenosine tri-phosphate (ATP) from the nerve terminals (Sneddon and Burnstock, 1984). 
These neurotransmitters act post-junctionally on α1- and α2-adrenoceptors (ARs) and P2X 
purinoceptors located on smooth muscle cells. Activation of these receptors alters vessel 
tone and therefore influences blood pressure. Historically, α1-AR blockers effect on reducing 
arteriolar resistance have been used to treat hypertension and so genetic removal of some or 
all of the α1-AR subtypes would be expected to have an effect on blood pressure. 
 
3.1.2 Genetically Modified Mice 
 
The generation of genetically modified mice lacking either one, two or three α1-AR subtypes 
have been developed in order to simplify the complex pharmacology (Cavalli et al., 1997; 
Rokosh and Simpson, 2002; Tanoue et al., 2002; Hosoda et al., 2005; Sanbe et al., 2007; 
Methven et al., 2009b). The α1AD-AR knock out (ADKO) and the α1ABD-KO (α1-null) mouse 
strains have been utilised presently in the study of systolic blood pressure (SBP). 
 
3.1.3 Measuring Blood Pressure 
 
The tail-cuff method is one way in which SBP can be measured in mice. This is a low cost, 
non-invasive procedure that utilises a sphygmomanometer together with a pulse signal 
which determines blood pressure (BP) in conscious mice. Various lab groups have utilised 
this method in BP recording of wild type (WT) and genetically modified mice.  SBP 
measured in WT mice was found to range between 99 mm Hg and 109 mm Hg (Tanoue et 
al., 2002; Hosoda et al., 2005; Sanbe et al., 2007). The α1D-AR KO was found to have a 
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significantly lower SBP compared to WT mice (Tanoue et al., 2002; Hosoda et al., 2005) as 
did the α1BD-AR KO and the α1-null mice (Hosoda et al., 2005; Sanbe et al., 2007). Where 
cardiac function was investigated, no change was detected between the WT mice and the 
KO mice (Tanoue et al., 2002; Hosoda et al., 2005).  
 
Other labs employed a carotid catheter to establish mean arterial pressure (MAP) in KO 
mice. With this method, the α1A-AR KO mice were found to be hypotensive (Rokosh and 
Simpson, 2002). The α1B-AR KO mice were shown to have a similar MAP to their WT 
controls (Cavalli et al., 1997). However, in mice with an overexpression of α1B-ARs, basal 
hypertension and bradycardia occurred alongside reproductive problems and weight loss 
which are characteristics of autonomic failure (Zuscik et al., 2001). Additionally, the α1D-
AR KO mice were also found to have a significantly lowered BP compared to the WT 
controls.    
 
In this study, the effect genetic removal of the α1-ARs had on SBP was investigated using 
the tail-cuff method in WT, ADKO and α1-null mice. 
 
3.2 Methods 
 
A full description on how the measurements were recorded can be found in Chapter 2. 
Briefly, six WT, six ADKO and five α1-null male mice aged 4 – 6 months had their SBP 
measured using the motorised tail cuff system. Mice were placed on a heat mat to ensure tail 
artery vasodilation before placing the cuff close to the base of the tail and recording pressure. 
On average, six measurements were recorded in each mouse. Measurements were taken from 
each mouse on five days over a two week period following three days of training. The 
equipment used did not reliably record diastolic pressures or heart rate (HR) and so only 
results from the systolic pressure measurements are shown here.  
 
Results were analysed using a one way ANOVA with Bonferonni’s post-test. Significance 
was taken as P < 0.05.  
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3.3 Results 
 
Analysis of recorded SBP did not reveal any significant differences between the strains 
(Table 3-1).  
 
 
 
Strain 
WT 
n = 6 
ADKO 
n = 6 
α1-null 
n = 5 
Systolic Blood Pressure 
mm Hg 
(± S.E.M) 
140 ± 2 mm Hg 139 ± 2 mm Hg 145 ± 2 mm Hg 
 
 
3.4 Discussion 
 
The results recorded here suggest that removal of the α1A- and α1D-ARs, or removal of all 
α1-AR subtypes has no impact on the SBP. However, when comparing the values with those 
of the lab groups mentioned in the introduction (Hosoda et al., 2005; Sanbe et al., 2007; 
Tanoue et al., 2002), the values recorded presently are higher. Therefore, it is possible that 
the present acclimatisation/training protocol was not long enough for the animals to produce 
a resting SBP. If the mice were agitated it would suggest that under pressure, the effect on 
vascular tone is similar between the strains. Conversely, this group of mice may have had 
isolated systolic hypertension; a potential consequence of having to be moved from one 
animal house to another. Determination of aortic stiffness could have confirmed this theory.   
 
The results presented here differ from previously published results which show resting SBP 
to be lower in α1-AR KO mice. This correlates with the effects seen in patients using α1-AR 
blockers in hypertension; where the systolic and diastolic pressures are reduced to lessen 
strain on the myocardium. However, currently α1-AR antagonists are generally only 
Table 3-1: Average systolic blood pressure measurements from WT, ADKO and 
α1-null mice.  
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prescribed as an additive measure in patients with uncontrolled blood pressure. This is partly 
due to the adverse effects reported in some clinical trials where major cardiovascular events 
occurred (Chapman et al., 2010). Combined with present results, resting SBP may rely on 
α1-AR input. However, whilst under pressure/ agitated, the vessels respond in a similar way, 
regardless of strain.  
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Chapter Four 
 
Does the sensory neurotoxin capsaicin affect 
response to sympathetic nerve stimulation in 
mouse tail and mesenteric arteries? 
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4.1 Introduction 
 
As well as a dense plexus of sympathetic nerve terminals, primary afferent sensory nerve 
terminals are present in the adventitia of many arterial vessels (Kawasaki et al., 1988; 
Sneddon and Burnstock, 1984). Recently, mouse models lacking one or more α1-
adrenoceptor (AR) subtype (α1-AR KO) have been developed which allows a greater 
understanding of the postjunctional receptors. However, sensory nerves can release potent 
vasodilators which may mask the full contractile effect of postjunctional receptor activation 
when all of the perivascular nerves are stimulated electrically. The vasodilator effect could 
be altered in the genetically modified mice as loss of α1-ARs may have a potential effect on 
the vasoconstrictor response and so may reveal a vasodilator response.  
 
The sensory nervous system is comprised of cell bodies located in spinal and cranial sensory 
ganglia with axons projecting centrally and peripherally. To maintain homeostasis, the 
sensory nerves respond to alterations in the internal and external environment. However, the 
sensory nerves can also exert effects locally, including vascular smooth muscle relaxation 
(Lee et al., 1978). 
 
Determination of the relationship between sensory nerves and vessel relaxation has been 
ongoing since the 1960’s. Discovery of the neuropeptide calcitonin gene-related peptide 
(CGRP) occurred in 1983 by tissue-specific RNA processing (Rosenfeld et al., 1983) and 
was suggested to be a potential modulator of noradrenergic sympathetic outflow in the 
peripheral nervous system (PNS) (Fisher et al., 1983). Intradermal injection of CGRP was 
shown to vasodilate certain blood vessels in a potent manner (Brain et al., 1985) with CGRP 
containing nerves shown to be present throughout the sensory nervous system and in some 
cases present before the development of noradrenergic nerves (Dhall et al., 1986; 
Tornebrandt et al., 1987). The distribution of CGRP containing nerves throughout the guinea 
pig mesenteric arteries was shown by Uddman et al. who demonstrated that with raised 
vessel tone, addition of CGRP induced a relaxation which became more pronounced with 
increasing concentration of CGRP (Uddman et al., 1986). CGRP binding sites were found, 
by radioligand binding studies, to be numerous in the rat mesenteric arteries (Wimalawansa 
and MacIntyre, 1988). 
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Caterina et al., (1997) cloned the VR1 receptor and noted that activation of this receptor, 
which is voltage sensitive, was found to have a high permeability to Ca2+ and continued 
excitation of the receptor could lead to desensitisation but only in the presence of 
extracellular Ca2+. These results provided the link between the VR1 receptor and the 
transient receptor potential vanilloid (TRPV) superfamily of ion channels (Caterina et al., 
1997). TRPV channels are found on sensory nerves and activation of the TRPV1 via nerve 
stimulation has been shown to cause release of calcitonin gene-related peptide (CGRP) 
(Wang et al., 2006). The TRPV1 channels are voltage sensitive and so membrane 
depolarisation through electrical field stimulation (EFS) can stimulate the release of CGRP 
(Voets et al., 2004). 
 
As CGRP can act as a potent vasodilator following nerve stimulation, it may be masking the 
vasoconstrictor effect of sympathetic activity and so a blockade of CGRP release could 
augment postjunctional receptor activation. One such substance able to desensitise the 
CGRP containing nerves is capsaicin, a sensory neurotoxin derived from capsicum peppers. 
Capsaicin has been shown to have multiple actions on sensory nerves including excitation 
of the nerves and a prolonged neurotoxic effect (Caterina et al., 1997). CGRP concentrations 
in the rat have been shown to originate mainly from capsaicin-sensitive perivascular nerves 
(Zaidi et al., 1985). The link between CGRP activity and capsaicin was further shown in 
1986 by Wharton et al. who used capsaicin injections to show a reduced CGRP content in 
the rat superior mesenteric arteries (Wharton et al., 1986). In 1988, Kawasaki et al. utilised 
peripheral nerve stimulation (PNS) in perfused rat mesenteric arteries. They showed that 
with raised tone, PNS elicited a relaxation that could be inhibited by capsaicin pre-treatment 
and that the relaxation shown was due to release of CGRP. Immunohistochemistry studies 
also revealed CGRP containing nerves (Kawasaki et al., 1988). Fujiwara et al. have now 
shown this in the mouse mesenteric arteries and conclude that the arteries are densely 
innervated by CGRP containing nerves (Fujiwara et al., 2012).  
 
It is therefore possible that pre-treatment with capsaicin will result in an increased peak 
response to EFS as the ‘masking’ vasodilation will be removed. The effect of capsaicin on 
excitatory junctional potentials (EJP) in rat mesenteric arteries was investigated by Dunn et 
al. who reported an increase in EJP amplitude following removal of CGRP (Dunn et al., 
2003). It is unknown whether EFS response in the mouse mesenteric arteries or tail artery 
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will be altered by capsaicin. However, previous data suggests that as both tissues contain 
CGRP, a difference may be recorded (Morrison et al., 2009).  
 
In this study, the effects of capsaicin treatment on the amplitude of contractile responses to 
EFS were tested on mesenteric and tail arteries from WT, ADKO and α1-null mice. 
 
4.2 Methods 
 
A full description of the methods used can be found in Chapter Two. Briefly, six male mice, 
aged four to six months from each strain (WT; ADKO; α1-null) were utilised. First order 
mesenteric arteries and proximal and distal tail artery were removed and set up in myograph 
baths. Capsaicin’s vasodilatory effect was tested by raising mesenteric artery vessel tone 
with 1 µM NA and then applying 1 µM capsaicin. Following the vessel reactivity tests, 
vessels were stimulated with various patterns of perivascular electrical stimuli before and 
after capsaicin treatment. The amplitudes of the responses were recorded and analysed using 
a paired t-test with a P value < 0.05 taken as significant and shown alongside standard error 
of the mean (S.E.M). 
 
4.3 Results 
 
4.3.1 Mesenteric Arteries 
 
When vessel tone was raised using 1 µM NA, 1 µM capsaicin was added and the vessel 
relaxed by 73 % 5 minutes following administration - indicating the presence of CGRP 
containing sensory nerves (Figure 4-1). Regardless of strain or frequency, the addition of 
capsaicin was not shown to alter the response significantly to nerve stimulation (Figures 4-
2 – 4-4; Table 4-1). For example, the amplitude of the WT response following capsaicin 
treatment decreased, on average, by 7.3 % ± 6.8 for each frequency. Furthermore, the shape 
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of the response does not alter following the addition of capsaicin to the bath (Figures 4-2 - 
4-4).  
 
 
 
 
 
 
 
 
  
      
 
 
 
Strain Frequency 
Contractile Response (mg ± S.E.M) 
Before Capsaicin Following Capsaicin 
WT 
n = 6 
2 Hz 62 ± 8 60 ± 16 
8 Hz 197 ± 14 189 ± 21 
16 Hz 273 ± 13 264 ± 20 
ADKO 
n = 6 
2 Hz 22 ± 5 16 ± 5 
8 Hz 66 ± 13 45 ± 15 
16 Hz 92 ± 12 67 ± 12 
α1-null 
n = 6 
2 Hz 13 ± 7 9 ± 4 
8 Hz 30 ± 18 22 ± 10 
16 Hz 40 ± 19 34 ± 12 
 
 
 
 
 
Table 4-1: Comparison of nerve responses before and after capsaicin treatment (1 
µM for 30 minutes) in mouse mesenteric arteries from WT, ADKO and α1-null 
strains.  
 
1 µM NA 
1 µM Capsaicin 
Figure 4-1: Representative trace showing WT mesenteric arteries responding to NA 
and capsaicin exposure. Vessel relaxed to 73 % of the peak response 5 minutes 
following administration. 
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Figure 4-2: Averaged traces from 6 wild type mouse mesenteric arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 2 Hz (a), 
8 Hz (b) and 16 Hz (c). Responses in mg tension with error bars at the peak responses ± 
S.E.M.  
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Figure 4-3: Averaged traces from 6 ADKO mouse mesenteric arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 2 Hz 
(a), 8 Hz (b) and 16 Hz (c). Responses in mg tension with error bars at the peak 
responses ± S.E.M.  
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Figure 4-4: Averaged traces from 6 α1-null mouse mesenteric arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 2 Hz (a), 
8 Hz (b) and 16 Hz (c). Responses in mg tension with error bars at the peak responses ± 
S.E.M.  
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4.3.2 Tail Artery 
 
When vessel tone was raised using 1 µM 5-HT, 1 µM capsaicin was added and the vessel 
did not relax; suggesting that CGRP is not released from the nerves under these stimulation 
parameters (Figure 4-5). In WT and α1-null tail arteries, the addition of capsaicin to the 
myograph baths did not significantly alter their responses to nerve stimulation, regardless of 
location. However, the mean graphs were always larger than before capsaicin although this 
change was only significant in the ADKO, in which the addition of capsaicin increased the 
responses to 0.5 Hz in both proximal and distal sections (Figures 4-6 – 4-11; Table 4-2). At 
0.5 Hz proximal tissue response before capsaicin was 140 ± 27 mg and following capsaicin 
this increased to 211 ± 35 mg (n = 6). Distally, the initial response was 234 ± 43 mg and this 
increased to 299 ± 33 mg following capsaicin incubation (n = 6).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 µM 5-HT 1 µM Capsaicin 
Figure 4-5: Representative trace showing WT tail artery responding to 5-HT and 
capsaicin exposure.  
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Figure 4-6: Averaged traces from 6 proximal WT mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 0.5 
Hz (a) and 8 Hz (b). Responses in mg tension with error bars at the peak responses ± 
S.E.M.  
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Figure 4-7: Averaged traces from 6 distal WT mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 
0.5 Hz (a) and 8 Hz (b). Responses in mg tension with error bars at the peak 
responses ± S.E.M.  
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Figure 4-8: Averaged traces from 6 proximal ADKO mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 0.5 Hz 
(a) and 8 Hz (b). Responses in mg tension with error bars at the peak responses ± S.E.M. 
** indicates a significant difference in peak tension before and after capsaicin 
treatment. 
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Figure 4-9: Averaged traces from 6 distal ADKO mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 0.5 Hz 
(a) and 8 Hz (b). Responses in mg tension with error bars at the peak responses ± 
S.E.M. * indicates a significant difference in peak tension before and after capsaicin 
treatment.  
* 
0 20 40 60 80 
Time (s) 
0 
50 
100 
150 
250 
T
en
si
o
n
 (
m
g
) 
200 
300 
350 
Time (s) 
0 10 20 30 40 5
0 
60 
0 
50 
100 
150 
250 
T
en
si
o
n
 (
m
g
) 
200 
300 
350 No Capsaicin 
Capsaicin 
a b 
No Capsaicin Capsaicin 
85 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-11: Averaged traces from 6 distal α1-null mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 0.5 Hz 
(a) and 8 Hz (b). Responses in mg tension with error bars at the peak responses ± S.E.M.  
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Figure 4-10: Averaged traces from 6 proximal α1-null mouse tail arteries taken before 
capsaicin treatment and following capsaicin treatment (1 µM for 30 minutes) at 0.5 Hz 
(a) and 8 Hz (b). Responses in mg tension with error bars at the peak responses ± 
S.E.M.  
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Strain Location Frequency 
Response (mg ± S.E.M) 
Before Capsaicin Following Capsaicin 
WT 
n = 6 
Proximal 
0.5 Hz 385 ± 97 413 ± 77 
8 Hz 589 ± 86 599 ± 87 
Distal 
0.5 Hz 270 ± 82 291 ± 79 
8 Hz 445 ± 79 403 ± 72 
ADKO 
n = 6 
Proximal 
0.5 Hz 140 ± 27 211 ± 35 ** 
8 Hz 264 ± 27 284 ± 42 
Distal 
0.5 Hz 234 ± 43 299 ± 33 * 
8 Hz 314 ± 34 335 ± 27 
α1-null 
n = 6 
Proximal 
0.5 Hz 165 ± 33 218 ± 44 
8 Hz 208 ± 28 219 ± 39 
Distal 
0.5 Hz 279 ± 65 337 ± 53 
8 Hz 324 ± 50 352 ± 50 
 
 
 
4.4 Discussion 
 
The nonadrenergic noncholinergic (NANC) response in the vasculature is now known to be 
mediated, in part, by CGRP-containing sensory nerves. These nerves are capable of 
contributing to the maintenance of homeostasis by monitoring the vessels environment and 
responding to changes. They are also sensitive to capsaicin, which induces peptide release 
and results in subsequent desensitisation of the nerves (Caterina et al., 1997). Capsaicin has 
also been shown to inhibit ATP release from the nerves following EFS in the guinea pig vas 
deferens through a suggested action on a pre-junctional receptor (Ellis and Burnstock, 1989). 
The actions of the sympathetic and sensory nerves are not completely separate and therefore 
may be able to influence the actions of either group of receptors.  It has been suggested that 
CGRP release may be inhibited by NA acting on α2-ARs located on sensory nerves. This 
study was conducted using the rat mesenteric arteries and utilised EFS. The response to 
various antagonists including yohimbine (α2-AR antagonist) revealed an inhibition in CGRP 
release when yohimbine was present (Kawasaki et al., 1990).   
Table 4-2: Comparison of nerve responses before and after capsaicin treatment (1 
µM for 30 minutes) in mouse tail arteries from WT, ADKO and α1-null strains.  
 
* P < 0.05, ** P < 0.01 compared with response before capsaicin treatment. Paired 
t-test. 
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4.4.1 Mouse Mesenteric Arteries 
 
Initial tests with capsaicin whilst tone was raised in the vessels suggest that CGRP containing 
nerves are present in mouse mesenteric arteries. This supports the experiments carried out 
by Fujiwara et al. in the mouse mesentery (Fujiwara et al., 2012). However, effects on nerve-
mediated responses have not been reported. Here, peak response to perivascular nerve 
stimulation was not affected by capsaicin. Using capsaicin revealed that nerve stimulation 
within the aforementioned parameters does not expose a vasodilatory effect. Therefore 
simultaneous activation of the CGRP containing nerves present in the mesentery does not 
influence the contractile response to sympathetic nerve stimulation. However, a recent paper 
by Sheykhzade et al., (2011) showed that, in the mouse vas deferens, there is a triphasic 
response to capsaicin. This variation in vessel reaction to capsaicin is dependent on the 
concentration of capsaicin administered. At low doses (1 nM – 300 nM) capsaicin induced 
CGRP release decreased the response to nerve stimulation; at an intermediate dose (100 nM 
– 10 µM) the response was augmented and at high doses (10 µM – 1 mM) the response was 
again decreased. If a similar response occurs in the mesentery then at 1 µM, capsaicin 
incubation may be exerting a dual effect whereby released CGRP leads to desensitisation 
and augments the response but the non-specific effects of capsaicin attenuates the response. 
This could result in little change being seen in the response (Sheykhzade et al., 2011).  
 
Interestingly, Fujii et al. have shown that exogenously added 5-hydroxytryptamine (5-HT) 
can be stored in adrenergic nerves and exert an inhibitory effect on CGRP containing nerves 
upon release (Fujii et al., 2012). The vessel reactivity tests performed at the beginning of 
these experiments include response to 1 µM 5-HT. Consequently, if this 5-HT can be stored 
in the same way as in the rat it is possible that any vasodilatory effect would be lost. 
Repeating the experiments without 5-HT addition would determine whether it was having 
an inhibitory effect.  
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4.4.2 Mouse Tail Artery 
 
Few studies have investigated the effect of CGRP release in the rat tail artery and none have 
investigated the mouse tail artery. If CGRP is released following nerve stimulation, the full 
contractile effect of postjunctional receptor activation will not be seen. This complicates the 
investigation of neurotransmitter release. However, it has been shown here that capsaicin 
incubation has no significant effects on the peak response to nerve stimulation in both WT 
and α1-null mice. This suggests that under the parameters tested, CGRP is not released in 
significant enough quantities to produce a vasodilatory effect. In the ADKO mice, responses 
both proximally and distally at 0.5 Hz were significantly increased following capsaicin 
exposure. To date, there has been no correlation reported between the α1-ARs and CGRP 
activity. In the WT and α1-null mouse tail artery, there was a trend to increase the response 
following capsaicin treatment. Further investigations, including increasing the number of 
experiments, utilising α1-AR antagonists and immunohistochemistry (IHC) would contribute 
to revealing capsaicin’s effect.  
 
Furthermore, as suggested in the mesenteric arteries, capsaicin may have a dual effect in 
response to sympathetic nerve stimulation in the tail artery. A 1 µM administration of 
capsaicin may result in the release of CGRP to augment the response but may also result in 
non-specific actions of capsaicin which may attenuate the response. Non-specific actions of 
capsaicin include altering voltage dependent sodium channel regulation at high capsaicin 
concentrations (Lundbaek et al., 2005; Sheykhzade et al., 2011). 
 
4.4.3 Conclusion 
 
It has been shown here that nerve stimulation induced responses are not alone masked by a 
vasodilatory action of CGRP release from sensory nerves in mesenteric arteries from each 
mouse strain or in WT and α1-null tail arteries. This may be due to a dual capsaicin effect on 
the blood vessels. Whereby capsaicin is able to stimulate release of CGRP and desensitise 
the nerves as well as initiate non-specific effects which may alter voltage dependent sodium 
channels and trigger vessel contraction. In the mouse tail artery, capsaicin incubation results 
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in an increase in peak response in the ADKO strain suggesting that CGRP release can reveal 
a vasodilatory effect. This may be due to an interaction between the α1A- and α1B-ARs that 
is masked in the WT mice, lost in the α1-null mice and revealed in the ADKO mice. 
However, as both the WT and α1-null tail artery preparations showed a trend to increase in 
response following capsaicin treatment, further investigations are required to clarify 
capsaicin’s effect.  
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Chapter Five 
 
Pharmacological analysis of post junctional 
receptors in mouse mesenteric and tail arteries 
involved in contractions evoked by short trains of 
perivascular nerve impulses. 
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5.1 Introduction 
 
Sympathetic neurovascular transmission involves the release of neurotransmitters from the 
nerve terminals and subsequent activation of receptors located pre- and post-junctionally. 
Activation of such receptors modulates vascular tone and can therefore increase blood 
pressure via narrowing of the blood vessels caused by smooth muscle cell contraction. 
Release of noradrenaline (NA) from the nerve terminals can act at post-junctional α1- and 
α2-ARs to initiate vasoconstriction or act pre-junctionally at α2-ARs to inhibit further 
neurotransmitter release (Msghina et al., 1992; Brock and Cunnane, 1999). Adenosine Tri-
phosphate (ATP) is also released from the nerve terminals and acts post-junctionally at P2X 
receptors to initiate vasoconstriction (Burnstock, 1972).  
 
Studies in rat mesenteric and tail arteries have been extensive and have demonstrated the 
presence of the α1-, α2-ARs and P2X receptors. Nerve stimulation experiments in the rat 
mesenteric arteries revealed α1-AR activation to be dominant in constricting the vessels with 
the P2X receptors also contributing and in some instances interacting with the α1-ARs. There 
is also a population of pre-junctional α2-ARs which, when activated by NA, inhibit further 
neurotransmitter release (Angus et al., 1988; Gitterman and Evans, 2001; Brock et al., 2006). 
More recently, evidence of an adrenergic component in the response to nerve stimulation in 
the mouse mesenteric arteries has been published (Fujiwara et al., 2012). In the rat tail artery, 
the α1- and α2-ARs have been shown to contribute to the slow portion of the nerve response, 
with activation of the P2X receptors producing the initial contraction (Sneddon and 
Burnstock, 1984; Bao et al., 1990). There is also evidence to show that ATP release has a 
dual effect, activating P2X receptors and inhibiting the adrenergic response (Bao and 
Stjarne, 1993). Evidence of α2-AR involvement has been shown pre- and post-junctionally, 
with increased α2-AR sensitivity shown in distal tail artery segments (Msghina et al., 1999; 
Weiss et al., 1983; Medgett, 1985). 
 
The development of transgenic mice and, in particular, the α1-AR KO mice, has allowed the 
functional pharmacology in the mouse vasculature to be simplified (Cavalli et al., 1997; 
Rokosh and Simpson, 2002; Tanoue et al., 2002). The α1-ARs are considered to be crucial 
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in the maintenance of vascular tone and so these KO mice will contribute to the 
understanding of how the blood vessels are regulated when these receptors are missing. 
Before responses to nerve stimulation in these mice can be studied in depth, the roles the 
receptors play must first be elucidated in WT mice. Presently, the mouse mesenteric arteries 
and tail artery have been employed and the responses to perivascular nerve stimulation 
studied. Therefore the aims of the following study were: 
 To characterise the roles of the α1-, α2-ARs and P2X receptors in the response to 
nerve stimulation in mouse mesenteric arteries. 
 To characterise the roles of the α1-, α2-ARs and P2X receptors in the response to 
nerve stimulation in the mouse proximal and distal tail artery 
 To determine whether there are any interactions between the receptors in either the 
mouse mesenteric arteries or the tail artery. 
 
 5.2 Methods 
 
A full description of the methods used can be found in Chapter Two (Materials and 
Methods). Briefly, wire myography studies were conducted using mouse mesenteric arteries 
and proximal and distal tail artery segments. The vessels were contained within two 
stimulating electrodes which could be controlled to deliver pulses of varying parameters of 
stimulation. All vessels were incubated with 1 µM capsaicin in order to deplete the sensory 
nerves of CGRP; a potent vasodilator. Control response to 2 Hz and 8 Hz (mesenteric 
arteries) and 0.5 Hz and 8 Hz (tail artery) were recorded before incubation with one of the 
following antagonists: 100 nM prazosin (α1-AR antagonist), 100 nM rauwolscine (α2-AR 
antagonist) or 1 mM suramin (P2X receptor antagonist). The vessels were then stimulated 
again using the same parameters. 
 
Statistical analysis was performed using GraphPad Prism (Version 5) with paired t-tests used 
when comparing control response with antagonist response and one way ANOVA with 
Bonferonni’s post-test utilised for comparing the antagonist sensitive components. A worked 
example of the component analysis, which revealed the antagonist sensitive response in 
93 
 
different incubation sequences is shown at the beginning of the mesenteric and tail artery 
results sections in Chapter Five. 
 
5.3 Results 
 
5.3.1 Mouse Mesenteric Artery 
 
Combined incubation with prazosin (100 nM), rauwolscine (100 nM) and suramin (1 mM) 
effectively blocked the α1-, α2-ARs and P2X receptors respectively in response to nerve 
stimulation at 2 Hz and 8 Hz in the mesenteric arteries and completely abolished the response 
(Figures 5-1 and 5-2). 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
Control 
100 nM Prazosin (P) + 
100 nM Rauwolscine (R) 
+ 1 mM Suramin (S) 
Figure 5-1: WT Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of the following antagonists: 100 nM prazosin, 100 
nM rauwolscine, 1 mM suramin (n = 4).  
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5.3.1.1 Revealing the α1-ARs role in the response to sympathetic 
nerve stimulation at 2 Hz. 
 
Following incubation with 100 nM prazosin (α1-AR antagonist), the response to stimulation 
of the sympathetic nerves was reduced; statistically affecting the rate of rise and both the 
peak tension and the tension recorded at the end of the stimulation period (Figure 5-3; Table 
5-1).  
 
 
 
 
 
 
 
 
 
 
Control 
100 nM P + 100 nM R 
+ 1 mM S 
Figure 5-2: WT Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the following antagonists: 100 nM prazosin, 
100 nM rauwolscine, 1 mM suramin (n = 4).  
Control 
100 nM Prazosin 
Figure 5-3: WT Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n =4).  
* P < 0.05 compared with control response. Paired t-test. 
* 
* 
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2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 4) 
% change following P 
incubation 
Time to Peak (seconds) 6.8 ± 0.5 7.5 ± 3.7 - 16 ± 24 
Peak Tension (mg) 81 ± 16 7 ± 1 * - 91 ± 1 
Rate of Rise (mg/s) 10.4 ± 1.4 1 ± 0.4 * - 88 ± 3 
Tension at End of pulse (mg) 34 ± 8 1 ± 1 * - 94 ± 4 
50 % Decay Time (seconds) 10.8 ± 3.9 3.2 ± 2.0 - 59 ± 29 
 
 
 
When investigating the different receptors involved in the formation of the response, a novel 
approach was taken in analysing the data. This allowed the data collected to be utilised fully 
and permitted the isolation of the receptor components in different ways. This was achieved 
by incubating the arteries in selected antagonists in different sequences. This analysis 
allowed investigation of whether there was any interaction between the three post-junctional 
receptors. If there were no interactions, then all of the components revealed would be similar. 
If there was synergy as has been shown for NA and ATP in the mesenteric artery (Ralevic 
and Burnstock, 1990), the sizes (or shapes) of the contractions would not be identical. 
 
The first analysis is shown in Figure 5-4 whereby the prazosin-sensitive (PS) component 
was isolated in three different ways. The PS component was identified by subtracting 
averaged traces in several incubation sequences as follows: 
 
1. The PS component was revealed as the difference between the control trace and the 
trace following prazosin incubation – when both the α2-ARs and P2X receptors were 
still activated by nerve-released transmitters (Figure 5-4a). The difference is shown 
in the shading and the key indicates that it is the PS component.  
 
2. The PS component in the absence of α2-AR activation was revealed by the difference 
between the trace in rauwolscine and that following rauwolscine plus prazosin 
Table 5-1: WT Mouse mesenteric artery response to nerve stimulation in control and 
prazosin (100 nM) incubated vessels at 2 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
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(Figure 5-4b). Shown in brackets are the additional antagonists present; in this 
example, rauwolscine. 
 
3. Finally, when the arteries were incubated in both suramin and rauwolscine, so that 
neither P2X receptors nor α2-ARs were activated, the PS component was revealed 
(Figure 5-4c). Shown in brackets are the additional antagonists present and in the 
order the tissues were incubated; in this example, suramin plus rauwolscine. 
 
The trapezoidal methods for calculating the area under the curve was used to determine the 
shaded areas which were taken to represent the total magnitude of the response due to 
activation of the α1-ARs. The values calculated are represented as a percentage of the control 
response (Figure 5-5). There was no statistical significance between the PS components 
derived in the three different conditions (Table 5-2).  
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Control 
100 nM Prazosin 
PS 
100 nM R 
100 nM R + 100 nM P 
PS (R) 
Control 
Control 
1 mM S + 100 nM R  
PS (S+R)  
a 
b 
c 
Figure 5-4: Traces showing the revealed prazosin sensitive (PS) components at 2 Hz 
isolated in three different ways – (a) shows the PS component when the α2-ARs and 
P2X receptors are active; (b) shows the PS component when the α2-ARs are blocked 
and the P2X receptors are active; (c) shows the PS component when the P2X 
receptors and α2-ARs are blocked.   
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Prazosin-sensitive component as a 
% of the Control Response 
 2 Hz 8 Hz 
PS 97 ± 3 87 ± 4 
PS 
(R) 
86 ± 19 85 ± 15 
PS 
(S+R) 
72 ± 27 36 ± 9 * 
 
 
 
 
 
 
 
0
50
100
P
ra
z
o
s
in
-s
e
n
s
it
iv
e
 c
o
m
p
o
n
e
n
t 
a
s
 a
 %
 o
f 
th
e
 C
o
n
tr
o
l 
R
e
s
p
o
n
s
e
PS PS 
(R) 
PS 
(S+R) 
Figure 5-5: WT mouse mesenteric artery – the prazosin sensitive (PS) component at 2 
Hz when the α2-ARs and P2X receptors are functional (white) (n=4), α2-ARs are 
blocked (grey) (n=7), P2X receptors and α2-ARs are blocked (black) (n=6). The 
presence of additional antagonists are shown in brackets. 
Table 5-2: WT mouse mesenteric artery response - revealing the prazosin sensitive 
component as a % of control area under the curves. Data taken from Figures 5-5 and 
5-7. 
* P < 0.05 compared with PS component when the α2-ARs are blocked. One way ANOVA 
with Bonferonni’s post-test. 
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5.3.1.2 Revealing the α1-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz. 
 
At 8 Hz, the response to EFS following blockade of α1-ARs reduced the peak tension and 
the tension recorded at the end of the stimulation period with the time taken to reach the peak 
and the rate of rise also being reduced (Figure 5-6; Table 5-3).  
            
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
+ 
Control 
100 nM Prazosin 
Figure 5-6: WT Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n = 4).  
** P < 0.01 compared with control response. Paired t-test.                                                
+ P < 0.05 compared with control time. Paired t-test. 
**
 
**
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 4) 
% change following P 
incubation 
Time to Peak (seconds) 5.5 ± 0.1 3.7 ± 0.4 + - 33 ± 8 
Peak Tension (mg) 228 ± 36 38 ± 10 ** - 83 ± 3 
Rate of Rise (mg/s) 37 ± 3 10 ± 1 ** - 75 ± 3 
Tension at End of pulse (mg) 225 ± 36 33 ± 10 ** - 85 ± 3 
50 % Decay Time (seconds) 3.8 ± 0.3 4.4 ± 0.5 13 ± 7 
 
 
 
The prazosin-sensitive components revealed at 8 Hz show that when the P2X receptors and 
α2-ARs are blocked, the resulting prazosin-sensitive component response is smaller than the 
component when only the α2-ARs are blocked (Figure 5-7; Table 5-2). 
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Figure 5-7: WT mouse mesenteric artery – the prazosin-sensitive (PS) component at 
8 Hz when the α2-ARs and P2X receptors are functional (white) (n=4), α2-ARs are 
blocked (grey) (n=7), P2X receptors and α2-ARs are blocked (black) (n=6). The 
presence of additional antagonists are shown in brackets. 
* P < 0.05 compared with PS component when the P2X receptors and α2-ARs are 
blocked. One way ANOVA with Bonferonni’s post-test. 
  
PS PS 
(R) 
PS 
(S+R) 
Table 5-3: WT Mouse mesenteric artery response to nerve stimulation in control and 
prazosin (100 nM) incubated vessels at 8 Hz.  
** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
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5.3.1.3 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 2 Hz. 
 
Following incubation with 100 nM rauwolscine (α2-AR antagonist), the response to 
stimulation of the sympathetic nerves is not significantly altered (Figure 5-8; Table 5-4). The 
graph shows that at 2 Hz, although not statistically significant, there is a trend to potentiate 
the response following blockade of the α2-ARs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 7) 
% change following R 
incubation 
Time to Peak (seconds) 7.3 ± 0.5 9.8 ± 1.7 20 ± 6 
Peak Tension (mg) 59 ± 10 77 ± 16 17 ± 11 
Rate of Rise (mg/s) 10 ± 1 10 ± 2 1 ± 13 
Tension at End of pulse (mg) 30 ± 10 41 ± 9 28 ± 17 
50 % Decay Time (seconds) 10.2 ± 3.3 12.6 ± 2.0 28 ± 19 
 
Control 
100 nM Rauwolscine 
Figure 5-8: WT Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of the α2-AR antagonist rauwolscine (100 nM) 
(n = 7).  
Table 5-4: WT Mouse mesenteric artery response to nerve stimulation in control and 
rauwolscine (100 nM) incubated vessels at 2 Hz.  
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Figure 5-9 displays the α2-AR components that were revealed under various conditions. 
There is a trend for the area under the curve to be smallest when the α1-ARs are blocked and 
the P2X receptors are functional (Figure 5-9; Table 5-5).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Rauwolscine-sensitive component 
as a % of Control Response 
  2 Hz 8 Hz 
RS 199 ± 63 130 ± 29 
RS 
(P) 
3 ± 2 * 108 ± 4 
RS 
(S) 
95 ± 59 72 ± 22 
 
 
 
Figure 5-9: WT mouse mesenteric artery – the rauwolscine-sensitive component at 2 
Hz when the α1-ARs and P2X receptors are functional (white) (n=7), α1-ARs are 
blocked (grey) (n=4), P2X receptors are blocked (black) (n=6). The presence of 
additional antagonists are shown in brackets. 
* P < 0.05 compared with the RS component when the α1-ARs and P2X receptors were 
functional. One way ANOVA with Bonferonni’s post-test. 
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Table 5-5: WT mouse mesenteric artery response - revealing the rauwolscine 
sensitive component as a % of control area under the curves. Data taken from 
Figures 5-9 and 5-11. 
* P < 0.05 compared with RS component when the α1-ARs and P2X receptors are 
functional. One way ANOVA with Bonferonni’s post-test. 
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5.3.1.4 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz. 
 
At 8 Hz, the response to EFS following blockade of α2-ARs significantly impacted all of the 
points studied. The peak tension and the tension recorded at the end of the stimulation period 
were significantly increased following rauwolscine incubation with the time taken to reach 
the peak prolonged, the decay time reduced and the rate of rise increased (Figure 5-10; Table 
5-6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
100 nM Rauwolscine 
Figure 5-10: WT Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the α2-AR antagonist rauwolscine (100 nM) 
(n = 7).  
* P < 0.05, ** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
++
+ 
**
 
* 
++
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 7) 
% change following 
R incubation 
Time to Peak (seconds) 6.0 ± 0.2 6.6 ± 0.2 +++ 11 ± 2 
Peak Tension (mg) 197 ± 26 265 ± 33 ** 24 ± 5 
Rate of Rise (mg/s) 37 ± 3 40 ± 6 * 16 ± 6 
Tension at End of pulse (mg) 192 ± 26 285 ± 35 * 23 ± 7 
50 % Decay Time (seconds) 3.8 ± 0.3 3.0 ± 0.1 ++ - 19 ± 4 
 
 
 
The rauwolscine-sensitive components were determined and analysis revealed no significant 
differences between the conditions (Figure 5-11; Table 5-5).  
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Figure 5-11: WT mouse mesenteric artery – rauwolscine-sensitive component at 8 Hz 
when the α1-ARs and P2X receptors are functional (white) (n=7), α1-ARs are blocked 
(grey) (n=4), P2X receptors are blocked (black) (n=6). The presence of additional 
antagonists are shown in brackets. 
RS RS 
(P) 
RS 
(S) 
Table 5-6: WT Mouse mesenteric artery response to nerve stimulation in control and 
rauwolscine (100 nM) incubated vessels at 8 Hz.  
* P < 0.05, ** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
105 
 
5.3.1.5 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 2 Hz. 
 
Following incubation with 1 mM suramin (P2X receptor antagonist), the response to 
stimulation of the sympathetic nerves resulted in a reduction in peak tension and rate of rise 
as well as a prolonged time to reach the peak and a shortened decay time (Figure 5-12; Table 
5-7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
1 mM Suramin 
Figure 5-12: WT Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n =6). 
* P < 0.05 compared with control response. Paired t-test.  
+ P < 0.05 compared with control time. Paired t-test. 
* 
+ 
+ 
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2 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 6) 
% change following S 
incubation 
Time to Peak (seconds) 7.3 ± 0.3 18.4 ± 3.3 + 51 ± 13 
Peak Tension (mg) 83 ± 22 31 ± 10 * - 50 ± 25 
Rate of Rise (mg/s) 10 ± 1 2 ± 0.4 * - 72 ± 17 
Tension at End of pulse (mg) 52 ± 19 26 ± 11 - 46 ± 27 
50 % Decay Time (seconds) 15.3 ± 3.6 4.6 ± 1.8 + - 73 ± 7 
 
 
 
 
The suramin-sensitive components were determined and analysis revealed is shown in 
Figure 5-13 (Table 5-8).  
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Figure 5-13: WT mouse mesenteric artery – the suramin-sensitive component at 2 Hz 
when the α1- and α2-ARs are functional (white) (n=6), α1- and α2-ARs are blocked 
(grey) (n=4), α2-ARs and α1-ARs are blocked (black) (n=7). 
** P < 0.01 compared with SS component when the α1- and α2-ARs are functional. 
One way ANOVA with Bonferonni’s post-test. 
  
SS SS 
(P+R) 
SS 
(R+P) 
Table 5-7: Mouse mesenteric artery response to nerve stimulation in control and 
suramin (1 mM) incubated vessels at 2 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
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Suramin-sensitive component as a 
% of Control Response 
  2 Hz 8 Hz 
SS 75 ± 7 90 ± 13 
SS 
(P+R) 
10 ± 4 ** 21 ± 6 ** 
SS 
(R+P) 
43 ± 11 46 ± 11 * 
 
 
 
5.3.1.6 Revealing the P2X receptors role in the response to 
sympathetic nerve stimulation at 8 Hz. 
 
At 8 Hz, the response to EFS following blockade of P2X receptors significantly impacted 
the peak tension, the tension at the end of the stimulation period and the rate of rise. The 
peak tension and the tension recorded at the end of the stimulation period were significantly 
reduced following suramin incubation with the rate of rise also being reduced (Figure 5-14; 
Table 5-9).  
 
 
 
 
 
 
 
 
 
 
 
Control 
1 mM Suramin 
Figure 5-14: WT Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n = 6).  
** P < 0.01 compared with control response. Paired t-test. 
**
 
**
 
Table 5-8: WT mouse mesenteric artery response - revealing the suramin-sensitive 
component as a % of control area under the curves. Data taken from Figures 5-13 
and 5-15. 
* P < 0.05; ** P < 0.01 compared with SS component when the α1- and α2-ARs were 
functional. One way ANOVA with Bonferonni’s post-test. 
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 6) 
% change following 
S incubation 
Time to Peak (seconds) 6.4 ± 0.3 7.1 ± 0.4 8 ± 5 
Peak Tension (mg) 248 ± 45 87 ± 27 ** - 61 ± 13 
Rate of Rise (mg/s) 37 ± 3 12 ± 4 ** - 65 ± 11 
Tension at End of pulse (mg) 237 ± 44 75 ± 27 ** - 66 ± 11 
50 % Decay Time (seconds) 4.5 ± 0.7 4.1 ± 0.7 - 12 ± 11 
 
 
 
Analysis of the suramin-sensitive (SS) components show the largest area to be when the α1- 
and α2-ARs are functional. This response is significantly larger than the responses recorded 
when α1- and α2-ARs are blocked; in either order (Figure 5-15; Table 5-8). 
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Figure 5-15: WT mouse mesenteric artery – the suramin-sensitive component at 8 Hz 
when the α1- and α2-ARs are functional (white) (n=6), α1- and α2-ARs are blocked 
(grey) (n=4), α2-ARs and α1-ARs are blocked (black) (n=7). 
* P < 0.05; ** P < 0.01 compared with SS component when the α1- and α2-ARs are 
functional. One way ANOVA with Bonferonni’s post-test. 
  
SS SS 
(P+R) 
SS 
(R+P) 
Table 5-9: WT Mouse mesenteric artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
** P < 0.01 compared with control response. Paired t-test. 
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5.3.2 Proximal and Distal Mouse Tail Artery 
 
The present results in the mouse tail artery indicate little difference between the proximal 
and distal segments (Tables 5-10 and 5-11). At the points studied, only the tension recorded 
at the second peak of the 8 Hz stimulation was lower in the distal segments compared to the 
proximal response. For this reason, the results section includes only graphs from one area of 
the tail and only discrepancies in results were noted.  
 
 
 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Proximal Distal 
Time to Peak (1st) (seconds) 2.4 ± 0.4 2.9 ± 0.4 
Peak Tension (1st) (mg) 50 ± 19 58 ± 17 
Rate of Rise (mg/s)  17 ± 4 17 ± 3 
Time to Peak (seconds) 37.6 ± 1.1 37.0 ± 2.8 
Peak Tension (mg) 344 ± 44 316 ± 46 
Tension at End of pulse (mg) 330 ± 43 303 ± 45 
50 % Decay Time (seconds) 15.0 ± 1.6 12.1 ± 2.9 
 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
Proximal Distal 
Tension at End of pulse (mg) 240 ± 32 183 ± 14 
Time to Peak (seconds) 4.9 ± 0.1 4.9 ± 0.1 
Peak Tension (mg) 563 ± 51 494 ± 29 
Rate of Rise (mg/s) 117 ± 11 85 ± 9 
Time to Peak (2nd) (seconds) 11.2 ± 0.5 12.3 ± 0.3 
Peak Tension (2nd) (mg) 369 ± 48 285 ± 22 * 
50 % Decay Time (seconds) 15.4 ± 1.8 13.3 ± 1.2 
 
 
Table 5-10: WT Proximal and Distal mouse tail artery response to nerve stimulation 
at 0.5 Hz.  
Table 5-11: WT Proximal and Distal mouse tail artery response to nerve stimulation 
at 8 Hz.  
* P < 0.05 compared with proximal response. Un-paired t-test. 
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Combined incubation with prazosin (100 nM), rauwolscine (100 nM) and suramin (1 mM) 
effectively blocked the α1-, α2-ARs and P2X receptors respectively in response to nerve 
stimulation at 0.5 Hz and 8 Hz in the tail artery and completely abolished the response 
(Figures 5-16 and 5-17). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Control 
100 nM Prazosin (P) + 
100 nM Rauwolscine (R) 
+ 1 mM Suramin (S) 
Figure 5-16: WT Proximal mouse tail artery response to nerve stimulation at 0.5 Hz 
in control vessels and in the presence of the following antagonists: 100 nM prazosin, 
100 nM rauwolscine, 1 mM suramin (n = 6).  
*** P < 0.001 compared with control response. Paired t-test. 
**
* 
**
* 
111 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.1 Revealing the α1-ARs role in the response to sympathetic 
nerve stimulation at 0.5 Hz. 
 
Following incubation with 100 nM prazosin (α1-AR antagonist), the response to stimulation 
of the sympathetic nerves was reduced; statistically affecting the rate of rise and both the 
peak tension and the tension recorded at the end of the stimulation period (Figure 5-18; Table 
5-12). In the distal tail artery, the tension recorded at the first peak was also significantly 
reduced following prazosin incubation (Table 5-13).  
 
 
 
 
 
 
Control 
100 nM P + 100 
nM R + 1 mM S 
Figure 5-17: WT Proximal mouse tail artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the following antagonists: 100 nM prazosin, 100 
nM rauwolscine, 1 mM suramin (n = 6).  
*** P < 0.001 compared with control response. Paired t-test. 
 
**
* 
**
* 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 12) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 2.4 ± 0.4 1.9 ± 0.3 - 21 ± 6  
Peak Tension (1st) (mg) 50 ± 19 14 ± 2  - 44 ± 14 
Rate of Rise (mg/s)  17 ± 4 8 ± 1 * - 42 ± 9 
Time to Peak (seconds) 37.6 ± 1.1 37.6 ± 1.5  6 ± 4 
Peak Tension (mg) 344 ± 44 206 ± 35 ***  - 33 ± 10 
Tension at End of pulse (mg) 330 ± 43 195 ± 33 ***  - 34 ± 10 
50 % Decay Time (seconds) 15.0 ± 1.6 14.4 ± 1.7  6 ± 11 
 
 
 
 
 
 
Table 5-12: WT Proximal mouse tail artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05, *** P < 0.001 compared with control response. Paired t-test. 
**
* 
**
* 
Figure 5-18: WT Proximal mouse tail artery response to nerve stimulation at 0.5 Hz 
in control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n 
= 12).  
*** P < 0.001 compared with control response. Paired t-test. 
Control 
100 nM Prazosin 
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 12) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 2.9 ± 0.4 2.2 ± 0.2 7 ± 13 
Peak Tension (1st) (mg) 58 ± 17 16 ± 3 * - 22 ± 21 
Rate of Rise (mg/s) 17 ± 3 8 ± 2 * - 44 ± 13 
Time to Peak (seconds) 37.0 ± 2.8 36.5 ± 1.5 8 ± 15 
Peak Tension (mg) 316 ± 46 227 ± 34 *** - 23 ± 6 
Tension at End of pulse (mg) 303 ± 45 217 ± 34 *** - 24 ± 7 
50 % Decay Time (seconds) 12.1 ± 2.9 14.9 ± 1.6 8 ± 9 
 
 
 
Figure 5-19 displays the prazosin-sensitive (PS) components that were isolated in five 
different ways. The PS component was identified by subtracting averaged traces in several 
incubation sequences as follows: 
 
1. The PS component was revealed as the difference between the control trace and the 
trace following prazosin incubation – when both the α2-ARs and P2X receptors were 
still activated by nerve-released transmitters (Figure 5-19a). The difference is shown 
in the shading and the key indicates that it is the PS component.  
 
2. The PS component in the absence of α2-AR activation was revealed by the difference 
between the trace in rauwolscine and that following rauwolscine plus prazosin 
(Figure 5-19b). Shown in brackets are the additional antagonists present; in this 
example, rauwolscine. 
 
3. The PS component in the absence of P2X receptor activation was revealed by the 
difference between the trace in suramin and that following suramin plus prazosin 
(Figure 5-19c). Shown in brackets are the additional antagonists present; in this 
example, suramin. 
 
4. When the arteries were incubated in both rauwolscine and suramin, so that neither 
the α2-ARs nor the P2X receptors were activated, the PS component was revealed 
Table 5-13: WT Distal mouse tail artery response to nerve stimulation in control and 
prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05, *** P < 0.001 compared with control response. Paired t-test. 
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(Figure 5-19d). Shown in brackets are the additional antagonists present and in the 
order the tissues were incubated; in this example, rauwolscine plus suramin. 
 
5. When the arteries were incubated in both suramin and rauwolscine, so that neither 
the P2X receptors nor the α2-ARs were activated, the PS component was revealed 
(Figure 5-19e). Shown in brackets are the additional antagonists present and in the 
order the tissues were incubated; in this example, suramin plus rauwolscine. 
 
The trapezoidal methods for calculating the area under the curve was used to determine the 
shaded areas which were taken to represent the total magnitude of the response due to 
activation of the α1-ARs. The values calculated are represented as a percentage of the control 
response (Figure 5-20; Table 5-14). The distal tail artery results produced the same 
significant differences as those in the proximal segments (Table 5-15). 
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Control 
100 nM Prazosin 
PS 
100 nM R 
100 nM R + 100 nM P 
PS (R) 
Control 
Control 
1 mM S  
PS (S)  
a 
b 
c 
1 mM S + 100 nM P 
Figure 5-19: Traces showing the revealed prazosin sensitive (PS) components isolated 
in five different ways (a-e). 
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Control 
1 mM S + 100 nM R  
Control 
100 nM R + 1 mM S  
PS (R+S)  
PS (S+R)  
Figure 5-19: Traces showing the revealed prazosin sensitive (PS) components isolated 
in five different ways – (a) shows the PS component when the α2-ARs and P2X 
receptors are active; (b) shows the PS component when the α2-ARs are blocked; (c) 
shows the PS component when the P2X receptors are blocked; (d) shows the PS 
component when the α2-ARs and P2X receptors are blocked; (e) shows the PS 
component when the P2X receptors and α2-ARs are blocked.   
d 
e 
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Prazosin-sensitive component as 
a % of the Control Response 
 0.5 Hz 8 Hz 
PS 44 ± 6 47 ± 3.6 
PS 
(R) 
14 ± 3 * 38 ± 7 
PS 
(S) 
69 ± 27 99 ± 31 
PS 
(R+S) 
7 ± 5 * 20 ± 9 ** 
PS 
(S+R) 
4 ± 2 ** 24 ± 13 ** 
 
 
 
* P < 0.05; ** P < 0.01 compared with the PS component when the P2X receptors are 
blocked. One way ANOVA with Bonferonni’s post-test. 
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Figure 5-20: WT Proximal mouse tail – the prazosin-sensitive component at 0.5 Hz 
when the P2X receptors and α2-ARs are functional (white) (n=13), α2-ARs are blocked 
(light grey) (n=8), P2X receptors blocked (dark grey) (n=7), the α2-ARs and P2X 
receptors are blocked (black) (n=6), P2X receptors and α2-ARs are blocked (striped) 
(n=7). 
* P < 0.05; ** P < 0.01 compared with PS component when the P2X receptors are 
blocked. One way ANOVA with Bonferonni’s post-test. 
PS PS 
(R) 
PS 
(S) 
PS 
(R+S) 
PS 
(S+R) 
Table 5-14: WT Proximal mouse tail artery – the prazosin-sensitive component as a 
% of control area under the curves. Data taken from Figures 5-20 and 5-22. 
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Prazosin-sensitive component as 
a % of the Control Response 
 0.5 Hz 8 Hz 
PS 31 ± 4 *** 38 ± 7 *** 
PS 
(R) 
31 ± 6 *** 35 ± 3 *** 
PS 
(S) 
112 ± 16 118 ± 24 
PS 
(R+S) 
22 ± 13 *** 38 ± 7 ** 
PS 
(S+R) 
11 ± 4 *** 38 ± 7 *** 
 
 
 
5.3.2.2 Revealing the α1-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz. 
 
At 8 Hz, the response to EFS following blockade of α1-ARs results in reduced peak tensions, 
and the tension recorded at the end of the stimulation with the time taken to reach both peaks 
occurring later (Figure 5-21; Table 5-16). This was true also for the distal tail artery 
responses (Table 5-17). 
 
 
 
 
 
 
 
 
 
Table 5-15: WT Distal mouse tail artery – the prazosin-sensitive component as a % 
of control area under the curves 
** P < 0.01; *** P < 0.001 compared with the PS component when the P2X receptors are 
blocked. One way ANOVA with Bonferonni’s post-test. 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 12) 
% change following P 
incubation 
Tension at End of pulse (mg) 240 ± 32 135 ± 21 *** - 35 ± 8 
Time to Peak (seconds) 4.9 ± 0.1 7.7 ± 1.3 + 29 ± 17 
Peak Tension (mg) 563 ± 51 267 ± 34 *** - 53 ± 5 
Rate of Rise (mg/s) 117 ± 11 42 ± 6 *** - 65 ± 4 
Time to Peak (2nd) (seconds) 11.2 ± 0.5 13.4 ± 0.7 + 11 ± 5 
Peak Tension (2nd) (mg) 369 ± 48 212 ± 34 *** - 40 ± 7 
50 % Decay Time (seconds) 15.4 ± 1.8 15.4 ± 1.6 4 ± 9 
 
 
 
 
  
**
* 
**
* 
**
* 
Figure 5-21: WT Proximal mouse tail artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n = 12).  
*** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
Control 
100 nM Prazosin 
+ 
+ 
**
* 
Table 5-16: Proximal mouse tail artery response to nerve stimulation in control and 
prazosin (100 nM) incubated vessels at 8 Hz.  
*** P < 0.001 compared with control response.  
Paired t-test. + P < 0.05 compared with control time. Paired t-test. 
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 12) 
% change following P 
incubation 
Tension at End of pulse (mg) 183 ± 14 93 ± 16 ** - 52 ± 6 
Time to Peak (seconds) 4.9 ± 0.1 7.4 ± 1.0 + 38 ± 10 
Peak Tension (mg) 494 ± 29 269 ± 35 *** - 39 ± 7 
Rate of Rise (mg/s) 85 ± 9 44 ± 7 *** - 52 ± 5 
Time to Peak (2nd) (seconds) 12.3 ± 0.3 15.6 ± 0.6 +++ 26 ± 6 
Peak Tension (2nd) (mg) 285 ± 22 217 ± 35 ** - 29 ± 6 
50 % Decay Time (seconds) 13.3 ± 1.2 16.6 ± 1.9 4 ± 8 
 
 
 
 
The influence of the α1-ARs on the response to nerve stimulation depends on the antagonist 
incubation sequence (Figure 5-22). The prazosin-sensitive component was greatest when 
prazosin was incubated following P2X receptor blockade; when the α2-ARs are still 
functional. The prazosin-sensitive component was smaller following blockade of the α2-ARs 
and the P2X receptors (Table 5-14). Distally, the prazosin-sensitive components were similar 
(Table 5-15). 
 
 
 
 
 
 
 
 
 
 
 
Table 5-17: Distal mouse tail artery response to nerve stimulation in control and 
prazosin (100 nM) incubated vessels at 8 Hz. 
** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05, +++ P < 0.001 compared with control time. Paired t-test. 
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5.3.2.3 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 0.5 Hz. 
 
Following incubation with 100 nM rauwolscine (α2-AR antagonist), the response to 
stimulation of the sympathetic nerves was reduced (Figure 5-23; Table 5-18). Distally, the 
peak tension, the tension at the end of the stimulation period and the time to reach the first 
peak were all reduced (Table 5-19).  
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Figure 5-22: WT Proximal mouse tail – the prazosin-sensitive component at 8 Hz when 
the P2X receptors and α2-ARs are functional (white) (n=13), α2-ARs are blocked (light 
grey) (n=8), P2X receptors blocked (dark grey) (n=7), the α2-ARs and P2X receptors 
are blocked (black) (n=6), P2X receptors and α2-ARs are blocked (striped) (n=7). 
** P < 0.01 compared with the PS component when the P2X receptors are blocked. 
One way ANOVA with Bonferonni’s post-test. 
  
PS PS 
(R) 
PS 
(S) 
PS 
(R+S) 
PS 
(S+R) 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 13) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 3.1 ± 0.3 1.6 ± 0.1 +++  - 42 ± 5 
Peak Tension (1st) (mg) 42 ± 12 12 ± 1 *  - 56 ± 6 
Rate of Rise (mg/s)  12 ± 2 8 ± 1 *  - 24 ± 10 
Time to Peak (seconds) 37.6 ± 1.4 27.4 ± 2.1 ++  - 26 ± 6 
Peak Tension (mg) 328 ± 20 81 ± 11 ***  - 75 ± 3 
Tension at End of pulse (mg) 317 ± 20 74 ± 11 ***  - 77 ± 3 
50 % Decay Time (seconds) 12.6 ± 1.8 17.3 ± 1.9 +  19 ± 10 
 
 
 
 
 
Table 5-18: WT Proximal mouse tail artery response to nerve stimulation in control 
and 100 nM rauwolscine incubated vessels at 0.5 Hz.  
Control 
100 nM Rauwolscine 
Figure 5-23: WT Proximal mouse tail artery response to nerve stimulation at 0.5 Hz 
in control vessels and in the presence of the α2-AR antagonist rauwolscine (100 nM) 
(n = 13).   
* P < 0.05; *** P < 0.001 compared with control response. Paired t-test.  
+ P < 0.05; ++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
  
* 
**
* 
**
* 
++
+ 
++
 
+ 
* P < 0.05; *** P < 0.001 compared with control response. Paired t-test. 
 + P < 0.05; ++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test.  
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 13) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 2.5 ± 0.2 2.1 ± 0.1 ++ - 17 ± 4 
Peak Tension (1st) (mg) 52 ± 22 21 ± 3 - 35 ± 9 
Rate of Rise (mg/s) 17 ± 5 10 ± 1 - 25 ± 10 
Time to Peak (seconds) 36 ± 3.3 35.1 ± 1.1 1 ± 10 
Peak Tension (mg) 324 ± 40 111 ± 17 *** - 64 ± 4 
Tension at End of pulse (mg) 307 ± 40 103 ± 16 *** - 64 ± 4 
50 % Decay Time (seconds) 18.3 ± 2.6 10.6 ± 1.3 + - 32.3 ± 9.0 
 
 
 
 
The prazosin-sensitive components that were revealed differed depending on whether the 
α2-ARs and P2X receptors were blocked or active. This result occurred both proximally and 
distally (Figure 5-24; Table 5-20 and 5-21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-19: WT Distal mouse tail artery response to nerve stimulation in control and 
rauwolscine (100 nM) incubated vessels at 0.5 Hz.  
*** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05; ++ P < 0.01 compared with control time. Paired t-test. 
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Table 5-20: WT Proximal mouse tail artery - revealing the rauwolscine-sensitive 
component as a % of control area under the curves. Data taken from Figures 5-24 
and 5-26. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Rauwolscine-sensitive component as a 
% of the Control Response  
  0.5 Hz 8 Hz 
RS 77 ± 3 48 ± 6 
RS 
(P) 
61 ± 12 49 ± 7 
RS 
(S) 
25 ± 8 * 16 ± 5 
RS 
(P+S) 
10 ± 7 *** + 14 ± 5 
RS 
(S+P) 
45 ± 27 46 ± 21 
 
 
+ P < 0.05 compared with the RS component when the α1-ARs are blocked. One way 
ANOVA with Bonferonni’s post-test. 
* P < 0.05; *** P < 0.001 compared with the RS component when the P2X receptors and 
α1-ARs are functional. One way ANOVA with Bonferonni’s post-test. 
RS RS 
(P) 
RS 
(S) 
RS 
(P+S) 
RS 
(S+P) 
Figure 5-24: WT Proximal mouse tail – the rauwolscine-sensitive component at 0.5 Hz 
when the P2X receptors and α1-ARs are functional (white) (n=14), α1-ARs are blocked 
(light grey) (n=7), P2X receptors are blocked (dark grey) (n=7), when α1-ARs and P2X 
receptors are blocked (black) (n=6), P2X receptors and α1-ARs are blocked (striped) 
(n=7).  
* P < 0.05, *** P < 0.001 compared with the RS component when the α1-ARs and the 
P2X receptors are functional. One way ANOVA with Bonferonni’s post-test. 
+ P < 0.05 compared with the RS component when the α1-ARs and P2X receptors are 
blocked. One way ANOVA with Bonferonni’s post-test. 
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Rauwolscine-sensitive component as a 
% of the Control Response 
  0.5 Hz 8 Hz 
RS 65 ± 4 46 ± 5 *** 
RS 
(P) 
70 ± 5 65 ± 3 * 
RS 
(S) 
86 ± 17 + 62 ± 7 * 
RS 
(P+S) 
40 ± 9 48 ± 11 ** 
RS 
(S+P) 
80 ± 13 126 ± 30 
 
 
 
 
 
 
5.3.2.4 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz. 
 
Following incubation with 100 nM rauwolscine, the proximal response to stimulation of the 
sympathetic nerves was reduced (Figure 5-25; Table 5-22). The distal response was similar; 
however the time to reach the peak response was statistically reduced by rauwolscine 
whereas the time taken to reach the second peak was not (Table 5-23).  
 
 
 
 
 
 
Table 5-21: WT Distal mouse tail artery - revealing the rauwolscine-sensitive 
component as a % of control area under the curves. 
+ P < 0.05 compared with the RS component when the α1-ARs and P2X receptors are 
blocked (in that order). One way ANOVA with Bonferonni’s post-test. 
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with the RS component when the P2X 
receptors and α1-ARs are blocked (in that order). One way ANOVA with Bonferonni’s 
post-test. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 13) 
% change following R 
incubation 
Tension at End of pulse (mg) 189 ± 18 194 ± 17 2 ± 11 
Time to Peak (seconds) 5.0 ± 0.1 4.6 ± 0.1 - 7 ± 4 
Peak Tension (mg) 554 ± 27 446 ± 30 *** - 19 ± 4 
Rate of Rise (mg/s) 112 ± 6 97 ± 5.8 * - 13 ± 5 
Time to Peak (2nd) (seconds) 11.4 ± 0.4 13.9 ± 0.8 ++ 16 ± 4 
Peak Tension (2nd) (mg) 352 ± 25 149 ± 17 *** - 56 ± 6 
50 % Decay Time (seconds) 12.5 ± 1.9 5.8 ± 0.6 +++ - 49 ± 8 
 
 
 
 
 
Control 
100 nM Rauwolscine 
Figure 5-25: WT Proximal mouse tail artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the α2-AR antagonist rauwolscine (100 nM) (n 
= 13). 
*** P < 0.001 compared with control response. Paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
**
* 
**
* 
++
 
++
+ 
Table 5-22: WT Proximal mouse tail artery response to nerve stimulation in control 
and 100 nM rauwolscine incubated vessels at 8 Hz.  
* P < 0.05, *** P < 0.001 compared with control response. Paired t-test.  
++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 14) 
% change following R 
incubation 
Tension at End of pulse (mg) 232 ± 24 229 ± 21 1 ± 11 
Time to Peak (seconds) 4.9 ± 0.1 4.5 ± 0.1 ++ - 10 ± 2 
Peak Tension (mg) 622 ± 32 483 ± 34 *** - 22 ± 4 
Rate of Rise (mg/s) 127 ± 7 109 ± 8 * - 13 ± 5 
Time to Peak (2nd) (seconds) 12.3 ± 0.5 12.9 ± 0.4 5 ± 3 
Peak Tension (2nd) (mg) 317 ± 32 147 ± 19 *** - 52 ± 5 
50 % Decay Time (seconds) 12.9 ± 2.2 3.6 ± 0.3 +++ - 53 ± 8 
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Figure 5-26: WT Proximal mouse tail – the rauwolscine-sensitive component at 8 Hz 
when the P2X receptors and α1-ARs are functional (white) (n=14), α1-ARs are blocked 
(light grey) (n=7), P2X receptors are blocked (dark grey) (n=7), when α1-ARs and P2X 
receptors are blocked (black) (n=6), P2X receptors and α1-ARs are blocked (striped) 
(n=7).  
RS RS 
(P) 
RS 
(S) 
RS 
(P+S) 
RS 
(S+P) 
Table 5-23: WT Distal mouse tail artery response to nerve stimulation in control and 
100 nM rauwolscine incubated vessels at 8 Hz.  
* P < 0.05, *** P < 0.001 compared with control response. Paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with control time. Paired t-test. 
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Figure 5-26 shows the individual proximal rauwolscine sensitive components (Figure 5-25; 
Table 5-20) and the distal rauwolscine sensitive components are shown in Figure 5-27 as 
these were different to the proximal results (Table 5-21; Figure 5-27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.3.2.5 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 0.5 Hz. 
 
Blockade of the P2X receptors proximally with 1 mM suramin results in a prolonged time 
to reach the 1st peak (Figure 5-28; Table 5-24). Distally, the time to reach the 1st peak is not 
significantly affected by suramin incubation. However, the rate of rise and the time to reach 
the peak response are both significantly altered (Table 5-25). 
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Figure 5-27: WT Distal mouse tail – the rauwolscine-sensitive component at 8 Hz when 
the P2X receptors and α1-ARs are functional (white) (n=14), α1-ARs are blocked (light 
grey) (n=6), P2X receptors are blocked (dark grey) (n=6), when α1-ARs and P2X 
receptors are blocked (black) (n=7), P2X receptors and α1-ARs are blocked  (striped) 
(n=7). 
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with the RS component when the P2X 
receptors and α1-ARs are blocked. One way ANOVA with Bonferonni’s post-test. 
RS RS 
(P) 
RS 
(S) 
RS 
(P+S) 
RS 
(S+P) 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 13) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 2.1 ± 0.1 4.4 ± 0.3 +++ 50 ± 6  
Peak Tension (1st) (mg) 21 ± 4 59 ± 20  13 ± 24 
Rate of Rise (mg/s)  10 ± 2 13 ± 4  - 13 ± 17 
Time to Peak (seconds) 36.2 ± 1.4 28.5 ± 1.9  9 ± 6 
Peak Tension (mg) 295 ± 44 308 ± 81  - 38 ± 17 
Tension at End of pulse (mg) 285 ± 43 293 ± 80  - 40 ± 17 
50 % Decay Time (seconds) 10.9 ± 1.3 10.5 ± 1.8  - 14 ± 13 
 
 
 
 
 
 
 
Control 
1 mM Suramin 
Figure 5-28: WT Proximal mouse tail artery response to nerve stimulation at 0.5 Hz 
in control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n = 13).  
 +++ P < 0.001 compared with control time. Paired t-test. 
++
+ 
Table 5-24: WT Proximal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 0.5 Hz.  
+++ P < 0.001 compared with control time. Paired t-test. 
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 13) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 2.3 ± 0.1 3.0 ± 0.4 23 ± 12 
Peak Tension (1st) (mg) 34 ± 7 29 ± 9 - 8 ± 26 
Rate of Rise (mg/s) 14 ± 3 8 ± 2 ** - 43 ± 12 
Time to Peak (seconds) 33 ± 2.3 37.0 ± 2.7 ++ 3 ± 9 
Peak Tension (mg) 270 ± 42 216 ± 42 - 8 ± 13 
Tension at End of pulse (mg) 260 ± 41 203 ± 39 - 6 ± 14 
50 % Decay Time (seconds) 11.8 ± 2.2 14.2 ± 2.9 - 21 ± 9 
 
 
 
The suramin-sensitive component of the response differed depending on whether suramin 
was incubated alone or following incubation with one or more antagonists (Figure 5-29; 
Table 5-26 and 5-27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-25: WT Distal mouse tail artery response to nerve stimulation in control and 
suramin (1 mM) incubated vessels at 0.5 Hz.  
** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
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Figure 5-29: WT Proximal mouse tail – the suramin-sensitive component at 0.5 Hz 
when the α1- and α2-ARs are functional (white) (n=14), α1-ARs are blocked (light grey) 
(n=6), α2-ARs are blocked (dark grey) (n=6) α1- and α2-ARs are blocked (black) (n=7), 
α2- and α1-ARs are blocked (striped) (n=8).  
** P < 0.01 compared with SS component when the α1- and α2-ARs are functional. One 
way ANOVA with Bonferonni’s post-test. 
SS SS 
(P) 
SS 
(R) 
SS 
(P+R) 
SS 
(R+P) 
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Suramin-sensitive component as a % 
of the Control Response 
  0.5 Hz 8 Hz 
SS 108 ± 25 54 ± 9 
SS 
(P) 
36 ± 10 31 ± 8 
SS 
(R) 
35 ± 15 37 ± 11 
SS 
(P+R) 
4 ± 1 ** 10 ± 3 * 
SS 
(R+P) 
3 ± 1 ** 7 ± 1 * 
 
 
 
 
 
  
Suramin-sensitive component as a 
% of the Control Response 
  0.5 Hz 8 Hz 
SS 60 ± 16 35 ± 7 * 
SS 
(P) 
48 ± 16 36 ± 6 * 
SS 
(R) 
15 ± 2 20 ± 3 
SS 
(P+R) 
45 ± 25 4 ± 1 
SS 
(R+P) 
11 ± 2 17 ± 4 
 
 
 
5.3.2.6 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 8 Hz. 
 
At 8 Hz, the response following block of the P2X receptors is more greatly affected than the 
response at 0.5 Hz. In both proximal and distal segments, the peak amplitude and the tension 
at the end of the stimulation period were both significantly reduced. These changes led to a 
* P < 0.05; ** P < 0.01 compared with area under the curve when the α1- and α2-ARs are 
functional. One way ANOVA with Bonferonni’s post-test. 
Table 5-26: WT Proximal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. Data taken from Figures 5-29 
and 5-31. 
Table 5-27: WT Distal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. 
* P < 0.05 compared with area under the curve when the α1- and α2-ARs are blocked. 
One way ANOVA with Bonferonni’s post-test. 
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reduction in the rate of rise. The time taken to reach the 2nd peak was prolonged following 
suramin incubation. (Figure 5-30; Table 5-28 and 5-29). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 13) 
% change following S 
incubation 
Tension at End of pulse (mg) 208 ± 28 62 ± 18 *** - 79 ± 7 
Time to Peak (seconds) 5.1 ± 0.2 7.1 ± 1.3 12 ± 10 
Peak Tension (mg) 554 ± 58 376 ± 76 ** - 49 ± 11 
Rate of Rise (mg/s) 110 ± 12 59 ± 13 *** - 52 ± 8 
Time to Peak (2nd) (seconds) 12.0 ± 0.4 15.0 ± 0.7 ++ 12 ± 6 
Peak Tension (2nd) (mg) 350 ± 45 280 ± 68 - 44 ± 17 
50 % Decay Time (seconds) 13.4 ± 1.7 13.0 ± 1.9 - 3 ± 16 
 
 
 
 
Control 
1 mM Suramin 
Figure 5-30: WT Proximal mouse tail artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n = 13). 
** P < 0.01, *** P < 0.001 compared with control response. Paired t-test.  
++ P < 0.01 compared with control time. Paired t-test. 
  
**
* 
**
 
++
 
Table 5-28: WT Proximal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 13) 
% change following S 
incubation 
Tension at End of pulse (mg) 164 ± 24 45 ± 12 *** - 58 ± 9 
Time to Peak (seconds) 4.8 ± 0.1 7.2 ± 1.3 19 ± 10 
Peak Tension (mg) 410 ± 50 272 ± 44 ** - 30 ± 8 
Rate of Rise (mg/s) 86 ± 10 46 ± 9 *** - 48 ± 8 
Time to Peak (2nd) (seconds) 11.9 ± 0.6 15.7 ± 0.7 +++ 32 ± 7 
Peak Tension (2nd) (mg) 246 ± 37 204 ± 36 - 9 ± 15 
50 % Decay Time (seconds) 12.2 ± 2.0 15.8 ± 2.6 10 ± 13 
 
 
 
The suramin-sensitive components were shown to have similar areas at 8 Hz in both 
proximal and distal segments (Figure 5-31, Tables 5-26 and 5-27). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-29: WT Distal mouse tail artery response to nerve stimulation in control and 
suramin (1 mM) incubated vessels at 8 Hz.  
** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control time. Paired t-test. 
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Figure 5-31: WT Proximal mouse tail – the suramin-sensitive component at 8 Hz when 
the α1- and α2-ARs are functional (white) (n=14), α1-ARs are blocked (light grey) 
(n=6), α2-ARs are blocked (dark grey) (n=6) α1- and α2-ARs are blocked (black) (n=7), 
α2- and α1-ARs are blocked (striped) (n=8).  
* P < 0.05 compared with the SS component when the α1- and α2-ARs are functional. 
One way ANOVA with Bonferonni’s post-test. 
SS SS 
(P) 
SS 
(R) 
SS 
(P+R) 
SS 
(R+P) 
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5.4 Discussion 
 
The present study was set out to determine the post-junctional receptors involved in 
mediating the response to nerve stimulation in WT mesenteric and tail arteries.  
 
5.4.1 Mouse Mesenteric Arteries 
 
Antagonists for α1-, α2-ARs and P2X receptors abolished the response to nerve stimulation 
at 2 Hz and 8 Hz. Therefore, the receptors involved in mediating the response to nerve 
stimulation may involve the α1-, α2-ARs and P2X receptors. This suggests a release of NA 
and ATP from the nerve terminals which has been shown by others in the rat mesenteric 
arteries. Previous studies have shown activation of post-junctional α1-ARs and P2X 
receptors to be responsible for vasoconstriction, with blockade of pre-junctional α2-ARs 
enhancing the response (Angus et al., 1988; Gitterman and Evans, 2001). The adrenergic 
nerves have also been shown to be involved in nerve stimulation in the mouse mesenteric 
arteries (Fujiwara et al., 2012). Presently, stimulation of the mouse mesenteric arteries 
produced frequency dependent responses. Therefore the response at 2 Hz was smaller than 
the response at 8 Hz. This is similar to the nerve responses in the rat mesenteric arteries 
(Gitterman and Evans, 2001). In these arteries, responses at low frequency were dominated 
by ATP (non-adrenergic) and at high frequencies are dominated by adrenergic receptor 
activation (Sjoblom-Widfeldt et al., 1990).  
 
By employing selective antagonists for the α1-, α2-ARs and P2X receptors, it was possible 
to isolate each component of the response to nerve stimulation. A novel way of analysing 
the results, as described in the General Methods and Results section, allowed each 
component to be viewed whilst the other receptors were either active or blocked. This 
therefore provided information on whether the receptors can produce a response 
independently or whether they rely on the other receptors. No evidence of post-junctional 
interactions in the mouse mesenteric arteries have been published. However, in the rat, it has 
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been suggested that NA and ATP can produce a synergistic post-junctional response (Brock 
et al., 2006).  
 
Various points during the response to nerve stimulation were studied to determine the roles 
each receptor played in the response. The results from incubation with a single antagonist 
were compared to the control responses and significant differences calculated. Firstly, the 
time taken to reach the peak tension provides information on which receptors are involved 
in initiating the contraction and ensuring it reached the peak. Secondly, the tension at the 
peak demonstrates which receptors are involved in producing the peak amplitude. Thirdly, 
the tension at the end of the stimulation period indicates which receptors are active at the 
end of the stimulation. Finally, the time for the peak amplitude to reduce by 50 % reveals 
the receptors still active or the signalling processes when there is no longer a stimulus, and 
so provides information on the active receptors that prolong the response. Combined, these 
points provide valuable information concerning the whole response. Furthermore, where the 
peak tensions are similar, the rate of rise could detect differences in the generation of the 
response.  
 
5.4.2 α1-AR role in Mouse Mesenteric Arteries 
 
Of the three antagonists utilised, prazosin had the greatest effect on reducing the response to 
nerve stimulation at both frequencies. This highlights the role of the α1-ARs in 
vasoconstriction which has been shown in the rat, whereby continuous stimulation of the 
nerves can be effectively reduced by prazosin incubation (Sjoblom-Widfeldt et al., 1990). 
Presently, under each incubation condition, various points during the response were recorded 
for analysis. At 2 Hz, prazosin incubation reduced the peak tension and the tension recorded 
at the end of the stimulation period by 91 % ± 1 and 94 % ± 4 respectively. The remaining 
response was minimal, yet its time to peak response was not significantly different to the 
control. These results show the α1-ARs to be the main receptor responsible for producing the 
amplitude of the response. At 8 Hz, prazosin incubation still reduced the peak tensions 
recorded but it also reduced the time taken to reach the peak tension. This response may be 
due to the decrease in tension; allowing a faster initial increase. However, it may reveal an 
inhibitory action of the α1-ARs in prolonging the time taken to reach the peak tension. 
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The component analysis aimed to determine whether the α1-ARs act independently or 
whether they can interact with the other receptors by isolating the prazosin-sensitive 
component. This component was investigated when the α2-ARs and P2X receptors were 
active, when only the P2X receptors were active and when the α2-ARs and P2X receptors 
were blocked. At 2 Hz, the components were similar, suggesting that the α1-ARs do not 
require interaction with the other receptors at low frequency in order to produce a 
contraction. At 8 Hz, the α1-AR component that remained following α2-AR and P2X receptor 
blockade was significantly smaller than the component when only the P2X receptors were 
active. The component when the α2-ARs and P2X receptors were active showed a similar 
trend. It is the loss of active P2X receptors which leads to the smaller α1-AR component and 
thus suggests an interaction between these two receptors. Evidence of synergy has been 
reported in the rat mesenteric arteries where the reduction in nerve response following 
prazosin or suramin incubation was ~ 80 % and 40 – 70 % respectively (Brock et al., 2006). 
A value exceeding 100 % occurs when these results are combined and so the loss of one 
receptor impacts the remaining response.  
 
5.4.3 α2-AR role in Mouse Mesenteric Arteries 
 
The role of the α2-ARs was first recognised pre-junctionally as a mediator of 
neurotransmitter release before being accepted also as a post-junctional receptor, capable of 
producing a vasoconstriction (Docherty et al., 1979). Previous studies in the rat mesenteric 
arteries show α2-ARs to be limited to a pre-junctional location and so blockade of the 
receptors results in potentiation of the response due to increase transmitter output (Angus et 
al., 1988). In the present study, stimulation at 2 Hz in the presence of rauwolscine showed a 
trend to increase the peak response. At 8 Hz, this potentiation of the response was 
significantly larger than the control thus providing evidence that pre-junctional α2-ARs are 
present and activation with NA inhibits transmitter release. Interestingly, blockade of the α2-
ARs prolongs the time to peak suggesting that these receptors (most likely post-junctional) 
are involved in initiation of the contraction before the pre-junctional effect occurs. 
Furthermore, as the time taken for the peak response to decrease by 50 % was reduced, this 
would suggest again that post-junctional α2-ARs are present and, when activated by NA they 
can prolong the response. These results suggest that there are both pre- and post-junctional 
α2-ARs that are active at different times during the response. It is possible that initial NA 
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release following nerve stimulation acts at post-junctional α2-ARs to initiate the contraction. 
Then, during the pulse duration, NA acts at pre-junctional α2-ARs to modulate NA release. 
Following the end of the stimulation period, NA still present at the junction then acts at post-
junctional α2-ARs to prolong the contraction.  
 
The potentiation of the peak response is shown clearly in the component analysis. The 
rauwolscine sensitive component (when the α1-ARs and P2X receptors are active) is greater 
than the control response at both frequencies. This is due to increased transmitter output that 
can then act at post-junctional α1ARs and P2X receptors. There is some debate over whether 
NA and ATP are released together in similar quantities and whether release of ATP can also 
be mediated by pre-junctional α2-ARs. In the guinea pig mesenteric arteries, modulation of 
ATP release via pre-junctional α2-ARs occurred mainly at lower frequencies which included 
8 Hz (Mutafova-Yambolieva and Keef, 2001). The present results, at 2 Hz, show that when 
the α1-ARs are blocked, the rauwolscine sensitive component is significantly smaller than 
when the α1-ARs and P2X receptors are active. There is a trend to a similar result when the 
P2X receptors have been blocked but this change in component size is not as effective as 
when the α1-ARs are blocked. Therefore, this result suggests that the post-junctional α1-ARs 
are more greatly affected by pre-junctional α2-AR activity compared to the P2X receptors. 
Interestingly, this variation in component magnitude is less obvious at 8 Hz. Here, the 
increase in transmitter output does not favour either receptor and the rauwolscine sensitive 
components are similar, regardless of which receptors are active or blocked. As mentioned 
previously, synergy has been suggested in rat mesenteric arteries (Brock et al., 2006). This 
could also be true in the mouse as blockade of one receptor may be compensated for by 
another thus enabling the effect of pre-junctional α2-ARs to be maintained.  
 
 
5.4.4 P2X receptor role in Mouse Mesenteric Arteries 
 
Present results show activation of post-junctional P2X receptors are involved in initiation of 
the response to nerve stimulation, particularly at 2 Hz. This result can be expected as the 
P2X receptors are fast acting ion channels. Activation of the P2X receptors also contributes 
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to the amplitude of the response. Furthermore, at 2 Hz, the P2X receptor role continues 
beyond the end of the stimulation period with the receptors involved in prolonging the 
response and therefore lengthening the decay time. This is demonstrated by the shortened 
decay time when the vessels are incubated with suramin. 
 
The suramin sensitive component differed depending on the active receptors and the 
antagonist incubation sequences. At both frequencies, when the α1- and α2-ARs were active, 
the suramin sensitive component was greater than when the α1- and α2-ARs were blocked. 
This therefore indicates an interaction between the receptors whereby the P2X receptor 
response is partly dependent on the presence of the α-ARs. The sequence of blockade also 
appears to be important. When the α1-ARs are blocked before the α2-ARs the resulting P2X 
component shows a trend to be smaller than when blocked in the opposite order. In the 
mesenteric arteries interaction is most likely between the α1-ARs and the P2X receptors due 
to the large α1-AR involvement in this tissue (Brock et al., 2006). Furthermore, a synergy 
between these receptors has been demonstrated in the rat mesenteric arteries (Brock et al., 
2006).  
 
5.4.5 Proximal and Distal Mouse Tail Artery 
 
Co-incubation of prazosin, rauwolscine and suramin effectively blocked the α1-, α2-ARs and 
P2X receptors respectively and abolished the response to nerve stimulation at 0.5 Hz and 8 
Hz in proximal and distal tail artery. These same receptors have been shown to be responsible 
for the response to nerve stimulation in rat tail artery with simultaneous blockade abolishing 
the response (Bao et al., 1993b). In the present study, stimulation at 0.5 Hz and 8 Hz 
produced responses with two distinct peaks; an initial fast peak and a second slower peak. 
At 0.5 Hz, 20 pulses were delivered within 40 seconds and the peak response always 
occurred close to the end of the stimulation period. At 8 Hz, 20 pulses were delivered within 
2.5 seconds and the peak response always followed the end of the stimulation period. 
Various points from each response were analysed to determine which receptors were 
involved and at what part of the response. In the proximal rat tail artery, the initial response 
is due to activation of the P2X receptors, followed by α1-AR activation and finally α2-AR 
activation (Bao and Stjarne, 1993). 
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Initially, the response to nerve stimulation in mouse proximal and distal tail artery segments 
was investigated to determine whether the response changed along the length of the tail. This 
was shown to be true in the rat tail artery where the response to electrical stimulation was 
lower in distal compared to proximal segments (Medgett, 1985). Medgett also showed that 
proximally, the α1-ARs were more sensitive than distally and also indicated a role of pre-
junctional α2-ARs. This changes in distal segments, where the post-junctional effect of the 
α2-ARs are seen, but only when the α1-ARs are blocked; suggesting an interaction between 
these two receptors (Medgett, 1985). The present results in the mouse tail artery indicate 
little difference between the proximal and distal segments. At the points studied, only the 
tension recorded at the second peak of the 8 Hz stimulation was lower in the distal segments 
compared to the proximal response. This difference between mouse and rat tail artery could 
be due to the mouse tail being smaller, and therefore receptor population is similar so as to 
help maintain a homeostatic environment. The mouse tail artery has been implicated in 
thermoregulation whereby changes in tail artery constriction act as a protective measure 
against heat loss (Chotani et al., 2000). Therefore it may be more important to have 
consistent receptor input along the length of the tail. As few differences were found between 
proximal and distal segments, the results section included only graphs from one area of the 
tail and only discrepancies in results were noted.  
 
5.4.6 α1-AR role in Mouse Tail Artery 
 
In the present study, incubation with prazosin reduced the response to nerve stimulation at 
0.5 Hz and 8 Hz but not to the same degree as shown in the mesenteric arteries. The α1-ARs 
were shown to be involved throughout the response, particularly at 8 Hz where the receptors 
contributed to the initiation of the contraction. This was shown by prazosin prolonging the 
time taken to reach the peak and reducing the tension at the end of the stimulation period. 
These results differ from those shown in the rat whereby the post-junctional α1-ARs are 
believed to be responsible for the latter part of the response (Sneddon and Burnstock, 1984; 
Bao and Stjarne, 1993). However, the α1-ARs have also been shown to have a larger 
involvement at higher frequencies in the rat tail artery (Bao et al., 1993a). Presently, both 
proximal and distal results were similar.   
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The prazosin sensitive component at 0.5 Hz differed depending on the incubation sequence. 
The greatest component occurred when the P2X receptors had been blocked and the α2-ARs 
were active. When the P2X receptors and the α2-ARs were both blocked, the remaining α1-
AR component was small. This represents an example of interaction between all three of the 
receptors. Blockade of the P2X receptors enhances the α1-AR component but this component 
can only be enhanced if the α2-ARs are active. The same effect was seen at 8 Hz suggesting 
this is not frequency dependent. In the rat tail artery, studies have indicated an inhibitory role 
for the P2X receptors as αβme-ATP was able to enhance the second component of the 
response (Bao and Stjarne, 1993).  
 
5.4.7 α2-ARs role in Mouse Tail Artery 
 
Unlike the rat tail artery, where the α2-AR influence has been found to be secondary to the 
α1-AR response, in mouse tail artery the current study indicates a strong α2-AR component. 
At 0.5 Hz and 8 Hz, incubation with rauwolscine reduces the overall response and alters the 
time course of the response. At 0.5 Hz the time taken to reach both peaks is reduced by α2-
AR blockade suggesting that these receptors are involved in delaying vessel contraction and 
in inhibiting initiation of the response. This role has not been described previously in the rat 
tail artery. Conventionally, the α2-ARs have been shown to exist both pre- and post-
junctionally with pre-junctional block enhancing the response and post-junctional blockade 
inhibiting the response to nerve stimulation (Msghina et al., 1999; Bao and Stjarne, 1993; 
Weiss et al., 1983; Brock and Tan, 2004; Bao et al., 1993a). Interestingly, in proximal but 
not distal segments, there was evidence of pre-junctional α2-ARs; revealed when α2-AR 
blockade prolonged the time taken for the peak response to decay by 50 %. This could be 
explained by block of pre-junctional α2-ARs and subsequent enhancement of transmitter 
output. The opposite occurs distally whereby the decay time is reduced in the presence of 
rauwolscine. It is possible that blockade of pre-junctional α2-ARs and enhancement of 
transmitter output may either prolong the response by ensuring the post-junctional receptors 
remain active or the increase in transmitter output may accelerate transmitter uptake and 
smooth muscle relaxation via an unknown mechanism.  
 
141 
 
At 8 Hz, the α2-ARs have little involvement in the initiation of the contraction as the tension 
at the end of the stimulation period was not affected by rauwolscine incubation. Both of the 
peak tensions were reduced and so the α2-ARs play a definite role in contributing to the peak 
amplitude of the response, again more so than in the rat tail artery. A pre-junctional α2-AR 
presence is evident during the second peak component as rauwolscine incubation prolonged 
the time taken to reach this peak. However, the peak tension was not enhanced. Furthermore, 
when the vessels were incubated with rauwolscine, the decay time was reduced, again 
suggesting an alternative role for α2-ARs in smooth muscle relaxation.  
 
As these experiments focussed only on the smooth muscle, it is possible that this response 
to α2-AR antagonism was due to an endothelium dependent mechanism. Such a mechanism 
has been suggested by Crassous et al. who studied the effect α2-AR antagonism had on 
various agonists in the mouse tail artery. When the endothelium was present, α2-AR 
antagonism, in the presence of AR agonist, caused a vasodilation (Crassous et al., 2009).  
 
The rauwolscine sensitive component was found to vary depending on frequency, location 
and presence of the other receptors, therefore displaying complicated interactions with the 
other receptors. Proximally, at 0.5 Hz, the greatest rauwolscine sensitive component was 
revealed whilst the α1-ARs and P2X receptors were active, with this component being larger 
than when the P2X receptors were blocked and also when the α1-ARs and P2X receptors 
were both blocked. Therefore, although the α2-ARs have been shown to contribute most to 
the response, they are somewhat dependent on the presence of the other receptors, 
particularly the P2X receptors. Further evidence of this was shown when comparing the 
rauwolscine sensitive component when the P2X receptors were active (and α1-ARs blocked) 
and when both receptors were blocked. The loss of P2X receptor activity reduced the 
rauwolscine sensitive component significantly.  
 
Distally, at 0.5 Hz, the rauwolscine sensitive components were mostly similar, indicating 
that at this location, the α2-ARs are not dependent on the presence or absence of the other 
receptors. However, the component revealed when the α1-ARs and P2X receptors were 
blocked (in that order) was smaller than the component revealed when the α1-ARs were 
active (and P2X receptors blocked). This is opposite to the proximal response which suggests 
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that the α2-ARs could be somewhat dependent on the α1-ARs. Furthermore, this difference 
only occurs when the α1-ARs have been blocked first. This introduces a further complication 
by suggesting that the incubation sequence is important and so when prazosin is incubated 
first, it is in the bath for a longer period of time and may therefore exert a more profound 
antagonism than if incubated for a shorter time as is the case when the P2X receptors are 
blocked first.  
 
At 8 Hz, the proximal rauwolscine sensitive components were all found to be similar, 
although there was a trend for the components when the α1-ARs and P2X receptors were 
blocked to be smaller. As this did not reach significance the α2-ARs can be described as 
being able to produce a similar response that is independent of the other receptors. Distally, 
the response remaining following blockade of the P2X receptors and α1-ARs was greater 
than the initial control response and all of the other revealed components. This was due to 
an enhancement of the second slower component of the response which has been shown to 
occur in the rat tail artery (Bao and Stjarne, 1993; Bao et al., 1990). This effect did not occur 
when the α1-ARs were blocked first, again demonstrating the importance of the incubation 
sequence and suggesting that when the P2X receptors are antagonised for a longer period, 
the response can be enhanced. The other revealed components were all of a similar 
magnitude indicating little interaction between the receptors.  
 
The component analysis performed here to reveal the rauwolscine component highlights the 
complex interactions that occur between the receptors and show these interactions can 
change by altering the frequency or studying a different location. The α2-ARs could 
independently cause a contraction of proximal mouse tail artery when the nerves were 
stimulated at 8 Hz; these would be the most useful parameters for studying the α2-AR 
response without input from the other receptors.  
 
5.4.8 P2X receptor role in Mouse Tail Artery 
 
In the rat tail artery, ATP released from the nerve terminals has been indicated in activation 
of post-junctional P2X receptors and subsequent fast initiation of a contractile response 
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(Sneddon and Burnstock, 1984; Bao and Stjarne, 1993). The present results indicate that this 
also occurs in the mouse tail artery as P2X receptor antagonism with suramin prolonged the 
time taken to reach the peak tensions at both frequencies and also contributed more to the 
overall contractile response at 8 Hz.  
 
The suramin sensitive components differed depending on the activity of the α-ARs. When 
both receptors were active, the suramin sensitive component was greatest and significantly 
larger than when the α-ARs were blocked indicating an interaction between all three 
receptors. This response occurred at both frequencies.  
 
5.4.9 Conclusion 
 
In summary, the presence of α1-, α2-ARs and P2X receptors has been confirmed in the mouse 
mesenteric and tail arteries. There are complicated interactions between all three receptors 
that can differ with frequency and vessel type. The α1-ARs dominated the response to nerve 
stimulation in the mesenteric arteries with little interaction with the other receptors. 
Conversely, the α2-ARs dominated the response in the tail artery but had more of an 
interaction/dependence on the other receptors. Evidence of pre-junctional α2-ARs was more 
clearly shown in the mesenteric arteries compared to the tail artery and the P2X receptors 
mainly contributed to the initiation of the contractile responses in both vessels. These results 
provide a framework for future studies in the α1-null and ADKO mice with which the WT 
results could be compared. The complicated nature of the responses provides reasoning for 
the poor performance of α1-AR antagonists in the treatment of primary hypertension and 
highlights the requirement for further investigation into the other receptors and the 
mechanisms with which they interact. This should enhance knowledge in this area and 
provide novel therapies for the treatment of hypertension. The development of α1-AR KO 
mice should simplify the complex pharmacology and such mice have been utilised in the 
following two studies.  
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Chapter Six 
 
Role of α1B-AR in nerve-evoked contractions in tail 
and mesenteric arteries revealed by comparison of 
tissues from knock-out and wild-type mice. 
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6.1 Introduction 
 
In Chapter Five, the receptors involved in the response to sympathetic nerve stimulation 
were characterised. The results suggested that in the mesenteric arteries, the α1-ARs are the 
main receptors involved in contraction. In the tail artery, α2-AR activation predominates with 
interactions between all three of the receptors studied. The findings from Chapter Five can 
now be used as controls for the present study in which mice lacking the α1A- and α1D-AR 
subtypes were utilised. 
 
Stimulation of the perivascular sympathetic nerves can induce the release of the 
neurotransmitters noradrenaline (NA) and adenosine tri-phosphate (ATP). These exert 
effects on smooth muscle post-junctional receptors in order to initiate vessel contraction 
(Bao and Stjarne, 1993) and can also activate pre-junctional receptors which mediate the 
further release of neurotransmitters from the nerve terminals (Msghina et al., 1999). 
 
The majority of studied vessels in the vasculature, including the mesenteric arteries, have 
been shown to constrict mainly through activation of post-junctional α1-ARs by NA (Angus 
et al., 1988). Other receptors have also been implicated in vessel contraction including post-
junctional α2-ARs and P2X receptors which are stimulated by NA and ATP respectively 
(Weiss et al., 1983; Gitterman and Evans, 2001). Activation of pre-junctional α2-ARs 
inhibits transmitter release (Brock and Tan, 2004).  
 
There is some evidence of post-junctional α2-ARs in mouse mesenteric arteries and there is 
a definite α2-AR mediated contraction in the rat tail artery (Fujiwara et al., 2012; 
Rajanayagam and Medgett, 1987). The exact roles of the mentioned receptors have been 
difficult to define due to limited selective antagonists and complex pharmacology. The 
development of transgenic mice and in particular α1-AR knock-out (KO) mice allows the 
effect of genetic removal of these receptors to be studied. This should reduce the complex 
pharmacology and allow an enhanced study of the remaining receptors and show how they 
responde to the loss of the α1-ARs. 
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Studies thus far on the α1-AR KO mice have mainly focussed on post-junctional response to 
selective and non-selective agonists and antagonists. The results presented in Chapter Three 
suggest that the α1-ARs are not as important in blood pressure maintenance as was previously 
believed as systolic blood pressure responses from WT, ADKO and α1-null mice were 
similar. The interaction with the sensory nerves was investigated in Chapter Four whereby 
the responses before and after the neurotoxin capsaicin were compared. Capsaicin depletes 
the sensory nerves of the potent vasodilator calcitonin gene-related peptide (CGRP). The 
WT and α1-null responses were similar before and after capsaicin treatment. However, in the 
ADKO a complex balance between the individual α1-ARs was noted as the response 
following capsaicin treatment increased (see Chapter Four). 
 
Presently, the ADKO mouse was employed which lacks the dominant α1A- and α1D-AR 
subtypes and therefore only the α1B-AR remained functional. This provides an opportunity 
to study the α1B-AR which is believed to only play a minor modulating role in the vessels. 
Furthermore, the impact on the α2-ARs and P2X receptors response in the ADKO can be 
studied thus determining whether either vessel compensates for the loss in the mouse 
mesenteric and tail arteries. Therefore the aims of the following study were: 
 To determine whether loss of the α1A+D-ARs prevents the response to nerve 
stimulation in the mouse mesenteric or tail arteries occurring. 
 To investigate the difference in response between WT and ADKO mesenteric and 
tail arteries. 
 To establish the role of the α1B-ARs in the response to nerve stimulation in mesenteric 
and tail arteries.  
 To determine whether there are any changes in the interactions between the receptors 
compared to those seen in the WT responses and therefore establish any 
compensatory mechanisms.  
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6.2 Methods 
 
A full description of the methods used can be found in Chapter Two (Materials and 
Methods). Briefly, wire myography studies were conducted using mouse mesenteric arteries 
and proximal and distal tail artery segments. The vessels were mounted between two 
stimulating electrodes which could be used to deliver square wave pulses of varying 
parameters. All vessels were incubated with 1 µM capsaicin in order to deplete the sensory 
nerves of CGRP; a potent vasodilator. Control response to 2 Hz and 8 Hz (mesenteric 
arteries) and 0.5 Hz and 8 Hz (tail artery) were recorded before incubation with one of the 
following antagonists: 100 nM prazosin (α1-AR antagonist), 100 nM rauwolscine (α2-AR 
antagonist) or 1 mM suramin (P2X receptor antagonist). The vessels were then stimulated 
again using the same parameters. 
 
Statistical analysis was performed using GraphPad Prism (Version 5) with paired t-tests used 
when comparing control response with antagonist response and one way ANOVA with 
Bonferonni’s post-test utilised for comparing the antagonist sensitive components. A worked 
example of the component analysis, which revealed the antagonist sensitive response in 
different incubation sequences is shown at the beginning of the mesenteric and tail artery 
results sections in Chapter Five. The analyses of the antagonist sensitive components were 
only conducted in the tail artery responses as the mesenteric artery responses were too small 
to produce reliable statistics. 
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6.3 Results 
 
6.3.1 Mesenteric Artery 
 
6.3.1.1 Comparison of WT and ADKO response to nerve 
stimulation. 
 
Both WT and ADKO mesenteric arteries responded to nerve stimulation at 2 Hz and 8 Hz 
(Figure 6-1 and 6-2). At both frequencies the peak tension and the tension at the end of the 
stimulation periods were reduced in the ADKO mice. At 2 Hz, the time to reach the peak 
tension was altered in the ADKO mice (Figure 6-1 and 6-2; Tables 6-1 and 6-2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6-1: WT and ADKO mouse mesenteric arteries - response to nerve stimulation 
at 2 Hz (WT: n=17; ADKO: n=20).  
** P < 0.01; *** P < 0.001 compared with WT response. Un-paired t-test. 
+ P < 0.05 compared with WT time. Un-paired t-test. 
Wild Type 
ADKO **
* 
+ 
**
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2 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=17) 
ADKO 
(n=20) 
Time to Peak (seconds) 7.2 ± 0.2 13.0 ± 2.0 + 
Peak Tension (mg) 72 ± 9 15 ± 3 *** 
Rate of Rise (mg/s) 10 ± 1 2 ± 0.4 *** 
Tension at End of pulse (mg) 38 ± 8 11 ± 3 ** 
50 % Decay Time (seconds) 12.2 ± 2.0 7.5 ± 1.8 
 
 
 
 
 
 
 
 
 
Wild Type 
ADKO 
Figure 6-2: WT and ADKO mouse mesenteric arteries - response to nerve stimulation 
at 8 Hz (WT: n=17; ADKO: n=20).  
*** P < 0.001 compared with WT response. Un-paired t-test. 
**
* 
**
* 
Table 6-1: WT and ADKO mouse mesenteric arteries - response to nerve stimulation 
at 2 Hz.  
** P < 0.01; *** P < 0.001 compared with WT response. Un-paired t-test. 
+ P < 0.05 compared with WT time. Un-paired t-test. 
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8 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=17) 
α1-null 
(n=20) 
Time to Peak (seconds) 6.0 ± 0.2 5.8 ± 0.4 
Peak Tension (mg) 223 ± 20 42 ± 6 *** 
Rate of Rise (mg/s) 40 ± 3 7 ± 1 *** 
Tension at End of pulse (mg) 215 ± 20 36 ± 5 *** 
50 % Decay Time (seconds) 4.1 ± 0.3 5.0 ± 0.4 
 
 
Combined incubation with prazosin (100 nM), rauwolscine (100 nM) and suramin (1 mM)  
in the ADKO animals effectively blocked the α1-, α2-ARs and P2X receptors respectively in 
response to nerve stimulation at 2 Hz and 8 Hz in the mesenteric arteries and completely 
abolished the response (Figures 6-3 and 6-4). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-2: WT and ADKO mouse mesenteric arteries - response to nerve stimulation 
at 8 Hz.  
*** P < 0.001 compared with WT response. Un-paired t-test. 
 
Figure 6-3: ADKO Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of the following antagonists: prazosin (100 nM), 
rauwolscine (100 nM), suramin (1 mM) (n = 4).  
ADKO Control 
100 nM Prazosin (P) + 
100 nM Rauwolscine (R) 
+ 1 mM Suramin (S) 
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6.3.1.2 Revealing the response to sympathetic nerve stimulation at 
2 Hz. 
 
Individual incubations with 100 nM prazosin, 100 nM rauwolscine and 1 mM suramin did 
not result in a significant change in the response compared with the ADKO control response 
(Figure 6-5; Tables 6-3 – 6-5). 
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Figure 6-4: ADKO Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the following antagonists: prazosin (100 nM), 
rauwolscine (100 nM), suramin (1 mM) (n = 4).  
ADKO Control 
100 nM P + 
100 nM R + 
1 mM S 
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 ADKO Control 
100 nM Prazosin 
100 nM Rauwolscine 
1 mM Suramin 
Figure 6-5: ADKO Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of 100 nM prazosin (red) (n=6); 100 nM 
rauwolscine (purple) (n=7); 1 mM suramin (blue) (n=7).  
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2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 4) 
% change following P 
incubation 
Time to Peak (seconds) 11.1 ± 5.0 9.9 ± 4.9 - 7 ± 35 
Peak Tension (mg) 11 ± 5 8 ± 3 - 20 ± 24 
Rate of Rise (mg/s) 1 ± 0.4 1 ± 0.1 - 18 ± 31 
Tension at End of pulse (mg) 7 ± 5 4 ± 3 - 33 ± 47 
50 % Decay Time (seconds) 8.6 ± 4.1 3.8 ± 1.4 - 8 ± 45 
 
 
 
 
2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 9) 
% change following R 
incubation 
Time to Peak (seconds) 17.4 ± 2.8 12.0 ± 3.7 - 25 ± 18 
Peak Tension (mg) 12 ± 2 8 ± 2 - 24 ± 16 
Rate of Rise (mg/s) 1 ± 0.3 1 ± 0.3 - 4 ± 20 
Tension at End of pulse (mg) 8 ± 2 3 ± 2 - 54 ± 29 
50 % Decay Time (seconds) 6.2 ± 2.5 4.2 ± 2.9 - 40 ± 25 
 
 
 
 
2 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Time to Peak (seconds) 8.5 ± 2.5 10.5 ± 4.5 - 30 ± 23 
Peak Tension (mg) 23 ± 8 15 ± 8 - 51 ± 17 
Rate of Rise (mg/s) 3 ± 1 1 ± 0.4 - 40 ± 15 
Tension at End of pulse (mg) 17 ± 9 10 ± 8 - 80 ± 25 
50 % Decay Time (seconds) 8.5 ± 3.5 5.7 ± 2.7 - 61 ± 15 
 
 
Table 6-3: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 2 Hz.  
Table 6-4: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 2 Hz.  
Table 6-5: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 2 Hz.  
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When the mesenteric arteries where incubated with more than one antagonist, there was 
greater statistical significance in the response compared to incubation with one antagonist 
(Table 6-6). 
 
 
 
2 Hz Contractile Response (average ± S.E.M) 
Part of response affected by 
antagonist incubation 
Antagonist Incubation sequence 
1 mM S + 
100 nM R 
100 nM R, 100 nM P,  
1 mM S 
1 mM S, 100 nM R, 
100 nM P 
Time to Peak (seconds)   +++ 
Rate of Rise (mg/s) *  * 
Tension at End of pulse (mg)  *  
50 % Decay Time (seconds) +   
 
 
 
 
6.3.1.3 Revealing the response to sympathetic nerve stimulation at 
8 Hz. 
 
Prazosin incubated alone did not result in a significant change in the response compared with 
the ADKO control response. However, incubation with 100 nM rauwolscine reduced the 
time to reach the peak tension and incubation with 1 mM suramin significantly reduced the 
peak tension, the tension at the end of the stimulation period and the rate of rise (Figure 6-
6; Tables 6-7 – 6-9).  
 
 
 
 
Table 6-6: The significant changes to the response at 2 Hz when incubation was 
with more than one antagonist.  
* P < 0.05 compared with control response. Paired t-test. 
+ P < 0.05; +++ P < 0.001 compared with control time. Paired t-test. 
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 4) 
% change following P 
incubation 
Time to Peak (seconds) 4.8 ± 0.9 4.8 ± 0.8 3 ± 11 
Peak Tension (mg) 36 ± 5 31 ± 6 - 13 ± 15 
Rate of Rise (mg/s) 8 ± 1 7 ± 1 - 18 ± 7 
Tension at End of pulse (mg) 32 ± 4 28 ± 5 - 11 ± 17 
50 % Decay Time (seconds) 5.7 ± 0.6 4.6 ± 0.2 - 17 ± 8 
 
 
 
 
 
 
 
50
40
30
20
10
0
T
e
n
s
io
n
 (
m
g
)
403020100
Time (s)
ADKO Control 
100 nM Prazosin 
100 nM Rauwolscine 
1 mM Suramin 
+ 
**
 
**
 
Figure 6-6: ADKO Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of 100 nM prazosin (red) (n=6); 100 nM 
rauwolscine (purple) (n=7); 1 mM suramin (blue) (n=7).  
** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
Table 6-7: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 8 Hz.  
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 9) 
% change following 
R incubation 
Time to Peak (seconds) 6.5 ± 0.4 5.5 ± 0.3 + - 13 ± 6 
Peak Tension (mg) 33 ± 5 30 ± 6 - 13 ± 13 
Rate of Rise (mg/s) 5 ± 1 5 ± 1 - 3 ± 12 
Tension at End of pulse (mg) 29 ± 4 28 ± 6 - 11 ± 5 
50 % Decay Time (seconds) 3.8 ± 0.4 3.0 ± 0.4 - 17 ± 11 
 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following 
S incubation 
Time to Peak (seconds) 5.4 ± 0.8 7.4 ± 2.0 4 ± 17 
Peak Tension (mg) 56 ± 16 28 ± 14 ** - 64 ± 10 
Rate of Rise (mg/s) 9 ± 1 3 ± 1 *** - 66 ± 9 
Tension at End of pulse (mg) 47 ± 12 18 ± 10 ** - 76 ± 12 
50 % Decay Time (seconds) 6.2 ± 0.9 4.7 ± 1.8 - 38 ± 20 
 
 
When the mesenteric arteries where incubated with more than one antagonist, there were 
additional changes in the response compared to incubation with one antagonist (Table 6-10).  
 
 
 
 
 
 
Table 6-8: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 8 Hz.  
+ P < 0.05 compared with control response. Paired t-test. 
Table 6-9: ADKO Mouse mesenteric artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
** P < 0.01; *** P < 0.001 compared with control response. Paired t-test. 
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8 Hz Contractile Response (average ± S.E.M) 
Part of response 
affected by 
antagonist 
incubation 
Antagonist Incubation sequence 
100 nM P 
100 nM R 
100 nM R 
100 nM P 
1 mM S 
100 nM R 
100 nM P 
100 nM R 
1 mM S 
100 nM R 
100 nM P 
1 mM S 
1 mM S 
100 nM R 
100 nM P 
Time to Peak 
(seconds) 
 +     
Peak Tension 
(mg) 
  ** ** ** * 
Rate of Rise 
(mg/s) 
**  *** * *** *** 
Tension at End 
of pulse (mg) 
  ** ** *** ** 
 
 
 
 
6.3.2 Mouse Tail Artery 
 
6.3.2.1 Comparison of WT and ADKO response to nerve 
stimulation. 
 
Both WT and ADKO tail artery responded to nerve stimulation at 0.5 Hz and 8 Hz with the 
response in the ADKO smaller than in the WT (Figure 6-7 and 6-8; Tables 6-11 and 6-12). 
 
 
 
 
 
 
 
Table 6-10: The significant changes to the response at 8 Hz when incubation was 
with more than one antagonist.  
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
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Figure 6-7: WT and ADKO mouse tail artery - response to nerve stimulation at 0.5 
Hz (WT: n=26; ADKO: n=25).  
* P < 0.05 compared with WT response. Un-paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with WT time. Un-paired t-test. 
Wild Type 
ADKO 
++
 
* 
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++
+ 
Figure 6-8: WT and ADKO mouse tail artery - response to nerve stimulation at 8 Hz 
(WT: n=26; ADKO: n=25).  
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with WT response. Un-paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with WT time. Un-paired t-test. 
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0.5 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=26) 
ADKO 
(n=25) 
Time to Peak (1st) (seconds) 2.6 ± 0.2 4.4 ± 0.2 +++ 
Peak Tension (1st) (mg) 34 ± 7 63 ± 10 * 
Rate of Rise (mg/s) 16 ± 3 15 ± 2 
Time to Peak (seconds) 37.2 ± 1.0 38.5 ± 1.0 
Peak Tension (mg) 338 ± 27 283 ± 31 
Tension at End of pulse (mg) 327 ± 26 283 ± 31 
50 % Decay Time (seconds) 12.8 ± 0.9 17.3 ± 1.3 ++ 
 
 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=26) 
ADKO 
(n=25) 
Tension at End of pulse (mg) 210 ± 19 135 ± 15 ** 
Time to Peak (seconds) 5.0 ± 0.1 6.5 ± 0.8 
Peak Tension (mg) 552 ± 32 365 ± 36 *** 
Rate of Rise (mg/s) 114 ± 6 67 ± 8 *** 
Time to Peak (2nd) (seconds) 11.8 ± 0.3 13.6 ± 0.5 ++ 
Peak Tension (2nd) (mg) 372 ± 29 284 ± 30 * 
50 % Decay Time (seconds) 13.7 ± 1.0 20.7 ± 0.9  +++ 
 
 
 
 
6.3.2.2 Revealing the effect of prazosin on the response to 
sympathetic nerve stimulation at 0.5 Hz. 
 
When the mouse tail artery was incubated with 100 nM prazosin, the response to nerve 
stimulation was similarly affected in both proximal and distal segments. Both showed a 
Table 6-11: WT and ADKO mouse tail arteries - response to nerve stimulation 
at 0.5 Hz.  
* P < 0.05 compared with WT response. Un-paired t-test. 
++ P < 0.01; +++ P < 0.01 compared with WT time. Un-paired t-test. 
Table 6-12: WT and ADKO mouse tail arteries - response to nerve stimulation 
at 8 Hz.  
* P < 0.05; ** P < 0.01; *** P < 0.001 compared with WT response. Un-paired t-test. 
++ P < 0.01; +++ P < 0.001 compared with WT time. Un-paired t-test. 
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reduction in tension at the first peak. Proximally, the time to reach this peak was reduced 
(Figure 6-9; Table 6-13). Distally, the rate of rise was reduced (Table 6-14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 4.3 ± 0.3 1.7 ± 0.4 +++ - 62 ± 8 
Peak Tension (1st) (mg) 26 ± 8 5 ± 1 * - 69 ± 13 
Rate of Rise (mg/s) 6 ± 1 3 ± 0.4 - 29 ± 17 
Time to Peak (seconds) 35.4 ± 3.1 39.5 ± 1.5 9 ± 10 
Peak Tension (mg) 150 ± 26 145 ± 38 - 9 ± 10 
Tension at End of pulse (mg) 143 ± 27 136 ± 39 - 11 ± 11 
50 % Decay Time (seconds) 19.3 ± 3.4 16.8 ± 1.8 - 2 ± 17 
 
 
ADKO Control 
100 nM Prazosin 
Figure 6-9: ADKO Proximal mouse tail artery response to nerve stimulation at 0.5 
Hz in control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) 
(n = 6).  
* P < 0.05 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control time. Paired t-test. 
++
+ 
* 
Table 6-13: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control time. Paired t-test. 
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 7) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 3.2 ± 0.5 2.6 ± 0.4 - 13 ± 14 
Peak Tension (1st) (mg) 22 ± 6 9 ± 2 * - 53 ± 11 
Rate of Rise (mg/s) 7 ± 1 3 ± 1 * - 46 ± 8 
Time to Peak (seconds) 39.6 ± 0.9 41.2 ± 0.5 4 ± 3 
Peak Tension (mg) 196 ± 30 169 ± 29 - 14 ± 8 
Tension at End of pulse (mg) 189 ± 30 162 ± 28 - 15 ± 8 
50 % Decay Time (seconds) 14.8 ± 1.7 14.0 ± 1.3 - 3 ± 8 
 
 
 
The prazosin sensitive components did not differ significantly from one another at either 
proximal or distal ends. However, there was a trend for the greatest prazosin sensitive 
component to be seen when the α2-ARs and P2X receptors were functional (Figure 6-10; 
Tables 6-15 and 6-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-14: ADKO Distal mouse tail artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
PS 
(R+S) 
Figure 6-10: ADKO Proximal mouse tail – the prazosin sensitive (PS) component at 
0.5 Hz when the P2X receptors and α2-AR are functional (white) (n=6), α2-ARs are 
blocked (light grey) (n=6), when the α2-ARs and P2X receptors are blocked (dark 
grey) (n=6), when the P2X receptors and α2-ARs are blocked (black) (n=7=).  
* P < 0.05 compared with PS component when the α
2
-ARs and P2X receptors are functional. 
One way ANOVA with Bonferonni’s post-test. 
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Table 6-15: ADKO Proximal mouse tail artery response – the prazosin sensitive (PS) 
component as a % of control area under the curves. Data taken from Figures 6-10 
and 6-12. 
 
 
 
Prazosin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
PS 20 ± 9 17 ± 3 
PS 
(R) 
13 ± 4 30 ± 6 
PS 
(R+S) 
5 ± 2 
14 ± 8 
PS 
(S+R) 
2 ± 1 * 15 ± 5 
 
 
 
 
 
 
Prazosin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
PS 35 ± 15 36 ± 18 
PS 
(R) 
15 ± 2 26 ± 4 
PS 
(R+S) 
12 ± 5 22 ± 7 
PS 
(S+R) 
7 ± 4 23 ± 11 
 
 
6.3.2.3 Revealing the effect of prazosin on the response to 
sympathetic nerve stimulation at 8 Hz. 
 
At 8 Hz prazosin (100 nM) was shown to reduce the peak tension and rate of rise in both 
proximal and distal segments as well as prolonging the time to reach the peak in proximal 
tail artery segments (Figure 6-11; Tables 6-17 and 6-18). 
 
 
 
* P < 0.05 compared with the PS component when the α2-ARs and P2X receptors are 
functional. One way ANOVA with Bonferonni’s post-test. 
Table 6-16: ADKO Distal mouse tail artery response - the prazosin sensitive (PS) 
component as a % of control area under the curves. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Tension at End of pulse (mg) 81 ± 18 58 ± 15 - 31 ± 14 
Time to Peak (seconds) 5.6 ± 0.5 7.1 ± 1.0 + 19 ± 5 
Peak Tension (mg) 219 ± 33 180 ± 37 ** - 21 ± 5 
Rate of Rise (mg/s) 40 ± 6 26 ± 5 ** - 36 ± 5 
Time to Peak (2nd) (seconds) 13.3 ± 1.1 14.7 ± 1.5 7 ± 12 
Peak Tension (2nd) (mg) 168 ± 34 138 ± 28 - 18 ± 6 
50 % Decay Time (seconds) 19.9 ± 1.5 22.5 ± 1.0 12 ± 6 
 
 
 
 
ADKO Control 
100 nM Prazosin 
Figure 6-11: ADKO Proximal mouse tail artery response to nerve stimulation at 8 Hz 
in control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n 
= 6).  
** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
  
+ 
**
 
Table 6-17: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and prazosin (100 nM) incubated vessels at 8 Hz.  
** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
163 
 
 
 
Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 7) 
% change following P 
incubation 
Tension at End of pulse (mg) 78 ± 10 58 ± 14 - 28 ± 17 
Time to Peak (seconds) 5.3 ± 0.2 6.8 ± 0.7 18 ± 7 
Peak Tension (mg) 250 ± 38 203 ± 36 ** - 21 ± 5 
Rate of Rise (mg/s) 46 ± 6 31 ± 6 ** - 36 ± 6 
Time to Peak (2nd) (seconds) 13.3 ± 0.7 14.6 ± 0.5 9 ± 6 
Peak Tension (2nd) (mg) 185 ± 37 171 ± 35 - 10 ± 7 
50 % Decay Time (seconds) 19.8 ± 1.8 20.2 ± 12 3 ± 7 
 
 
The prazosin sensitive components were similar for each of the incubation sequences in both 
proximal and distal tail artery segments (Figure 6-12; Tables 6-15 and 6-16). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-18: ADKO Distal mouse tail artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 8 Hz.  
** P < 0.01 compared with control response. Paired t-test. 
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Figure 6-12: ADKO Proximal mouse tail – the prazosin sensitive (PS) component at 8 
Hz when the P2X receptors and α2-AR are functional (white) (n=6), α2-ARs are 
blocked (light grey) (n=6), when the α2-ARs and P2X receptors are blocked (dark grey) 
(n=6), when the P2X receptors and α2-ARs are blocked (black) (n=7).  
PS PS 
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6.3.2.4 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 0.5 Hz. 
 
In proximal and distal segments, the response to nerve stimulation at 0.5 Hz when the vessels 
were incubated with 100 nM rauwolscine reduced both peak tensions and the tension at the 
end of the stimulation period (Tables 6-19 and 6-20). Additionally, in proximal segments, 
the rate of rise and time to reach the first peak were both reduced (Figure 6-13; Table 6-19).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ADKO Control 
100 nM Rauwolscine 
Figure 6-13: ADKO Proximal mouse tail artery response to nerve stimulation at 0.5 
Hz in control vessels and in the presence of the α2-AR antagonist rauwolscine (100 
nM) (n = 12).   
*** P < 0.001 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control time. Paired t-test. 
  
++
+ **
* 
**
* 
**
* 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 12) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 4.5 ± 0.3 1.8 ± 0.1 +++ - 59 ± 4 
Peak Tension (1st) (mg) 69 ± 13 11 ± 4 *** - 84 ± 3 
Rate of Rise (mg/s) 16 ± 3 6 ± 2 *** - 62 ± 8 
Time to Peak (seconds) 39.6 ± 1.2 31.7 ± 3.5 - 19 ± 9 
Peak Tension (mg) 326 ± 53 91 ± 28 *** - 76 ± 4 
Tension at End of pulse (mg) 335 ± 52 81 ± 26 *** - 79 ± 4 
50 % Decay Time (seconds) 16.4 ± 1.2 15.5 ± 2.3 - 18 ± 13 
 
 
 
 
 
 
Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 14) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 3.4 ± 0.4 2.5 ± 0.3 - 19 ± 11 
Peak Tension (1st) (mg) 69 ± 15 15 ± 4 ** - 56 ± 11 
Rate of Rise (mg/s) 19 ± 3 6 ± 2 - 57 ± 9 
Time to Peak (seconds) 36.4 ± 2.4 35.0 ± 1.8 - 2 ± 6 
Peak Tension (mg) 306 ± 17 83 ± 9 *** - 72 ± 3 
Tension at End of pulse (mg) 299 ± 18 75 ± 10 *** - 75 ± 3 
50 % Decay Time (seconds) 16.5 ± 2.4 12.4 ± 1.4 - 21 ± 8 
 
 
 
In proximal segments the rauwolscine sensitive (RS) component when the α1-ARs and the 
P2X receptors were blocked was smaller when compared to the other incubation conditions 
(Figure 6-14; Table 6-21). In distal segments, the areas under the curves where shown to be 
similar (Table 6-22). 
 
Table 6-19: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and rauwolscine (100 nM) incubated vessels at 0.5 Hz.  
*** P < 0.001 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control time. Paired t-test. 
Table 6-20: ADKO Distal mouse tail artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 0.5 Hz.  
** P < 0.01; *** P < 0.001 compared with control response. Paired t-test. 
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Table 6-21: ADKO Proximal mouse tail artery - revealing the rauwolscine-sensitive 
component as a % of control area under the curves. Data taken from Figures 6-14 
and 6-16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rauwolscine-sensitive component 
as a % of the Control Response 
 0.5 Hz 8 Hz 
RS 81 ± 4 * 49 ± 7 
RS 
(P) 
85 ± 13 * 68 ± 6 
RS 
(S) 
44 ± 14 42 ± 11 
 
 
 
 
 
 
 
 
* P < 0.05 compared with the RS component when the the P2X receptors are blocked. 
One way ANOVA with Bonferonni’s post-test. 
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Figure 6-14: ADKO Proximal mouse tail – the rauwolscine sensitive (RS) component 
at 0.5 Hz when the P2X receptors and α1-AR are functional (white) (n=12), α1-ARs are 
blocked (light grey) (n=6), P2X receptors are blocked (dark grey) (n=7).  
* P < 0.05 compared with RS component when the P2X receptors are blocked. One 
way ANOVA with Bonferonni’s post-test. 
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Rauwolscine-sensitive component 
as a % of the Control Response 
 0.5 Hz 8 Hz 
RS 77 ± 3 53 ± 3 
RS 
(P) 
65 ± 11 69 ± 5 
RS 
(S) 
57 ± 10 50 ± 8 
 
 
6.3.2.5 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz.  
 
The response to nerve stimulation at 8 Hz was reduced in the presence of 100 nM 
rauwolscine at both proximal and distal segments of the tail artery. In both segments the 
peak tensions, decay times and the time to reach the second peak were reduced. Proximally, 
the tension at the end of the stimulation period was also reduced (Figure 6-15; Table 6-23). 
Distally, the rate of rise was also reduced (Table 6-24).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-22: ADKO Distal mouse tail artery response - revealing the rauwolscine-
sensitive component as a % of control area under the curves. 
ADKO Control 
100 nM Rauwolscine 
Figure 6-15: ADKO Proximal mouse tail artery response to nerve stimulation at 8 
Hz in control vessels and in the presence of the α2-AR antagonist rauwolscine (100 
nM) (n = 12). 
* P < 0.05; *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05; ++ P < 0.01 compared with control time. Paired t-test. 
* 
**
* 
**
* +
+ 
+ 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 12) 
% change following R 
incubation 
Tension at End of pulse (mg) 148 ± 21 105 ± 14 * - 25 ± 10 
Time to Peak (seconds) 7.6 ± 1.6 4.9 ± 0.3 - 18 ± 8 
Peak Tension (mg) 420 ± 63 309 ± 55 *** - 29 ± 4 
Rate of Rise (mg/s) 72 ± 12 60 ± 9 8 ± 20 
Time to Peak (2nd) (seconds) 14.7 ± 0.7 11.2 ± 0.6 ++ - 22 ± 6 
Peak Tension (2nd) (mg) 339 ± 54 181 ± 38 *** - 49 ± 5 
50 % Decay Time (seconds) 20.9 ± 1.4 11.8 ± 2.8 + - 45 ± 11 
 
 
 
 
 
Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 14) 
% change following R 
incubation 
Tension at End of pulse (mg) 144 ± 19 109 ± 10 - 13 ± 10 
Time to Peak (seconds) 6.2 ± 1.1 4.9 ± 0.1 - 9 ± 6 
Peak Tension (mg) 407 ± 26 271 ± 21 *** - 34 ± 3 
Rate of Rise (mg/s) 78 ± 7 55 ± 4 *** - 24 ± 7 
Time to Peak (2nd) (seconds) 15.6 ± 0.6 12.6 ± 0.3 +++ - 18 ± 3 
Peak Tension (2nd) (mg) 277 ± 17 131 ± 13 *** - 53 ± 4 
50 % Decay Time (seconds) 21.2 ± 1.6 8.6 ± 1.6 +++ - 51 ± 8 
 
 
 
Under all conditions and at both proximal and distal segments, the rauwolscine sensitive 
component forms a large portion of the control response (Figure 6-16; Tables 6-21 and 6-
22). 
 
 
 
Table 6-23: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and rauwolscine (100 nM) incubated vessels at 8 Hz.  
* P < 0.05; *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05; ++ P < 0.01 compared with control time. Paired t-test. 
Table 6-24: ADKO Distal mouse tail artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 8 Hz.  
*** P < 0.001 compared with control response. Paired t-test. 
+++ P < 0.001 compared with control response. Paired t-test. 
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6.3.2.6 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 0.5 Hz. 
 
In both proximal and distal segments, the peak tension and the tension at the end of the 
stimulation period were reduced by 1 mM suramin incubation. Additionally, in proximal 
segments, the first peak tension and the rate of rise were also reduced (Figure 6-17; Table 6-
25 and 6-26).  
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Figure 6-16: ADKO Proximal mouse tail – the rauwolscine sensitive (RS) component 
at 8 Hz when the P2X receptors and α1-AR are functional (white) (n=12), α1-ARs are 
blocked (light grey) (n=6), P2X receptors are blocked (dark grey) (n=7).  
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 4.5 ± 0.5 4.3 ± 0.6 - 4 ± 15 
Peak Tension (1st) (mg) 83 ± 25 17 ± 9 * - 66 ± 18 
Rate of Rise (mg/s) 16 ± 4 3 ± 1 * - 73 ± 13 
Time to Peak (seconds) 39.3 ± 1.3 36.8 ± 2.3 - 6 ± 6 
Peak Tension (mg) 325 ± 35 162 ± 44 * - 48 ± 15 
Tension at End of pulse (mg) 316 ± 33 147 ± 43 * - 51 ± 15 
50 % Decay Time (seconds) 17.1 ± 3.0 16.4 ± 1.8 0.2 ± 12 
 
 
 
 
 
 
 
ADKO Control 
1 mM Suramin 
Figure 6-17: ADKO Proximal mouse tail artery response to nerve stimulation at 0.5 
Hz in control vessels and in the presence of the P2X receptor antagonist suramin (1 
mM) (n = 7). 
* P < 0.05 compared with control response. Paired t-test. 
  
* 
* * 
Table 6-25: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and suramin (1 mM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 2.4 ± 0.3 3.0 ± 0.1 15 ± 12 
Peak Tension (1st) (mg) 28 ± 12 9 ± 3 - 30 ± 22 
Rate of Rise (mg/s) 10 ± 4 3 ± 1 - 50 ± 15 
Time to Peak (seconds) 40.6 ± 1.6 42.3 ± 1.0 4 ± 2 
Peak Tension (mg) 298 ± 55 214 ± 53 * - 31 ± 11 
Tension at End of pulse (mg) 286 ± 54 197 ± 51 * - 33 ± 11 
50 % Decay Time (seconds) 16.7 ± 1.3 11.9 ± 1.1 - 19 ± 8 
 
 
In both proximal and distal segments the suramin sensitive component isolated when the α1- 
and α2-ARs were functional was greater in comparison to the other incubation conditions 
(Figure 6-18; Table 6-27 and 6-28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-26: ADKO Distal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
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Figure 6-18: ADKO Proximal mouse tail – the suramin sensitive component at 0.5 Hz 
when the α1- and α2-ARs are functional (white) (n=7), α2-ARs are blocked (light grey) 
(n=6), α1- and α2-ARs are blocked (dark grey) (n=6), α2-ARs and α1-ARs are blocked 
(black) (n=6).  
** P < 0.01; *** P < 0.001 compared with the SS component when the α1-ARs and P2X 
receptors are functional. One way ANOVA with Bonferonni’s post-test. 
SS SS 
(R) 
SS 
(R+P) 
SS 
(P+R) 
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Table 6-27: ADKO Proximal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. Data taken from Figures 6-18 
and 6-20. 
 
 
 
Suramin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
SS 58 ± 14 46 ± 13 
SS 
(R) 
15 ± 4 ** 33 ± 9 
SS 
(P+R) 
6 ± 2 *** 22 ± 4 
SS 
(R+P) 
9 ± 2 *** 24 ± 5 
 
 
 
 
 
 
Suramin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
SS 39 ± 10 60 ± 19 
SS 
(R) 
10 ± 3 ** 23 ± 5 
SS 
(P+R) 
7 ± 1 *** 20 ± 5 
SS 
(R+P) 
10 ± 1 ** 23 ± 2 
 
 
 
6.3.2.7 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 8 Hz. 
 
The response to nerve stimulation at 8 Hz in proximal and distal tail artery segments was 
significantly altered in the presence of 1 mM suramin. Both the peak tension and the rate of 
rise were significantly reduced (Table 6-30). Additionally, in proximal segments, the tension 
at the end of the stimulation period was reduced and the time to reach the second peak was 
prolonged (Figure 6-19; Table 6-29).  
** P < 0.01; *** P < 0.001 compared with the SS component when the α1- and α2-ARs are 
functional. One way ANOVA with Bonferonni’s post-test. 
Table 6-28: ADKO Distal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. 
** P < 0.01; *** P < 0.001 compared with the SS component when the α1- and α2-ARs are 
functional. One way ANOVA with Bonferonni’s post-test. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Tension at End of pulse (mg) 160 ± 29 31 ± 10 ** - 78 ± 7 
Time to Peak (seconds) 5.5 ± 0.4 7.6 ± 1.8 17 ± 9 
Peak Tension (mg) 394 ± 28 232 ± 46 * - 41 ± 12 
Rate of Rise (mg/s) 76 ± 9 34 ± 7 ** - 55 ± 8 
Time to Peak (2nd) (seconds) 11.9 ± 0.3 14.8 ± 0.8 ++ 18 ± 5 
Peak Tension (2nd) (mg) 290 ± 15 192 ± 49 - 36 ± 16 
50 % Decay Time (seconds) 21.0 ± 1.9 15.3 ± 3.2 - 32 ± 13 
 
 
 
 
 
 
Figure 6-19: ADKO Proximal mouse tail artery response to nerve stimulation at 8 Hz 
in control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n = 7). 
* P < 0.05, ** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
 
ADKO Control 
1 mM Suramin 
**
 
* 
++
 
Table 6-29: ADKO Proximal mouse tail artery response to nerve stimulation in 
control and suramin (1 mM) incubated vessels at 8 Hz.  
* P < 0.05; ** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
++ P < 0.1 compared with control time. Paired t-test. 
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Tension at End of pulse (mg) 100 ± 34 37 ± 6 - 36 ± 18 
Time to Peak (seconds) 5.8 ± 0.4 5.7 ± 0.4 - 2 ± 6 
Peak Tension (mg) 335 ± 57 243 ± 51  ** - 30 ± 7 
Rate of Rise (mg/s) 59 ± 11 41 ± 7 * - 29 ± 4 
Time to Peak (2nd) (seconds) 15.3 ± 0.7 14.4 ± 0.9 - 6 ± 4 
Peak Tension (2nd) (mg) 270 ± 47 199 ± 49 - 29 ± 12 
50 % Decay Time (seconds) 17.2 ± 0.8 21.8 ± 2.4 - 4 ± 8 
 
 
At both proximal and distal segments there was a trend for the suramin sensitive component 
when the α1- and α2-ARs were functional to be greater than the other components. However, 
this did not reach significance (Figure 6-20; Table 6-27 and 6-28).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 6-30: ADKO Distal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
* P < 0.05, ** P < 0.01 compared with control response. Paired t-test. 
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Figure 6-20: ADKO Proximal mouse tail – the suramin sensitive component at 8 Hz 
when the α1- and α2-ARs are functional (white) (n=7), α2-ARs are blocked (light grey) 
(n=6), α1- and α2-ARs are blocked (dark grey) (n=6), α2-ARs and α1-ARs are blocked 
(black) (n=6).  
SS SS 
(R) 
SS 
(R+P) 
SS 
(P+R) 
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6.4 Discussion 
 
The present study was set out to investigate the effect genetic removal of the α1A- and α1D-
ARs had on the response to nerve stimulation. Furthermore, the ADKO allows isolation of 
the α1B-ARs, of which little is known of its role in the vasculature.  
 
6.4.1 Mouse Mesenteric Arteries 
 
6.4.1.1 Comparison with WT response 
 
The loss of the α1AD-ARs has an effect at both frequencies. This supports previous 
knowledge of the α1-ARs dominating the contraction in the mesenteric arteries (Sjoblom-
Widfeldt et al., 1990) and in particular, the α1A-ARs (Methven et al., 2009a). The response 
in the ADKO vessels, which still display a fast onset, of transmitter induced contraction, 
may be due to activation of the remaining α1B-ARs or the α2-ARs and P2X receptors. In the 
WT, the response was due mainly to activation of the α1-ARs with a definite P2X receptor 
component and a minor post-junctional α2-AR influence. 
 
6.4.1.2 ADKO Control Response to Nerve Stimulation 
 
Blockade of the α1B-ARs, α2-ARs and P2X receptors abolished the response to nerve 
stimulation at both frequencies. Therefore, loss of the α1AD-ARs has not resulted in the 
emergence of a different receptor influence. 
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6.4.1.3 Receptor Role in Mouse Mesenteric Arteries 
 
As the responses to nerve stimulation were small, the response following treatment with any 
one of the antagonists did not reduce the response at 2 Hz. In some instances, even incubating 
the vessels with all three antagonists did not produce a significant reduction in response. 
This was most likely due to the size of the response which produced large error bars. 
However, there were some incubation sequences where treatment with two or three 
antagonists did affect the response. When the vessels were incubated with suramin and then 
rauwolscine, to block the P2X receptors and α2-ARs respectively, the rate of rise and 50 % 
decay time were reduced. This suggests a combined role for these receptors in initiating the 
response and ensuring the response continued beyond the end of the stimulation period. 
When the vessels were incubated with all three antagonists there were examples of reduced 
tension at the end of the stimulation period, decreased rate of rise and a prolonged time to 
reach each peak. The results at 2 Hz suggest that the vessels require interactions between at 
least two receptor types before the vessels can contract. This differs from the WT results 
shown in Chapter Five, where the α1-ARs dominated the contraction regardless of the 
presence of the other receptors. 
 
At 8 Hz, the response to nerve stimulation was greater and individual antagonist effects were 
recorded. The results suggest little α1B-AR influence as vessel incubation with prazosin did 
not alter the response. When the vessels were incubated with rauwolscine, the time taken to 
reach the peak response was reduced. Interestingly, this effect is opposite to the WT 
response. This is most likely due to the loss of active post-junctional α1-ARs as increased 
transmitter output following pre-junctional α2-AR block will have fewer receptors to act at. 
The response to vessel incubation with suramin was similar to that in the WT; reducing the 
peak tension, the tension at the end of the stimulation period and the rate of rise. Therefore, 
in the ADKO mesenteric arteries, there is little role for the α1B-ARs, the α2-ARs are mainly 
pre-junctional and the P2X receptors are the main receptors involved in vessel contraction. 
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6.4.2 Mouse Proximal and Distal Tail Artery 
 
Similar to the WT results, the ADKO data from only one location of the tail is shown and 
only discrepancies between the segments are shown. When comparing WT with ADKO 
response, the proximal results were used. 
 
6.4.2.1 Comparison with WT response 
 
At 0.5 Hz and 8 Hz, the ADKO vessels responded to nerve stimulation. At 0.5 Hz the ADKO 
response took longer to reach the first peak compared to the WT response and the tension at 
this peak was greater in the ADKO; although this is not clear from the Figure (6-7). The time 
for the peak response to decay by 50 % was prolonged in the ADKOs. These results suggest 
that the α1AD-ARs are important in initiating the contraction and ensuring vessel relaxation. 
At 8 Hz, the loss of the α1AD-ARs is seen more clearly on the response. All of the recorded 
tensions in the ADKO were reduced and the time to reach the second peak and the decay 
time were prolonged compared to the WT control response. This would suggest the α1AD-
ARs are important in the over-all response to nerve stimulation; contributing to the initiation 
and maintenance of the response.  
 
6.4.2.2 α1B-AR role in Mouse Tail Artery 
 
The effect of prazosin treatment was examined in the ADKO mice whereby prazosin should 
effectively block the remaining α1B-ARs. At 0.5 Hz, there was no noticeable change in the 
peak tension. However, a reduction in the time taken to reach the first peak tension and a 
reduced tension at this peak revealed a role for the α1B-ARs at the beginning of the 
contraction. The results suggest a modulatory or inhibitory role for these receptors which is 
not shown in the WT prazosin incubated vessels. The α1B-ARs have been described 
previously as having a modulatory role (Deighan et al., 2005) in response in the mouse 
carotid arteries. Therefore, presently, the α1B-AR modulatory role may be revealed due to 
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loss of the α1AD-ARs and, under normal conditions, these three subtypes may be in a balance. 
This also appears to be true of the systolic blood pressure measurements as described in 
Chapter Three. As was shown in the WT results, the available α1-AR subtypes can interact 
with the other receptors and when these receptors are active the prazosin sensitive 
component of the response is larger. 
 
At 8 Hz, the α1B-ARs are shown to be involved in initiation of the contraction as the time 
taken to reach the peak is prolonged and the peak tension is reduced following prazosin 
treatment. The initiation of the contractile response via α1B-ARs has been suggested 
previously in the mouse tail artery (Daly et al., 1998). The small prazosin sensitive 
component does not differ regardless of which of the other receptors are active and so do not 
depend on the α2-ARs or P2X receptors to produce this response. This is different to the WT 
response where the α1-ARs did interact with the α2-ARs suggesting that this interaction 
occurred between the α1A- or α1D-ARs. 
 
6.4.2.3 α2-AR role in Mouse Tail Artery 
 
Similar to the WT results, the main receptors involved in vessel contraction in the ADKOs 
were the α2-ARs. In the WT, each of the points studied at 0.5 Hz were altered following 
rauwolscine treatment whereas in the ADKO the time taken to reach the peak and the decay 
time were unaffected by rauwolscine treatment. This again highlights an interaction between 
the α1AD-ARs and the α2-ARs which is lost in the ADKOs. The presence of pre-junctional 
α2-ARs was evident as rauwolscine treatment reduced the time taken to reach the first peak. 
The potential for an interaction between the α2-ARs and P2X receptors was revealed by 
analyses of the rauwolscine sensitive components of the response. The component was 
greater when the P2X receptors were active compared to when they have been blocked by 
suramin. 
 
At 8 Hz, the ADKO response to rauwolscine treatment was similar to the WT response. 
However, the tension at the end of the stimulation period, which occurred at 2.5 seconds, 
was reduced in the ADKO but not the WT mice. In the WT vessels the reduction in response 
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occurred due to prazosin treatment and so in the ADKO, the α2-AR effect may be 
compensatory. Furthermore, at 8 Hz, activation of the α2-ARs occurred independently of the 
other receptors and was the main receptor involved in vessel contraction. 
 
6.4.2.4 P2X receptor role in Mouse Tail Artery 
 
When the ADKO tail artery segments were incubated with suramin, the reduction in 
response at 0.5 Hz appears to be greater than that shown in the WT vessels. In the WT, the 
P2X receptors are responsible for initiation of the response whereas in the ADKO, activation 
of P2X receptors accounts for the overall contraction. However, this influence on the 
contraction of the vessel is dependent on the presence of active α2-ARs as blockade of these 
receptors reduced the suramin sensitive component of the response. As this interaction was 
not revealed in the WT vessels, it could represent a compensatory mechanism for the loss of 
the α1AD-ARs which were shown to interact with the α2-ARs in the WT vessels. 
 
At 8 Hz, the response following suramin treatment was similar to that shown in the WT 
results confirming a role for the P2X receptors in initiation of the response. Unlike at 0.5 Hz, 
and the WT results, the suramin sensitive component at 8 Hz in the ADKO was similar 
regardless of which of the other receptors were active thus suggesting the P2X receptor 
response occurs independently.  
 
6.4.3 Conclusion 
 
In summary, the presence of α1B-ARs, α2-ARs and P2X receptors has been confirmed in the 
both mouse mesenteric arteries and tail artery in ADKO mice. The isolation of the α1B-AR 
subtype allowed its role in the response to be elucidated. Although activation of these 
receptors did not contribute greatly to the contractile response, there was evidence to suggest 
these receptors are involved in initiation of the contraction and, at the lower frequency they 
can interact with the α2-ARs. In comparison with the WT results, loss of the α1AD-ARs is 
more clearly shown in the mesenteric arteries. This is understandable as the WT results show 
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the α1-ARs predominate in the mesentery and the α2-ARs in the tail. Evidence of 
compensatory mechanisms are shown in the tail artery. At 0.5 Hz, in the WT tail artery, the 
α1- and α2-ARs interacted and this enhanced the α1-AR response. In the ADKO, this 
relationship occurred instead between the α2-ARs and P2X receptors. Furthermore, at 8 Hz, 
the initiation of the contraction in WT segments was due, in part, to activation of α1-ARs 
and this is lost in the ADKO. However, it appears that this role is supported by the α2-ARs 
in the ADKO vessels. In conclusion, the development of the ADKO strain simplified the 
pharmacology somewhat and revealed the potential for compensatory mechanisms. These 
results can now be studied alongside the α1-null and WT results in order to determine the 
effects removal of all three AR subtypes has on the nerve response.  
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Chapter Seven 
 
Comparison of pharmacological blockade of nerve-
evoked contractions in tail and mesenteric arteries 
of WT and α1-null mice 
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7.1 Introduction 
 
The previous two chapters have highlighted the roles of the α1-, α2-ARs and P2X receptors 
in response to sympathetic nerve stimulation. Chapter Five characterised the roles these 
receptors play in the WT and Chapter Six discussed the effects removal of two of the α1-AR 
subtypes had on the response. These results can now be compared with those presented here 
where mice lacking all three α1-AR subtypes have been utilised.  
 
Evidence has been shown in the rat and mouse vessels to support the findings shown in 
Chapters five and six; that the pharmacology in mouse mesenteric and tail arteries is 
complex, due to multiple receptors available and receptor interactions (Brock et al., 2006; 
Bao and Stjarne, 1993; Methven et al., 2009a). The development of transgenic mice lacking 
at least one of the α1-AR subtypes aims to simplify the pharmacology. In the ADKO mice, 
where only the α1B-ARs are present, the response in the mesenteric arteries is dramatically 
reduced, demonstrating that there is no mechanism able to fully compensate for the loss of 
the α1A- and α1D-ARs. A role in initiation of the contraction was revealed for the α1B-ARs 
(see Chapter Six). The α1B-AR has previously been reported as playing a modulatory role in 
the vasculature (Daly et al., 2002) and so the development of the ADKO has allowed a 
previously unknown mechanism to be revealed. There was no evidence of compensatory 
mechanisms. Loss of the α1AD-ARs does affect responses in the tail artery but not to the same 
degree as in the mesenteric arteries. The α1B-ARs are also shown here to contribute to the 
initiation of the response (Chapter Six). Furthermore, the results presented in Chapter Three 
show that loss of α1-AR activation via genetic deletion of the receptors does not alter systolic 
blood pressure in these mice. Therefore, the results presented thus far offer conflicting 
evidence on the importance of the α1-ARs in the vasculature. The blood pressure results 
suggest little requirement of the α1-ARs in order to maintain a normal blood pressure. A 
minor change in the overall response to nerve stimulation in ADKO tail artery supports this. 
However, the change in response to nerve stimulation in the mesenteric arteries of ADKO 
mice compared with WT suggests a large input from the α1-ARs in maintaining vascular 
tone.  
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Presently, mice lacking all three AR subtypes (α1-null) have been utilised and the responses 
to nerve stimulation in mesenteric and tail arteries studied. These experiments have not been 
performed elsewhere and so the results should allow a greater understanding into the role 
the α1-ARs play in response to nerve stimulation. Therefore the aims of the following study 
were: 
 To determine whether loss of the α1-ARs prevents the response to nerve stimulation 
in the mouse mesenteric or tail arteries from occurring. 
 To investigate the difference in response between WT, ADKO and α1-null mesenteric 
and tail arteries. 
 To determine whether there are any changes in the interactions between the receptors 
compared to those seen in the WT responses and therefore establish any 
compensatory mechanisms.  
 
7.2 Methods 
 
A full description of the methods used can be found in Chapter Two (Materials and 
Methods). Briefly, vessels were set up in myograph baths between two stimulating 
electrodes incubated with 1 µM capsaicin and with control responses to 2 Hz and 8 Hz 
(mesenteric arteries) and 0.5 Hz and 8 Hz (tail artery) recorded before incubation with one 
of the following antagonists: 100 nM prazosin (α1-AR antagonist), 100 nM rauwolscine (α2-
AR antagonist) or 1 mM suramin (P2X receptor antagonist). The vessels were then 
stimulated again using the same parameters. 
 
Statistical analysis was performed using GraphPad Prism (Version 5) with paired t-tests used 
when comparing control response with antagonist response and one way ANOVA with 
Bonferonni’s post-test utilised for comparing the antagonist sensitive components. A worked 
example of the component analysis, which revealed the antagonist sensitive response in 
difference incubation sequences is shown at the beginning of the mesenteric and tail artery 
results sections in Chapter Five. The analyses of the antagonist sensitive components was 
only conducted in the tail artery responses as the mesenteric artery responses were too small 
to produce reliable statistics.  
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7.3 Results 
 
7.3.1 Mesenteric Artery 
 
7.3.1.1 Comparison of WT and α1-null response to nerve 
stimulation. 
 
Both WT and α1-null mesenteric arteries responded to nerve stimulation at 2 Hz and 8 Hz 
(Figure 7-1 and 7-2). At both frequencies the peak tension and the tension at the end of the 
stimulation periods were significantly reduced in the α1-null mice. At 2 Hz, the time to reach 
the peak tension and the time to 50 % decay was also significantly altered in the α1-null mice 
(Figure 7-1 and 7-2; Tables 7-1 and 7-2). 
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Figure 7-1: WT and α1-null mouse mesenteric arteries - response to nerve stimulation 
at 2 Hz (WT: n=17; α1-null: n=20).  
*** P < 0.001 compared with WT response. Un-paired t-test. 
++ P < 0.01 compared with WT time. Un-paired t-test. 
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2 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=17) 
α1-null 
(n=20) 
Time to Peak (seconds) 7.2 ± 0.2 17.1 ± 2.9 ++ 
Peak Tension (mg) 72 ± 9 9 ± 2 *** 
Rate of Rise (mg/s) 10 ± 1 4 ± 3 
Tension at End of pulse (mg) 38 ± 8 3 ± 2 *** 
50 % Decay Time (seconds) 12.2 ± 2.0 4.7 ± 1.6 ++ 
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Figure 7-2: WT and α1-null mouse mesenteric arteries - response to nerve stimulation 
at 8 Hz (WT: n=17; α1-null: n=20).  
*** P < 0.001 compared with WT response. Un-paired t-test. 
Table 7-1: WT and α1-null mouse mesenteric arteries - response to nerve stimulation 
at 2 Hz.  
*** P < 0.001 compared with WT response. Un-paired t-test. 
++ P < 0.01 compared with WT time. Un-paired t-test. 
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8 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=17) 
α1-null 
(n=20) 
Time to Peak (seconds) 6.0 ± 0.2 7.7 ± 1.7 
Peak Tension (mg) 223 ± 20 20 ± 4 *** 
Rate of Rise (mg/s) 37 ± 3 3 ± 1 *** 
Tension at End of pulse (mg) 215 ± 20 16 ± 4 *** 
50 % Decay Time (seconds) 4.1 ± 0.3 4.3 ± 0.8 
 
 
Combined incubation with prazosin (100 nM), rauwolscine (100 nM) and suramin (1 mM) 
effectively blocked the α1-, α2-ARs and P2X receptors respectively in response to nerve 
stimulation at 2 Hz and 8 Hz in the KO mesenteric arteries and completely abolished the 
response (Figures 7-3 and 7-4). Figure 7-4 displays the effect of incubation with prazosin, 
rauwolscine and suramin on the response at 8 Hz. Although there is a response left following 
block of the α1-, α2-ARs and P2X receptors it is very small, as indicated by the y-axis values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 7-2: WT and α1-null mouse mesenteric arteries - response to nerve stimulation 
at 8 Hz.  
*** P < 0.001 compared with WT response. Un-paired t-test. 
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Figure 7-3: α1-null Mouse mesenteric artery response to nerve stimulation at 2 Hz 
in control vessels and in the presence of the following antagonists: 100 nM prazosin, 
100 nM rauwolscine, 1 mM suramin (n = 6).  
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7.3.1.2 Revealing the response to sympathetic nerve stimulation at 
2 Hz. 
 
Individual incubations with 100 nM prazosin, 100 nM rauwolscine and 1 mM suramin did 
not result in a significant change in the response compared with the control response (Figure 
7-5; Tables 7-3 – 7-5).  
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Figure 7-5: α1-null Mouse mesenteric artery response to nerve stimulation at 2 Hz in 
control vessels and in the presence of 100 nM prazosin (red) (n=6); 100 nM 
rauwolscine (purple) (n=7); 1 mM suramin (blue) (n=7).  
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Figure 7-4: α1-null Mouse mesenteric artery response to nerve stimulation at 8 Hz 
in control vessels and in the presence of the following antagonists: 100 nM prazosin, 
100 nM rauwolscine, 1 mM suramin (n = 6).  
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2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Time to Peak (seconds) 24.0 ± 5.5 17.4 ± 4.4 - 8 ± 24 
Peak Tension (mg) 11 ± 4 11 ± 4 3 ± 16 
Rate of Rise (mg/s) 4 ± 3 1 ± 0.3 - 2 ± 26 
Tension at End of pulse (mg) 6 ± 5 6 ± 5 - 49 ± 19 
50 % Decay Time (seconds) 4.2 ± 2.8 4.1 ± 3.3 - 3 ± 20 
 
 
 
 
2 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 7) 
% change following R 
incubation 
Time to Peak (seconds) 13.6 ± 5.3 8.7 ± 3.6 - 19 ± 27 
Peak Tension (mg) 4 ± 1 6 ± 2 10 ± 19 
Rate of Rise (mg/s) 7 ± 7 2 ± 1 29 ± 26 
Tension at End of pulse (mg) - 1 ± 3 2 ± 2 - 24 ± 44 
50 % Decay Time (seconds) 2.0 ± 1.5 1.2 ± 0.8 - 8 ± 28 
 
 
 
 
2 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Time to Peak (seconds) 14.5 ± 3.9 10.3 ± 3.8 - 38 ± 14 
Peak Tension (mg) 11 ± 3 8 ± 2 - 1 ± 20 
Rate of Rise (mg/s) 2 ± 1 8 ± 5 26 ± 24 
Tension at End of pulse (mg) 6 ± 5 4 ± 3 - 62 ± 17 
50 % Decay Time (seconds) 7.7 ± 3.6 2.2 ± 1.5 - 9 ± 26 
 
 
 
Table 7-3: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 2 Hz.  
Table 7-4: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 2 Hz.  
Table 7-5: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 2 Hz.  
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Regardless of antagonist incubation sequence or the number of antagonists incubated at the 
one time, the response to nerve stimulation at 2 Hz in the mesenteric arteries was not 
significantly changed.  
 
7.3.1.3 Revealing the response to sympathetic nerve stimulation at 
8 Hz. 
 
Individual incubations with either prazosin or rauwolscine did not result in a significant 
change in the response compared with the control response (Figure 7-6; Tables 7-6 and 7-
7). However, incubation with 1 mM suramin significantly reduced the force of contraction 
at the end of the stimulation period and the rate of rise (Figure 7-6; Table 7-8).  
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Figure 7-6: α1-null Mouse mesenteric artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of 100 nM prazosin (red) (n=6); 100 nM 
rauwolscine (purple) (n=7); 1 mM suramin (blue) (n=7).  
* P < 0.05 refers to significant difference between control response at the end of the 
stimulation period and the response following 1 mM suramin at the same point. 
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8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Time to Peak (seconds) 7.8 ± 1.6 5.9 ± 1.0 - 9 ± 17 
Peak Tension (mg) 22 ± 6 20 ± 8 - 24 ± 16 
Rate of Rise (mg/s) 3 ± 1 3 ± 1 - 7 ± 15 
Tension at End of pulse (mg) 16 ± 6 15 ± 6 - 3 ± 15 
50 % Decay Time (seconds) 4.8 ± 1.5 4.3 ± 1.2 - 16 ± 24 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 7) 
% change following 
R incubation 
Time to Peak (seconds) 9.8 ± 4.6 9.4 ± 4.7 - 5 ± 25 
Peak Tension (mg) 11 ± 3 9 ± 3 - 17 ± 12 
Rate of Rise (mg/s) 2 ± 1 2 ± 0.5 - 3 ± 25 
Tension at End of pulse (mg) 8 ± 3 8 ± 2 - 1 ± 21 
50 % Decay Time (seconds) 3.7 ± 1.3 2.8 ± 0.9 0.4 ± 32 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following 
S incubation 
Time to Peak (seconds) 5.5 ± 0.7 12.6 ± 2.7 41 ± 13 
Peak Tension (mg) 28 ± 9 13 ± 4 - 25 ± 21 
Rate of Rise (mg/s) 4 ± 1 1 ± 0.4 * - 60 ± 12 
Tension at End of pulse (mg) 23 ± 8 4 ± 3 * - 67 ± 18 
50 % Decay Time (seconds) 4.6 ± 1.4 3.5 ± 1.4 - 31 ± 22 
 
 
 
Table 7-6: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 8 Hz.  
Table 7-7: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 8 Hz.  
Table 7-8: α1-null Mouse mesenteric artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
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When the mesenteric arteries were incubated with more than one antagonist, there were more 
significant changes in the response compared to incubation with one antagonist (Table 7-9).  
 
 
 
8 Hz Contractile Response (average ± S.E.M) 
Part of response affected by 
antagonist incubation 
Antagonist Incubation sequence 
1 mM S + 
100 nM R 
1 mM S, 
100 nM R + 
100 nM P 
100 nM P, 
100 nM R + 
1 mM S 
Rate of Rise (mg/s) * * - 
Tension at End of pulse (mg) * * * 
 
 
 
7.3.2 Proximal and Distal Mouse Tail Artery 
 
7.3.2.1 Comparison of WT and α1-null response to nerve 
stimulation. 
 
Both WT and α1-null tail artery responded to nerve stimulation at 0.5 Hz and 8 Hz (Figure 
7-7 and 7-8). At both frequencies the peak tension and the tension at the end of the 
stimulation periods were significantly reduced and the decay time was prolonged in the α1-
null mice. At 8 Hz, all of the points studied were significantly altered in the α1-null mice 
(Figure 7-7 and 7-8; Tables 7-10 and 7-11). 
 
 
 
 
 
Table 7-9: The significant changes to the response at 8 Hz when incubation was 
with more than one antagonist.  
* P < 0.05 compared with control response. Paired t-test. 
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Figure 7-7: WT and α1-null mouse tail artery - response to nerve stimulation at 0.5 
Hz (WT: n=26; α1-null: n=24).  
*** P < 0.001 compared with WT response. Un-paired t-test. 
+++ P < 0.001 compared with WT time. Un-paired t-test. 
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Figure 7-8: WT and α1-null mouse tail artery - response to nerve stimulation at 8 Hz 
(WT: n=26; α1-null: n=24).  
*** P < 0.001 compared with WT response. Un-paired t-test. 
+ P < 0.05; +++ P < 0.001 compared with WT time. Un-paired t-test. 
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0.5 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=26) 
α1-null 
(n=24) 
Time to Peak (1st) (seconds) 2.6 ± 0.2 2.9 ± 0.2 
Peak Tension (1st) (mg) 34 ± 7 21 ± 5 
Rate of Rise (mg/s) 16 ± 3 9 ± 1 * 
Time to Peak (seconds) 37.2 ± 1.0 38.0 ± 0.9 
Peak Tension (mg) 338 ± 27 213 ± 20 *** 
Tension at End of pulse (mg) 327 ± 26 206 ± 20 *** 
50 % Decay Time (seconds) 12.8 ± 0.9 19.4 ± 1.3 +++ 
 
 
 
 
 
8 Hz 
Contractile Response (average ± S.E.M) 
WT 
(n=26) 
α1-null 
(n=24) 
Tension at End of pulse (mg) 210 ± 19 88 ± 14 *** 
Time to Peak (seconds) 5.0 ± 0.1 7.3 ± 0.5 +++ 
Peak Tension (mg) 552 ± 32 280 ± 29 *** 
Rate of Rise (mg/s) 114 ± 6 43 ± 5 *** 
Time to Peak (2nd) (seconds) 11.8 ± 0.3 13.7 ±  6 + 
Peak Tension (2nd) (mg) 372 ± 29 214 ± 21 *** 
50 % Decay Time (seconds) 13.7 ± 1.0 20.0 ± 1.4 +++ 
 
 
 
 
7.3.2.2 Revealing the effect of prazosin on the response to 
sympathetic nerve stimulation at 0.5 Hz. 
 
In proximal mouse tail artery, 100 nM prazosin incubation only significantly affects the rate 
of rise (Table 7-12). However in distal segments, 100 nM prazosin incubation results in a 
Table 7-10: WT and α1-null mouse tail artery - response to nerve stimulation at 0.5 
Hz.  
* P < 0.05; *** P < 0.001 compared with WT response. Un-paired t-test. 
+++ P < 0.01 compared with WT time. Un-paired t-test. 
Table 7-11: WT and α1-null mouse tail artery - response to nerve stimulation at 8 Hz.  
*** P < 0.001 compared with WT response. Un-paired t-test. 
+ P < 0.05; +++ P < 0.001 compared with WT time. Un-paired t-test. 
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prolonged time to reach the first peak and both the peak tension and the tension at the end 
of the stimulation period are significantly reduced (Figure 7-9; Table 7-13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 3.2 ± 0.3 2.8 ± 0.7 - 15 ± 16 
Peak Tension (1st) (mg) 16 ± 7 9 ± 6 - 52 ± 11 
Rate of Rise (mg/s) 5 ± 2 3 ± 1 * - 43 ± 7 
Time to Peak (seconds) 36.8 ± 2.9 41.0 ± 1.1 10 ± 7 
Peak Tension (mg) 171 ± 49 140 ± 38 - 18 ± 4 
Tension at End of pulse (mg) 165 ± 49 232 ± 92 - 2 ± 18 
50 % Decay Time (seconds) 23.0 ± 3.1 22.0 ± 2.5 1 ± 12 
  
Figure 7-9: α1-null Distal mouse tail artery response to nerve stimulation at 0.5 Hz in 
control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n = 
9).  
* P < 0.05 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
α1-null Control 
100 nM Prazosin 
+ 
* * 
Table 7-12: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
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Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 9) 
% change following P 
incubation 
Time to Peak (1st) (seconds) 2.8 ± 0.3 3.6 ± 0.4  + 54 ± 36 
Peak Tension (1st) (mg) 13 ± 3 11 ± 4 - 15 ± 16 
Rate of Rise (mg/s) 5 ± 2 3 ± 1 - 31 ± 14 
Time to Peak (seconds) 37.3 ± 2.4 37.8 ± 2.6 1 ± 5 
Peak Tension (mg) 192 ± 42 155 ± 37 * - 11 ± 13 
Tension at End of pulse (mg) 180 ± 40 139 ± 34 * - 20 ± 8 
50 % Decay Time (seconds) 18.5 ± 2.5 18.3 ± 2.8 - 3 ± 7 
 
 
 
 
Traces showing the isolation of the prazosin sensitive component from the various 
incubation conditions were analysed therefore establishing whether the prazosin sensitive 
component can be altered depending on what other receptors are still functional. The areas 
were expressed as a % of the control area. In both proximal and distal segments, the prazosin 
sensitive component was greatest when the α2-ARs and P2X receptors were functional 
compared to when these receptors where blocked (Figure 7-10; Tables 7-14 and 7-15).  
 
 
 
 
 
 
 
 
 
Table 7-13: α1-null Distal mouse tail artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 0.5 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
 
196 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prazosin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
PS 21 ± 4 22 ± 3 
PS 
(R) 
12 ± 2 19 ± 7 
PS 
(R+S) 
2 ± 1 ** 4 ± 2 
PS 
(S+R) 
7 ± 4 * 13 ± 6 
 
 
 
 
 
 
 
Table 7-14: α1-null Proximal mouse tail artery – revealing the prazosin sensitive (PS) 
component as a % of control area under the curves. Data taken from Figures 7-10 
and 7-12. 
* P < 0.05; ** P < 0.01 compared with the PS component when the α2-ARs and P2X 
receptors are functional. One way ANOVA with Bonferonni’s post-test. 
Figure 7-10: α1-null Proximal mouse tail – the prazosin sensitive (PS) component at 
0.5 Hz when the P2X receptors and α2-ARs are functional (white) (n=6), α2-ARs are 
blocked (light grey) (n=12), when the α2-ARs and P2X receptors were blocked (dark 
grey) (n=6), the P2X receptors and α2-ARs were blocked (black) (n=6). 
* P < 0.05; ** P < 0.01 compared with PS component when the α2-ARs and P2X 
receptors are functional. One way ANOVA with Bonferonni’s post-test. 
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Prazosin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
PS 43 ± 15 24 ± 6 
PS 
(R) 
15 ± 5 27 ± 9 
PS 
(R+S) 
3 ± 1 * 7 ± 3 
PS 
(S+R) 
9 ± 2 * 20 ± 5 
 
 
 
7.3.2.3 Revealing the effect of prazosin on the response to 
sympathetic nerve stimulation at 8 Hz. 
 
At 8 Hz, the proximal segments incubated with 100 nM prazosin had significantly lower 
peak tensions compared to control responses (Table 7-16). Distally, prazosin had more of an 
effect on the response; reducing the peak tension, the tension at the end of the stimulation 
period, the rate of rise and prolonging the time to reach the peak tension (Figure 7-11; Table 
7-17). 
 
 
 
 
 
 
 
 
 
* P < 0.05 compared with PS component when the α2-ARs and P2X receptors are 
functional. One way ANOVA with Bonferonni’s post-test. 
Table 7-15: α1-null Distal mouse tail artery response - revealing the prazosin sensitive 
(PS) component as a % of control area under the curves. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 6) 
% change following P 
incubation 
Tension at End of pulse (mg) 40 ± 10 42 ± 16 - 9 ± 10 
Time to Peak (seconds) 9.4 ± 1.5 9.1 ± 0.8 0.5 ± 9 
Peak Tension (mg) 188 ± 39 155 ± 36 ** - 20 ± 2 
Rate of Rise (mg/s) 24 ± 7 18 ± 5 - 19 ± 8 
Time to Peak (2nd) (seconds) 15.5 ± 1.9 17.3 ± 1.3 11 ± 7 
Peak Tension (2nd) (mg) 160 ± 34 139 ± 34 ** - 16 ± 4 
50 % Decay Time (seconds) 22.8 ± 2.1 23.4 ± 2.1 2 ± 5 
 
 
 
** P < 0.01 compared with control response. Paired t-test. 
α1-null Control 
100 nM Prazosin 
Figure 7-11: α1-null Distal mouse tail artery response to nerve stimulation at 8 Hz in 
control vessels and in the presence of the α1-AR antagonist prazosin (100 nM) (n = 
9).  
* P < 0.05, ** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
* 
**
 +
+ 
Table 7-16: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and prazosin (100 nM) incubated vessels at 8 Hz.  
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Prazosin (P) 
(n = 9) 
% change following P 
incubation 
Tension at End of pulse (mg) 47 ± 11 23 ± 6 * - 42 ± 12 
Time to Peak (seconds) 7.5 ± 1.1 9.5 ± 1.5 ++ 19 ± 4 
Peak Tension (mg) 234 ± 45 183 ± 41 ** - 22 ± 5 
Rate of Rise (mg/s) 39 ± 9 24 ± 6 *** - 37 ± 4 
Time to Peak (2nd) (seconds) 14.6 ± 0.5 18.6 ± 2.2 17 ± 7 
Peak Tension (2nd) (mg) 146 ± 28 135 ± 33 - 14 ± 7 
50 % Decay Time (seconds) 17.1 ± 2.3 17.5 ± 1.9 6 ± 8 
 
 
 
The analysis of the prazosin sensitive components was similar for each component and at 
each segment studied (Figure 7-12; Tables 7-14 and 7-15). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-12: α1-null Proximal mouse tail – the prazosin sensitive (PS) component at 8 
Hz when the P2X receptors and α2-ARs are functional (white) (n=6), α2-ARs are 
blocked (light grey) (n=12), when the α2-ARs and P2X receptors were blocked (dark 
grey) (n=6), the P2X receptors and α2-ARs were blocked (black) (n=6). 
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Table 7-17: α1-null Distal mouse tail artery response to nerve stimulation in control 
and prazosin (100 nM) incubated vessels at 8 Hz. 
* P < 0.05, ** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
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7.3.2.4 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 0.5 Hz. 
 
When rauwolscine (100 nM) was incubated, the response to nerve stimulation in the 
proximal and distal segments was altered. Proximally and distally, the peak tension and the 
tension at the end of the stimulation period were reduced in amplitude (Table 7-18). 
Furthermore, distally, the tension at the first peak and the rate of rise were also reduced 
(Figure 7-13; Table 7-19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
α1-null Control 
100 nM Rauwolscine 
Figure 7-13: α1-null Distal mouse tail artery response to nerve stimulation at 0.5 Hz 
in control vessels and in the presence of the α2-AR antagonist rauwolscine (n = 13).   
** P < 0.01; *** P < 0.001 compared with control response. Paired t-test. 
  
**
 
**
* 
**
* 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 12) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 2.7 ±0.3 3.4 ± 0.7 6 ± 12 
Peak Tension (1st) (mg) 23 ± 8 9 ± 2 - 38 ± 12 
Rate of Rise (mg/s) 8 ± 2 4 ± 1 - 38 ± 13 
Time to Peak (seconds) 38.8 ± 0.9 33.1 ± 3.1 - 15 ± 9 
Peak Tension (mg) 240 ± 19 63 ± 8 *** - 73 ± 3 
Tension at End of pulse (mg) 231 ± 19 56 ± 8 *** - 75 ± 3 
50 % Decay Time (seconds) 19.0 ± 1.9 16.7 ± 1.4 - 5 ± 9 
 
 
 
 
Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 13) 
% change following R 
incubation 
Time to Peak (1st) (seconds) 3.2 ± 0.3 3.9 ± 0.6 7 ± 11 
Peak Tension (1st) (mg) 38 ± 9 12 ± 3 ** - 61 ± 7 
Rate of Rise (mg/s) 11 ± 2 3 ± 1 ** - 65 ± 7 
Time to Peak (seconds) 37.8 ± 2.6 33.7 ± 2.4 - 8 ± 8 
Peak Tension (mg) 250 ± 29 86 ± 21  *** - 67 ± 5 
Tension at End of pulse (mg) 236 ± 29 76 ± 19 *** - 70 ± 5 
50 % Decay Time (seconds) 20.0 ± 2.9 16.1 ± 1.9 - 11 ± 10 
 
 
Proximally, the rauwolscine sensitive component was shown to be greatest when the P2X 
receptors were functional and smallest when the P2X receptors were blocked (Figure 7-14; 
Table 7-20). Distally, the rauwolscine sensitive component was not found to be different 
when comparing the incubation conditions (Table 7-21).  
 
 
 
 
Table 7-18: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and rauwolscine (100 nM) incubated vessels at 0.5 Hz.  
*** P < 0.001 compared with control response. Paired t-test. 
Table 7-19: α1-null Distal mouse tail artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 0.5 Hz.  
** P < 0.01, *** P < 0.001 compared with control response. Paired t-test. 
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Table 7-20: α1-null Proximal mouse tail artery - revealing the rauwolscine-sensitive 
(RS) component as a % of control area under the curves. Data taken from Figures 
7-14 and 7-16. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Rauwolscine-sensitive component 
as a % of the Control Response 
 0.5 Hz 8 Hz 
RS 78 ± 3 *** 54 ± 5 
RS 
(P) 
67 ± 4 *** 68 ± 6 
RS 
(S) 
24 ± 7 42 ± 15 
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Figure 7-14: α1-null Proximal mouse tail – the rauwolscine sensitive component at 0.5 
Hz when the P2X receptors are functional (white) (n=12), prazosin sensitive 
component is blocked (light grey) (n=6), P2X receptors are blocked (black) (n=6).  
*** P < 0.001 compared with area under the curve when the α1-ARs are functional 
and the P2X receptors are blocked. One way ANOVA with Bonferonni’s post-test. 
  
RS RS 
(P) 
RS 
(S) 
*** P < 0.001 compared with RS component when the α1-ARs are functional and the P2X 
receptors are blocked. One way ANOVA with Bonferonni’s post-test. 
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Rauwolscine-sensitive component as 
a % of the Control Response 
 0.5 Hz 8 Hz 
RS 70 ± 5 47 ± 6 
RS 
(P) 
62 ± 5 61 ± 6 
RS 
(S) 
69 ± 47 55 ± 29 
 
 
7.3.2.5 Revealing the α2-ARs role in the response to sympathetic 
nerve stimulation at 8 Hz.  
 
At 8 Hz, the response to nerve stimulation in both proximal and distal segments was inhibited 
by rauwolscine (100 nM) incubation. At both segments, the peak tensions were significantly 
reduced and the rate of rise was also reduced (Figure 7-15; Table 7-22 and 7-23). 
Additionally, proximal response was also reduced at the end of the stimulation period and 
the 50% decay time was shortened.  
 
 
 
 
 
 
 
 
 
 
Table 7-21: α1-null Distal mouse tail artery response - revealing the rauwolscine-
sensitive (RS) component as a % of control area under the curves. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
100 nM 
Rauwolscine (R) 
(n = 12) 
% change following R 
incubation 
Tension at End of pulse (mg) 120 ± 20 80 ± 12 * - 27 ± 7 
Time to Peak (seconds) 6.2 ± 0.4 5.0 ± 0.4 - 16 ± 8 
Peak Tension (mg) 334 ± 40 188 ± 31 *** - 47 ± 4 
Rate of Rise (mg/s) 58 ± 9 39 ± 7 *** - 33 ± 5 
Time to Peak (2nd) (seconds) 12.9 ± 0.7 12.2 ± 0.4 - 4 ± 5 
Peak Tension (2nd) (mg) 241 ± 21 112 ± 15 *** - 55 ± 4 
50 % Decay Time (seconds) 20 ± 2.1 15.1 ± 2.2 + - 25 ± 6 
 
 
 
 
 
α1-null Control 
100 nM Rauwolscine 
Figure 7-15: α1-null Proximal mouse tail artery response to nerve stimulation at 8 Hz 
in control vessels and in the presence of the α2-AR antagonist rauwolscine (100 nM) 
(n = 12). 
* P < 0.05; *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
* 
**
* 
**
* 
+ 
Table 7-22: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and rauwolscine (100 nM) incubated vessels at 8 Hz.  
* P < 0.05, *** P < 0.001 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
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Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
Rauwolscine (R) 
(n = 13) 
% change following R 
incubation 
Tension at End of pulse (mg) 73 ± 10 74 ± 9 3 ± 11 
Time to Peak (seconds) 7.0 ± 1.0 5.8 ± 0.3 - 11 ± 6 
Peak Tension (mg) 310 ± 26 184 ± 23 *** - 41 ± 4 
Rate of Rise (mg/s) 49 ± 5 33 ± 4 *** - 32 ± 6 
Time to Peak (2nd) (seconds) 14.8 ± 0.7 13.4 ± 0.5 - 9 ± 5 
Peak Tension (2nd) (mg) 226 ± 24 118 ± 18 *** - 47 ± 5 
50 % Decay Time (seconds) 20.0 ± 2.3 14.4 ± 2.6 - 24 ± 8 
 
 
Neither the proximal or distal segments displayed significant variations in rauwolscine 
sensitive component regardless of incubation condition. Under all conditions, the 
rauwolscine sensitive component represented a large portion of the control response (Figure 
7-16; Tables 7-20 and 7-21). 
 
 
 
 
 
 
 
 
 
 
 
 
 
*** P < 0.001 compared with control response. Paired t-test. 
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Figure 7-16: α1-null Proximal mouse tail – the rauwolscine sensitive component at 8 
Hz when the P2X receptors are functional (white) (n=12), prazosin sensitive 
component is blocked (light grey) (n=6), P2X receptors are blocked (black) (n=6).  
  
RS RS 
(P) 
RS 
(S) 
Table 7-23: α1-null Distal mouse tail artery response to nerve stimulation in control 
and rauwolscine (100 nM) incubated vessels at 8 Hz.  
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7.3.2.6 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 0.5 Hz. 
 
Proximally, suramin (1 mM) significantly reduced the peak tension and the tension at the 
end of the stimulation period and prolonged the time to reach the first peak (Figure 7-17; 
Table 7-24). The distal responses showed a similar trend but the results were not found to be 
significantly different (Table 7-25). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-17: α1-null Proximal mouse tail artery response to nerve stimulation at 0.5 
Hz in control vessels and in the presence of the P2X receptor antagonist suramin (1 
mM) (n = 6). 
* P < 0.05; ** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
α1-null Control 
1 mM Suramin 
+ 
**
 
* 
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Proximal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 6) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 3.1 ± 0.2 4.2 ± 0.2 + 25 ± 9 
Peak Tension (1st) (mg) 22 ± 10 11 ± 6 - 36 ± 19 
Rate of Rise (mg/s) 7 ± 3 3 ± 1 - 53 ± 14 
Time to Peak (seconds) 37.5 ± 1.4 36.0 ± 2.7 - 5 ± 7 
Peak Tension (mg) 201 ± 54 75 ± 37 ** - 63 ± 8 
Tension at End of pulse (mg) 195 ± 54 65 ± 31 * - 70 ± 8 
50 % Decay Time (seconds) 16.6 ± 0.9 13.1 ± 2.9 - 23 ± 21 
 
 
 
 
 
Distal 
0.5 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Time to Peak (1st) (seconds) 3.0 ± 0.4 4.3 ± 0.5 21 ± 14 
Peak Tension (1st) (mg) 41 ± 19 24 ± 16 - 36 ± 25 
Rate of Rise (mg/s) 11 ± 4 4 ± 2 - 45 ± 24 
Time to Peak (seconds) 31.8 ± 5.3 29.9 ± 5.0 - 5 ± 19 
Peak Tension (mg) 157 ± 38 78 ± 28 - 47 ± 21 
Tension at End of pulse (mg) 147 ± 37 67 ± 25 - 50 ± 21 
50 % Decay Time (seconds) 20.8 ± 4.4 21.9 ± 4.9 - 0.4 ± 21 
 
 
In proximal segments the suramin sensitive component was significantly greater when the 
α2-ARs were functional compared with the other incubation conditions (Figure 7-18; Table 
7-26 and 7-27). 
 
 
 
Table 7-24: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and suramin (1 mM) incubated vessels at 0.5 Hz.  
* P < 0.05; ** P < 0.01 compared with control response. Paired t-test. 
+ P < 0.05 compared with control time. Paired t-test. 
Table 7-25: α1-null Distal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 0.5 Hz.  
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Table 7-26: α1-null Proximal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. Data taken from Figures 7-18 
and 7-20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Suramin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
SS 70 ± 7 78 ± 14 
SS 
(R) 
18 ± 3 *** 33 ± 6 ** 
SS 
(P+R) 
11 ± 2 *** 14 ± 2 *** 
SS 
(R+P) 
15 ± 2 *** 37 ± 2 ** 
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Figure 7-18: α1-null Proximal mouse tail – the suramin sensitive component at 0.5 Hz 
when the α2-ARs are functional (white) (n=6), α2-ARs are blocked (light grey) (n=6), 
α2-ARs are blocked (dark grey and black) (n=6).  
*** P < 0.001 compared with SS component when the α1- and α2-ARs are functional. 
One way ANOVA with Bonferonni’s post-test. 
  
SS SS 
(R) 
SS 
(P+R) 
SS 
(R+P) 
** P < 0.01; *** P < 0.001 compared with SS component when the α2-ARs are functional. 
One way ANOVA with Bonferonni’s post-test. 
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Suramin-sensitive component as a 
% of the Control Response 
 0.5 Hz 8 Hz 
SS 112 ± 42 88 ± 30 
SS 
(R) 
24 ± 6 38 ± 6 
SS 
(P+R) 
17 ± 11 * 20 ± 11 
SS 
(R+P) 
19 ± 4 34 ± 8 
 
 
 
7.3.2.7 Revealing the P2X receptor role in the response to 
sympathetic nerve stimulation at 8 Hz. 
 
Proximally, both peak tensions and the rate of rise were reduced (Figure 7-19; Table 7-28). 
Distally, the peak tension and the tension at the end of the stimulation period were reduced. 
The rate of rise was also reduced and the time to reach the peak was prolonged (Table 7-29). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-19: α1-null Proximal mouse tail artery response to nerve stimulation at 8 Hz 
in control vessels and in the presence of the P2X receptor antagonist suramin (1 mM) 
(n = 6). 
* P < 0.05 compared with control response. Paired t-test. 
α1-null Control 
1 mM Suramin 
* 
* 
Table 7-27: α1-null Distal mouse tail artery response - the suramin-sensitive (SS) 
component as a % of control area under the curves. 
* P < 0.05 compared with SS component when the α2-ARs are functional. One way 
ANOVA with Bonferonni’s post-test. 
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Proximal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
1 mM 
Suramin (S) 
(n = 6) 
% change following S 
incubation 
Tension at End of pulse (mg) 71 ± 25 6 ± 1 - 67 ± 18 
Time to Peak (seconds) 7.3 ± 0.8 8.6 ± 1.8 7 ± 12 
Peak Tension (mg) 264 ± 65 105 ± 41 * - 52 ± 14 
Rate of Rise (mg/s) 40 ± 10 13 ± 5 * - 51 ± 21 
Time to Peak (2nd) (seconds) 13.4 ± 0.9 15.6 ± 1.9 9 ± 11 
Peak Tension (2nd) (mg) 213 ± 61 87 ± 35 * - 48 ± 17 
50 % Decay Time (seconds) 17.0 ± 3.3 14.6 ± 1.6 - 3 ± 17 
 
 
 
 
 
Distal 
8 Hz 
Contractile Response (average ± S.E.M) 
Control 
Suramin (S) 
(n = 7) 
% change following S 
incubation 
Tension at End of pulse (mg) 83 ± 22 11 ± 2 * - 74 ± 12 
Time to Peak (seconds) 5.5 ± 0.4 6.5 ± 0.4 ++ 16 ± 4 
Peak Tension (mg) 245 ± 39 133 ± 38 * - 48 ± 11 
Rate of Rise (mg/s) 47 ± 9 21 ± 6 ** - 58 ± 8 
Time to Peak (2nd) (seconds) 13.6 ± 0.7 14.7 ± 0.4 7 ± 4 
Peak Tension (2nd) (mg) 137 ± 27 94 ± 31 - 36 ± 20 
50 % Decay Time (seconds) 15.8 ± 3.6 16.0 ± 1.1 2 ± 19 
 
 
 
Analysis of the suramin sensitive components extracted from each of the incubation 
conditions in proximal tail artery revealed the area under the curve when the α2-ARs are 
functional to be significantly greater than the other incubation conditions (Figure 7-20; Table 
7-26). This trend also occurred in distal segments although no significant differences were 
recorded (Table 7-27).  
 
 
Table 7-28: α1-null Proximal mouse tail artery response to nerve stimulation in 
control and suramin (1 mM) incubated vessels at 8 Hz.  
* P < 0.05 compared with control response. Paired t-test. 
Table 7-29: α1-null Distal mouse tail artery response to nerve stimulation in control 
and suramin (1 mM) incubated vessels at 8 Hz.  
* P < 0.05, ** P < 0.01 compared with control response. Paired t-test. 
++ P < 0.01 compared with control time. Paired t-test. 
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Figure 7-20: α1-null Proximal mouse tail – the suramin sensitive component at 8 Hz 
when the α2-ARs were functional (white) (n=6), α2-ARs were blocked (light grey) 
(n=6), α1- and α2-ARs are blocked (dark grey and black) (n=6).  
** P < 0.01; *** P < 0.001 compared with SS component when the α2-ARs receptors 
are functional. One way ANOVA with Bonferonni’s post-test. 
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7.4 Discussion 
 
The present study was set out to determine the effect genetic removal of all three α1-ARs 
had on the response to nerve stimulation. The dominant α1-AR component was confirmed in 
the mouse mesenteric arteries and the possibility of compensatory mechanisms in mesenteric 
and tail arteries were studied. 
 
7.4.1 Mouse Mesenteric Arteries 
 
7.4.1.1 Comparison with WT response 
 
The loss of the α1-ARs was shown clearly in the response at both frequencies. Similar to the 
ADKO response, this response also supports previous knowledge of the α1-ARs dominating 
the contraction in mesenteric arteries (Sjoblom-Widfeldt et al., 1990). The response is almost 
completely abolished at 2 Hz and only a small response remains at 8 Hz. Therefore, in this 
vessel, the response due to α1-AR activation is not fully compensated for by another receptor. 
At 2 Hz, as well as a reduction in contractile response, the time taken to reach the peak was 
prolonged and the decay time was reduced. Therefore, the overall response was affected by 
loss of the α1-ARs. In the WT vessels, no interactions were noted between the α1-ARs and 
the other studied receptors and this may be the reason why the response in the α1-null is 
small. If no interactions occur in the WT vessels then genetic removal of the α1-ARs may 
have no influence on the other receptors and so no compensatory mechanisms would be 
initiated. 
 
7.4.1.2 α1-null Control response to Nerve Stimulation 
 
Incubation with prazosin, rauwolscine and suramin reduced the response to nerve 
stimulation. However, the figures shown suggest that there is still a component of the 
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response remaining following co-incubation with the antagonists. On experimental days, this 
residual contraction was not visible on the LabChart traces and so the y-axis scale shown in 
the results section should be observed, as should the error bars. It was due to these small 
responses that the antagonist sensitive component analysis was not used, as there was 
potential for the response to fluctuate just below and above the baseline.  
 
7.4.1.3 Receptor role in the Mouse Mesenteric Arteries 
 
As the responses to nerve stimulation at 2 Hz were small, the response following treatment 
with any of the antagonists did not reduce the response. Combined incubation of the three 
antagonists was not able to reduce the response further therefore suggesting that the response 
was too small to statistically determine which receptors were involved in the contraction. At 
8 Hz, the P2X receptors were involved in the contractile response as suramin was able to 
exert a change in the response. As expected, prazosin had no effect on the response. In the 
WT, a population of pre-junctional α2-ARs exists, which when blocked, enhanced the 
response. This did not occur in the α1-null mesenteric arteries and this is most likely due to 
loss of the α1-ARs. The pre-junctional α2-ARs may still have been blocked by rauwolscine 
treatment but the enhanced transmitter output would not have been able to fully exert its 
effect post-junctionally due to the loss of the α1-ARs. Even the presence of the α1B-ARs in 
the ADKO was enough to reveal these α2-AR effects. The reduction in response to single 
and combined antagonist treatment in the α1-null compared to the ADKO further supports a 
role for the α1B-ARs. Therefore, in the mesenteric arteries, loss of the α1-ARs considerably 
reduced the response and no compensatory mechanisms were revealed. 
 
7.4.2 Mouse Proximal and Distal Tail Artery 
 
Similar to Chapters Five and Six, the α1-null results displayed only data from one area of the 
tail and only discrepancies between the segments were discussed. When comparing the WT 
and α1null responses, the proximal results were shown. 
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7.4.2.1 Comparison with WT 
 
At 0.5 Hz and 8 Hz, the α1-null vessels were able to produce a contractile response to nerve 
stimulation. At 0.5 Hz, the initial response to nerve stimulation was unaltered in the α1-null 
vessels. This corresponds with the WT response where the P2X receptors initiate the 
contraction. The loss of the α1-ARs is demonstrated by a reduction in the peak tension, a 
difference which was not shown in the ADKO arteries and therefore is due to loss of the α1B-
ARs. This may be due to a direct loss of available receptors to stimulate or it may be the loss 
of an interaction between receptors. Similar to the ADKO, the decay time was prolonged in 
the α1-null vessels thus reaffirming the role of the α1-ARs in ensuring completion of the 
response. 
 
At 8 Hz, like in the ADKO, the loss of the α1-ARs is seen more clearly on the response. All 
of the recorded tensions in the α1-null vessels were reduced and both peak times and the 
decay time were prolonged, compared to the WT response. This further supports the view 
that the α1-ARs contribute to the overall response.  
 
7.4.2.2 Revealing the effect of Prazosin on the Response to 
Sympathetic Nerve Stimulation 
 
In the α1-null vessels, there should be no effect of prazosin treatment. All experiments to 
date have described prazosin as an α1-AR antagonist and results suggest that only the α1-
ARs are blocked by prazosin. Also, a lack of response to prazosin at 8 Hz in the α1-null 
mesenteric arteries confirms the selectivity of prazosin. However, in the α1-null tail artery, 
100 nM prazosin treatment was able to alter the nerve response and this was more clearly 
shown in the distal segments. Here, vessels incubated with prazosin produced a response 
with a prolonged time to first peak and a decreased peak tension. The most likely reason for 
this result is that prazosin was able to block the α2-ARs – an effect not obvious in the WT 
vessels as rauwolscine incubation following α1-AR block by prazosin always further reduced 
the response significantly. Therefore, the results obtained may have occurred due to a 
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compensatory mechanism which caused an increase in α2-AR sensitivity in distal segments. 
An increased α2-AR sensitivity in distal segments was proposed by Medgett in 1985 who 
studied the rat tail artery and concluded that the α2-ARs were able to mediate more of the 
contractile response distally (Medgett, 1985). Therefore, if α2-AR sensitivity was increased 
in the α1-null mice, prazosin (100 nM) may be able to block some of the α2-ARs and thus 
affect the response to nerve stimulation. At 8 Hz, prazosin was able to reduce the peak 
tensions. However, compared to the rauwolscine response, this response to nerve stimulation 
was only altered in a minor way and so if the receptors are able to bind prazosin, then only 
a small proportion of the α2-ARs were blocked. The mouse tail artery has been implicated in 
thermoregulation with the main receptor involved being the α2C-ARs (Chotani et al., 2000) 
and this receptor subtype has also been shown to bind prazosin, although at a much lower 
affinity than rauwolscine in the rat tail artery (Jantschak et al., 2010). When investigating 
the prazosin-sensitive components, following rauwolscine and suramin treatments, the 
remaining component was virtually abolished, therefore confirming that the prazosin effect 
was not due to blockade of an unknown receptor.  
 
A similar response to prazosin incubation was shown at 8 Hz whereby the peak tension was 
reduced both proximally and distally. Additionally, the distal segments were again more 
sensitive to prazosin treatment with the tension at the end of the stimulation period reduced 
and the time to peak prolonged. The prazosin-sensitive components were small regardless 
of incubation sequence. However, there was a trend for the component to be smaller when 
the vessels were incubated with rauwolscine and suramin. 
 
7.4.2.3 α2-AR role in Mouse Tail Artery 
 
Similar to both the WT and ADKO results, the main receptors involved in vessel contraction 
in the α1-null were the α2-ARs. In support of an increase in the α2-AR component, 
particularly in distal segments, the response was affected more by rauwolscine treatment in 
distal segments. Proximally, only the peak tension and the tension at the end of the 
stimulation period were reduced. Distally, the first peak tension was also reduced. However, 
these responses to rauwolscine treatment were reduced compared with the WT where the 
response timings were also affected by α2-AR blockade. This highlights an interaction 
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between the α2- and α1-ARs, shown in the WT analysis and lost in the α1-null vessels. 
Therefore, although the α2ARs are the main receptors involved in contraction of the tail, they 
require assistance from functional α1-ARs and this is not clearly compensated for in the α1-
null vessels. When investigating the rauwolscine-sensitive component, an interaction with 
the P2X receptors was revealed, similar to that shown in the WT vessels whereby the 
rauwolscine-sensitive component was reduced when the P2X receptors were blocked. 
Interestingly, this interaction with the P2X receptors was not shown in distal segments. This 
therefore suggests than an increase in α2-AR sensitivity distally removes the α2-AR 
dependency on the P2X receptors.  
 
At 8 Hz, rauwolscine treatment affects more of the response to nerve stimulation compared 
to 0.5 Hz and the results are similar regardless of location. Therefore, the α2-ARs contribute 
to the overall contractile response. As was described in the ADKOs (Chapter Six), the 
tension recorded at the end of the stimulation period was reduced in the α1-null but not the 
WT vessels. In the WT vessels, the reduction in response occurred due to prazosin treatment 
and so presently, this result may represent a compensatory mechanism. At 8 Hz, activation 
of the α2-ARs occurred independently of the P2X receptors and was the main receptor 
involved in vessel contraction. 
 
7.4.2.4 P2X receptor role in Mouse Tail Artery 
 
At 0.5 Hz, incubation of the vessels with suramin, to block P2X receptors revealed a role for 
the P2X receptors in the initiation of the response as well as contributing to the overall 
contraction. The ability to initiate the contraction was also shown in the WT vessels. 
However, the reduction in peak tension, shown following suramin treatment, occurred in the 
α1-null vessels but not in the WT vessels. In the WT, the latter stages of the response were 
driven mainly by the α2-ARs and α1-ARs. It is therefore possible that in the α1-null, the P2X 
receptors compensate for the loss of the α1-ARs. However, this mechanism can only occur 
when the α2-ARs are active and therefore provides evidence of an interaction between these 
two receptors. This is similar to the ADKO response suggesting that the loss of the α1B-ARs 
does not further alter the response. 
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At 8 Hz, the response to suramin treatment differed depending on the location, with the distal 
segments being more suramin sensitive and less dependent on the α2-ARs. If the α2-AR 
sensitivity is increased distally and not dependent on the P2X receptors being active, the 
P2X receptors may have adapted in the α1-null to be independent of the α2-ARs in distal 
segments. Proximally, suramin treatment was still able to reduce the contractile response. 
However, the response was dependent on the α2-ARs being active. 
 
7.4.3 Conclusion 
 
In summary, the presence of α2-ARs and P2X receptors has been confirmed in the mesenteric 
and tail arteries of α1-null mice. The presence of a contractile response in both of these 
vessels confirms that activation of the remaining receptors can result in vasoconstriction. 
Similar to the ADKO results, the loss of the α1-ARs is most clearly shown in the mesenteric 
arteries. As the α1-ARs were shown to contribute most to the contraction of the mesenteric 
arteries in the WT, this result is understandable and also confirms that no other receptor was 
capable of fully compensating for the lost response. Evidence of minor compensatory 
mechanisms were revealed in the tail artery where the sensitivity of the α2-ARs appears to 
be increased, particularly in distal segments as the vessel response was altered following 
prazosin treatment. This effect was most likely due to activation of α2C-ARs. At 0.5 Hz, there 
was evidence to suggest P2X receptor activation compensating for the loss of the α1-ARs 
and potential P2X receptor adaptation in distal segments, at 8 Hz. In conclusion, the 
development of the α1-null mice has confirmed the importance of the α1-ARs in smooth 
muscle contraction, particularly in mesenteric arteries. It has also been revealed that in the 
KO animals, other receptors can compensate for the loss of the knocked-out receptor. The 
pharmacology was somewhat simplified, however the unexpected effect of prazosin and the 
compensatory mechanisms made it difficult to determine the exact roles of the receptors 
involved in smooth muscle contraction.  
 
The two vessels studied highlight the differences in receptor population that can occur 
throughout the vasculature. The results from the α1-null mice provide a useful framework, 
along with the WT and ADKO results, for the study of independent receptor activation and 
receptor interactions. The responses to nerve stimulation in the mouse mesenteric arteries 
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were shown to be mainly α1-AR mediated with no obvious interactions with the other 
receptors, and so can be utilised to demonstrate the importance of α1-ARs. Conversely, the 
responses to nerve stimulation in the mouse tail artery were shown to be mainly α2-AR 
mediated with clear interactions with α1-ARs and P2X receptors. Therefore this vessel can 
be utilised to study receptor interactions in a vessel where the α1-AR mediated response is 
not crucial to vessel contraction. The treatment of primary hypertension with α1-AR 
antagonists has been largely unsuccessful. The results shown presently indicate that this may 
be due to differences in receptor population and receptor interactions throughout the 
vasculature. Further investigations utilising the mesenteric and tail artery may help in the 
development of novel therapies for treating this disorder. 
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Chapter Eight 
 
General Discussion 
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Activation of post-junctional α1-ARs has been shown throughout the vasculature to be 
responsible for sympathetic vasoconstriction and so can contribute to the control of arterial 
blood pressure. However, treatment of primary hypertension using α1-AR antagonists has 
been largely unsuccessful, unless therapy is combined with another blood pressure (BP) 
lowering agent (Chapman et al., 2010). Therefore, a greater understanding of the various 
receptors in the vasculature is required in order to improve patient response to BP treatment. 
This has been difficult due to the complex pharmacology present in many blood vessels 
whereby synergy and interactions between receptors prevents clear assessment of the 
individual receptor roles. The results presented in this thesis utilised mouse mesenteric and 
tail arteries as evidence suggested that they contained different proportions of α1- and α2-
ARs as well as a P2X receptor population (Gitterman and Evans, 2001; Brock et al., 2006) 
(Bao et al., 1990; Bao and Stjarne, 1993). Transgenic mice lacking at least one α1-AR 
subtype have been developed and the α1AD-AR KO and α1-null mice were utilised here to 
determine the effects that loss of some or all of the α1-ARs has on the response to nerve 
stimulation in the aforementioned vessels. Comparing with WT results and using selective 
antagonists it was hoped that the findings would provide a clearer representation of the 
functional role of the three main vasoconstrictor receptors; α1-, α2-ARs and P2X receptors. 
This will hopefully guide the development of novel therapies targeted at the studied 
receptors. 
 
8.1 Systolic Blood Pressure 
 
Initially, the systolic blood pressure was measured from WT, ADKO, and α1-null mice to 
determine whether loss of some or all of the α1-ARs has a direct effect on lowering BP as 
has been shown in other studies (Rokosh and Simpson, 2002; Hosoda et al., 2005; Sanbe et 
al., 2007; Tanoue et al., 2002). However, the present results indicated that the α1-ARs were 
either not implicated in blood pressure maintenance or, another receptor was able to 
compensate for the loss. It was also concluded that, under the circumstances, the mice may 
have been more agitated and so this may have masked the BP at rest. Nonetheless, if the 
mice were agitated, it would suggest that, under pressure, the effect on vascular tone is 
similar between the strains.  
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8.2 Calcitonin Gene-Related Peptide (CGRP) 
As well as a dense plexus of sympathetic nerve terminals, primary afferent sensory nerve 
terminals are present in the adventitia of many arteries (Kawasaki et al., 1988; Sneddon and 
Burnstock, 1984) and activation of receptors present on the nerves can lead to release of 
potent vasodilators including CGRP (Brain et al., 1985; Tornebrandt et al., 1987; Uddman 
et al., 1986). It was proposed that if CGRP was released during electrical field stimulation, 
then under the parameters of stimulation utilised, a CGRP effect may prevent the full 
contractile effect from being visualised. Therefore, all vessels were incubated with capsaicin, 
which depletes the sensory nerves of CGRP (Caterina et al., 1997) and responses before and 
after capsaicin treatment compared in WT, ADKO and α1-null mesenteric and tail arteries. 
A CGRP effect was not noted in the mesenteric arteries from each strain, nor in the WT and 
α1-null tail artery. However, the peak response at 0.5 Hz in the ADKO tail artery was 
enhanced following capsaicin treatment. This response was not shown statistically in the WT 
or the α1-null tail artery, yet there was a trend for the response to increase following capsaicin 
treatment. Therefore, increasing the experimental number should clarify capsaicin’s effect 
in the mouse tail artery.   
 
8.3 Receptor role in Mouse Mesenteric Arteries 
 
Previous studies in the rat mesenteric arteries implicated the main role in the contractile 
response to be due to activation of the α1-ARs with a P2X receptor influence and modulation 
via activation of pre-junctional α2-ARs (Angus et al., 1988; Gitterman and Evans, 2001; 
Brock et al., 2006). The results shown presently, in the mouse mesenteric arteries, supports 
the previous observations in the rat. Activation of the α1-ARs predominates in the contractile 
response and shows no definite interactions with the other receptors. Activation of P2X 
receptors contributes to the initiation of the response and activation of pre-junctional α2-ARs 
modulates transmitter release. The P2X receptor response is partly dependent on the 
presence of active α2-ARs (Chapter Five). In the ADKO, the remaining α1B-ARs were not 
shown to contribute to the contractile response. As the loss of the α1-ARs are not 
compensated for by other receptors, and the SBP remains unchanged, this would suggest 
that activation of these receptors, in the mouse mesenteric arteries, are not crucial in the 
maintenance of vascular tone. This is surprising as the mesenteric arteries provide a large 
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framework of peripheral vessels. However, it is possible than compensatory mechanisms 
occur in the superior mesenteric artery or on the smaller divisions of the mesenteric arcades. 
 
8.4 Receptor role in the Mouse Tail Artery 
 
In the rat tail artery, the α1- and α2-ARs have been shown to contribute to the slow portion 
of the nerve response, with activation of P2X receptors producing the initial contraction 
(Sneddon and Burnstock, 1984; Bao et al., 1990). The results presented here demonstrate a 
strong role for the α2-ARs in the contractile response to nerve stimulation. However, the 
large contractile response is due, in part, to interactions with the α1-ARs and P2X receptors. 
The KO vessel response to nerve stimulation was affected in the tail artery but not as much 
as in the mesenteric arteries. There was some evidence of pre-junctional α2-ARs with 
blockade of the receptors increasing the rate at which the response occurred but not 
enhancing the size of the response. Initiation of the response occurred due to activation of 
P2X receptors and α1-ARs. Unlike in the mesenteric arteries, the KO tail artery responses 
displayed compensatory mechanisms. There was an increase in P2X receptor response and 
an interaction between the α2-ARs and P2X receptors which compensated for the loss of the 
interaction between the α1- and α2-ARs in the WT strain. Responses in the ADKO tail artery 
revealed a role for the α1B-ARs in initiation of the response with interactions greater at the 
lower frequency. The loss of the α1ARs revealed a complex relationship between proximal 
and distal segments. As this is an α2-AR dominated vessel, the response to nerve stimulation 
wouldn’t have been expected to be as affected by α1-AR removal in comparison to the 
mesenteric arteries. However, as removal of the α1-ARs revealed compensatory 
mechanisms, the pharmacology remained complex. 
 
8.5 Future Research 
 
It has been proposed that α1-AR activation is crucial in the maintenance of vascular tone. 
However, the poor performance of α1-AR antagonists in the treatment of primary 
hypertension suggests more complex mechanisms are involved. Results presented here 
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support this idea, that there is more than one main receptor involved in vessel contraction 
and this may change depending on the vessel. Therefore, greater insight is required into the 
individual receptors roles in various vessels to determine whether the α1-ARs are crucial in 
blood pressure maintenance. For example, the mesenteric artery results described presently 
indicate a dramatic reduction in response to nerve stimulation that doesn’t appear to have 
implications on mouse survival. However, the arteries studied were first order mesenteric 
arteries and so investigations into the other mesenteric arteries, particularly the superior 
artery, may reveal a compensatory mechanism. Furthermore, complex interactions in the 
mouse tail artery which changed in response to frequency and/or vessel location made it 
difficult to elucidate the exact receptor roles as the KO animals produced varying responses. 
Therefore, a more detailed analysis of the tail artery is required whereby the changes in 
receptor role along the length of the tail can be determined. The myography protocol used 
presently could be further utilised in experiments involving the superior mesenteric artery 
and the whole tail artery. Visualisation techniques such as confocal laser scanning 
microscopy and fluorescent drugs would establish the location of the α-ARs. This would be 
particularly useful in the tail artery which has yet to be studied in this way. Utilising these 
techniques on other vessels will help elucidate the complex pharmacology and further reveal 
drug targets in the control of hypertension and other vascular concerns such as Raynaud’s 
syndrome. 
 
8.6 General Conclusions 
 
The mouse mesenteric and tail arteries have not been utilised fully in previous studies 
concerning stimulation of the nerves, and so a number of conclusions and novel findings that 
have not been reported elsewhere, can be derived from the studies presented in the previous 
chapters. 
1. The α1-, α2-ARs and P2X receptors have been shown to be involved in the contractile 
response to nerve stimulation in mouse mesenteric and tail arteries with no evidence 
of involvement from other receptors.  
2. The α1-AR mediated contractile response was dominant in the mesenteric arteries 
and was not fully compensated for in the KO animals. 
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3. The α2-AR mediated contractile response was dominant in both proximal and distal 
tail artery segments and loss of the α1-ARs only marginally affected the response in 
the KO vessels. 
4. A novel role in the initiation of the contractile response for the α1B-ARs was revealed 
in the ADKO tail artery.  
5. Interactions between the receptors occurred more in the tail than in the mesenteric 
arteries. 
6. Use of the α1-AR KO mice allowed, for the first time, minor compensatory 
mechanisms to be detected in both vessels, and these mechanisms changed 
depending on the stimulation parameters and the location of the vessel. This made 
analysis of the results complex. 
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